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ABSTRACT 
 
MicroRNAs (miRNAs) are endogenous, non-coding RNA species that regulate gene 
expression at the post-transcriptional level. Recent studies have shown that miRNAs are 
important for cardiac hypertrophy and heart failure, and are critical determinants of 
tissue metabolism.  
 
To investigate the role(s) of miRNAs in the insulin resistant heart, left ventricular 
biopsies were collected from patients with normal ventricular function with or without 
type 2 diabetes, and patients with left ventricular dysfunction (LVD). Using TaqMan 
based reverse transcriptase PCR, quantitative expression levels of 155 mature miRNAs 
in normal and diabetic hearts were determined. Five miRNAs were significantly 
upregulated in the diabetic human heart. Among these, miR-223 was upregulated in 
both diabetic heart and patients with LVD. Adenoviral-mediated overexpression of 
miR-223 increased baseline glucose uptake in cardiac myocytes in vitro with an effect 
size similar to that observed for insulin stimulation. This increase was associated with 
increase in Glut4 protein expression but independent of PI3K/Akt signalling and AMPK 
activity. In contrast to findings in other cells, in cardiac myocytes miR-223 did not 
downregulate protein levels of Mef2c or Igf1r, and an unexpected increase in NfIa 
protein was observed, where all three genes are miR-223 targets in immune cells.  
 
Systemic inhibition of miR-223 in vivo decreased blood glucose level 48 hours after 
administration and increased Glut4 protein level in the skeletal muscle, however Glut4 
levels were decreased in the heart. Cardiac-specific transgenic mice overexpressing 
miR-223 showed no detectable changes in Glut4 protein level and cardiac insulin 
signalling at baseline.  
 
Collectively, these data characterise the expression of miRNAs in the human heart,    
demonstrate that miRNAs regulate gene targets in a cell/tissue type specific manner, 
they can unexpectedly increase protein expression in cardiac myocytes, and miR-223 
regulates cardiac glucose metabolism through a non-canonical pathway, which may 
have implications for future investigations and treatment of insulin resistance.
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CHAPTER ONE 
Introduction 
A class of small non-coding RNA molecules, termed microRNA (miRNA), have been 
implicated to have major roles in heart development, cardiac hypertrophy and the 
pathophysiology of metabolic disease. This chapter outlines the functional and 
biological effects of miRNA, describes the role for miRNA in the development of 
cardiac hypertrophy and insulin resistance, and discusses the potential role of miRNA in 
the pathogenesis of human heart diseases and its therapeutic implications.  
1.1  miRNA 
miRNAs are a newly discovered RNA species. This section describes the biological 
processing mechanisms and molecular functions of miRNA known to date; and outlines 
experimental methodologies developed for studying miRNA.  
1.1.1 Expression and processing  
miRNAs are endogenously expressed ~22-nucleotide non-coding RNAs that primarily 
regulate gene expression at the translational level by binding to complementary 
sequences in phylogenetically conserved targets in the 3’ untranslated regions (UTRs) 
of protein encoding messenger RNAs (mRNAs; Bartel, 2004). To date, almost 700 
miRNAs have been identified in Humans (miRBASE: http://miRNA.sanger.ac.uk/). 
Figure 1.1 depicts the miRNA processing pathway in a mammalian cell (adapted from 
Kim, 2005). Similar to mRNA in protein coding genes, miRNAs are transcribed as 
primary-miRNA (pri-miRNA) by RNA polymerase II from a template DNA sequence. 
These templates can be embedded among introns or protein exons of coding genes or 
located intergenically between known protein coding genes (Cai et al., 2004; Lee et al., 
2004). While in the nucleus, pri-miRNA transcript is cleaved into a short hairpin
Chapter One 
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Figure 1.1 miRNA biogenesis pathway in mammalian cells. Primary-miRNA 
transcript is cleaved into a short hairpin pre-miRNAs (approx 70-100nt) by the nuclear 
RNase III, Drosha. After being transported to the cytoplasm, the hairpin sequence is 
processed further by cytosolic RNase III Dicer to generate mature miRNA:miRNA* 
duplex (miRNA* denotes the RNA strand that contains the reverse compliment 
sequence to the mature miRNA). The mature miRNA then associates with RNA 
induced silencing complex (RISC) and bind to the 3’ untranslated region (UTR) of 
target mRNA.  
Dicer 
Drosha 
cytoplasm 
RNA Pol II 
pri-miRNA 
pre-miRNA 
miRNA:miRNA* 
A(n)3’ 5’ 
Target mRNA 
DNA 
nucleus 
miRNA/miRISC 
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pre-miRNA (approx 70-100nt) by the nuclear RNase III, Drosha (Lee et al., 2003). A 
nuclear transport factor, Exportin 5, then actively transports the pre-miRNA out of the 
nucleus into the cytoplasm (Yi et al., 2003). Here the hairpin sequence is processed 
further by cytosolic RNase III, Dicer, generating double stranded miRNA:miRNA* 
duplexes, where miRNA* denotes the RNA strand that contains the reverse complement 
sequence to the mature miRNA. Depending on the relative stability of the two ends of 
the duplex, the mature miRNA strand is nearly always the one whose 5′ end is less 
tightly paired (Khvorova et al., 2003). Once processed, the mature miRNA associates 
with a ribonucleoprotein complex, the miRNA induced silencing complex (miRISC), 
and binds to the 3’ untranslated region (UTR) of target mRNA, at which time the 
miRNA* sequence is removed and degraded (Figure 1.1).  
1.1.2 Gene regulation: mechanisms and function 
Once bound to a target mRNA, miRNAs are thought to regulate gene expression 
through a number of mechanisms (Figure 1.2). The classical silencing mechanism of 
miRNA occurs at the translational level. This can be achieved through three distinct 
ways: (1) inhibition of translation elongation (Petersen et al., 2006); (2) premature 
termination of translation as a result of ribosome ‘drop-off’ (Petersen et al., 2006); and 
(3) inhibition of translation initiation through blocking translation completely by 
targeting either the capping or the adenylation of the target mRNA (Mathonnet et al., 
2007; Wakiyama et al., 2007). All mechanisms results in a decrease in levels of protein 
the mRNA encodes. Apart from translational interference, miRNA mediated gene 
silencing can also occur through degradation of target mRNA, which affects protein as 
well as mRNA transcript levels. This effect was shown in a study using genome wide 
microarray analysis of mammalian cells where upon exogenous miRNA expression, 
large numbers of transcripts were downregulated (Lim et al., 2005). In addition to 
  
2
0
 
 
 
Figure 1.2 miRNA mediated gene regulation. Mature miRNA associates with argonaute (AGO) proteins to form miRNA induced silencing 
complex and bind to the target mRNA. Upon binding, the miRISC can induce mRNA silencing by a number of mechanisms, this includes 
inhibitions of capping or tailing of the mRNA, inhibition of initiation or elongation of protein translation, or promoting mRNA degradation. 
miRISC 
AGO proteins AGO2-FXR1 
A(n)3’ 5’Cap ORF 
Inhibition of translational 
initiation and elongation  
A(n)3’ 5’ Cap ORF 
mRNA degradation 
A(n)3’ 5’ Cap ORF 
Gene 
repression 
Inhibition of capping or tailing 
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regulation at the post-transcriptional level, miRNA may also alter gene expression by 
interfering with transcription. Studies of double stranded small interfering RNAs 
(siRNA) have been shown to result in changes in chromatin structure by triggering 
DNA methylation. This shows that double-stranded RNAs (dsRNA) can form a 
negative feedback loop to modulate the accessibility of cis-regulatory DNA elements in 
close proximity to the mRNA target’s physical position  (Kawasaki and Taira, 2006; 
Mathieu and Bender, 2004). These findings may also apply to miRNA-mediated gene 
inhibitory mechanisms, but have yet to be proven.  
 
Since their discovery fifteen years ago, miRNAs have been generally considered as 
negative regulators of gene expression. However, more recent studies of cell cycle 
variation and the cellular stress response have revealed that mRNAs repressed by 
miRNAs in one cellular state can be reactivated in another state and that miRNAs can 
also ‘paradoxically’ activate translation (Bhattacharyya et al., 2006; Vasudevan et al., 
2008). Vasudevan et al. showed upon cell cycle arrest, miR-396-3 directs the 
recruitment of microRNP (micro-ribonucleoprotein complex) associated factors, such as 
argonaute (AGO) and fragile-X mental-retardation–related protein 1 (FXR1), to the 
AU-rich element (ARE) in the 3’UTR of tumour necrosis factor-α (TNFα) mRNA to 
activate translation. Interestingly, they also showed let-7, a well studied miRNA, can 
not only repress translation in proliferating cells but can also induce translation of target 
mRNA during cell-cycle arrest (Vasudevan et al., 2007).  
 
Collectively, these findings demonstrate differing mechanisms for miRNA mediated 
gene regulation, which suggest miRNAs can regulate gene expression through a broad 
range of mechanisms depending on the specific miRNA, the mRNA target, the cell type 
Chapter One 
22 
and cell cycle involved, or the interaction of miRNA with other unknown RNA binding 
proteins. The relative importance of each mechanism and the processes controlling 
miRNA specificity remain to be determined.  
1.1.3 Biological functions of miRNAs 
Binding of miRNAs to target sequence is often not fully complementary, this allows 
miRNAs to interact with multiple targets as opposed to a single or limited transcript(s) 
(Brennecke et al., 2005), which suggests miRNAs may have a wide range of biological 
functions. Indeed, miRNAs are important regulators for a diverse range of biological 
processes, such as cell and tissue differentiation, apoptosis, metabolism and cancer 
formation (Baehrecke, 2003; Chen et al., 2004; Esquela-Kerscher and Slack, 2006; 
Gregory and Shiekhattar, 2005; Poy et al., 2004). A miRNA expression study by 
Krichevsky and colleagues showed the expression of 8 mature miRNA sequences were 
significantly differentially regulated during brain development, of which miR-9 and 
miR-131 were dysregulated in presenilin-1 null mice with severe brain developmental 
defects (Krichevsky et al., 2003). In the pancreas, miR-375 suppresses glucose-induced 
insulin secretion by inhibiting myotrophin (Poy et al., 2004). In addition, miRNA-122 is 
a regulator of lipid metabolism and inhibition of miR-122 expression resulted in 
decreased plasma cholesterol levels, increased hepatic fatty-acid oxidation, and a 
decrease in hepatic fatty-acid and cholesterol synthesis rates in mice (Esau et al., 2006). 
These studies indicate miRNAs are important regulators of both pre- and post-natal 
tissue physiology.  
1.1.4 miRNA nomenclature  
The rapid growth of the miRNA field has driven the development of a dedicated 
miRNA database (miRBase, http://miRNA.sanger.ac.uk) which provides access to 
miRNA sequence information, target prediction programs, and allows for online 
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submission for newly discovered miRNAs (miRBase Registry). An annotation scheme 
has been implemented for assigning unique miRNA identifiers. Newly identified 
miRNAs are named by a sequential number (e.g. miR-1, miR-2… miR-133, etc), unless 
they are orthologues of known miRNAs, in which case the same number is used. For 
animals, the species from which the miRNA derives is shown as abbreviated three letter 
prefixes, for instance, hsa-miR-218 (Homo sapiens) or rno-miR-22 (Rattus norvegicus). 
Mature miRNA sequences that differ by one or two nucleotides (nt) are grouped as a 
family, with an alphabetical suffix denoting individual sequences (e.g. miR-30b, miR-
30c). If two mature miRNAs are processed from a common hairpin precursor, they are 
distinguished on the basis of which arm they derive from, for example, miR-126-5p 
(from 5’ arm) and miR-126-3p (from 3’ arm). An asterisk denotes the antisense 
sequence produced from miRNA processing (Figure 1.1, e.g. miR-223*), these 
sequences usually have a short half-life and are degraded once the complementary 
mature miRNA enters the miRISC. Different genomic loci that give rise to identical 
mature miRNA sequences are designated with number suffix, for example, mmu-mir-
16-1 and mmu-mir-16-2 in mouse (Ambros et al., 2003; Griffiths-Jones et al., 2006).  
1.1.5 miRNA target prediction  
miRNA function is mediated by inhibiting translation of target mRNAs, thus, 
identification of the target is an essential step towards understanding the biological 
role(s) of a miRNA. How do miRNAs recognise their target mRNAs? In plants, most 
miRNAs exhibit extended sequence complementarity to mRNA targets’ 3’UTRs 
(Rhoades et al., 2002). In animals however, most miRNA target sites contain seven 
nucleotides that base pair with positions 2-8 from the 5’ end of the miRNA. The 
complementarity of this seed with the target site is crucial for target recognition. Studies 
in HeLa cells have shown that mismatches within the core seed binding region inhibit 
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miRNA binding to target mRNAs, and prevent either target cleavage or translational 
repression regardless of the degree of complementarity elsewhere in the miRNA 
binding site. However, core seed pairing supplemented by just a few flanking base 
pairings appears to be sufficient to mediate translational repression in cooperation with 
other RISCs bound to the target mRNA (Lewis et al., 2003).  
 
Applying this knowledge of sequence complementarity and other determinants of 
miRNA-mRNA interactions, a number of mathematical algorithms for miRNA target 
prediction have been developed. The basic principles of in silico predictions reply on: (1) 
complementarity of miRNA sequence to the 3’UTR of the target mRNA, (2) strong 
binding of the 5’ end of the miRNA to target compared to 3’ end, (3) the degree of 
sequence conservation of the target recognition site on the mRNA across species (Krek 
et al., 2005), (4) thermodynamic stability of the miRNA-target duplex (Kertesz et al., 
2007), and (5) accessibility of the mRNA target site, where miRNA binding can be 
hindered by strong secondary RNA structure.    
 
TargetScan (http://www.targetscan.org; Lewis et al., 2005; Lewis et al., 2003), a web-
based program for the prediction of vertebrate miRNA target prediction, searches the 
3’UTR of the mRNA for 7-nt complementary seed sequences, it allows the G:U wobble 
base pairing and optimises base pairing by analysing the 3’UTR of the mRNA with the 
RNA-fold program. Prioritised target sites are tested further for sequence conservation 
across human, mouse, rat, chicken and dog genomes, and conserved sequences flanking 
the seed match are considered to increase the specificity of the predication. All 
predicted UTRs are then scored and ranked. According to its developers, the false 
positive rate was estimated ~22% for targets conserved in mammals.  
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In 2004, John and colleagues (John et al., 2004) developed miRanda 
(http://www.miRNA.org) for prediction of miRNA targets in mouse, rat and man. In 
addition to sequence complementarity and cross species conservation, miRanda also 
takes into account the thermodynamics of the miRNA:mRNA duplex, the physical 
position of the predicted site on the 3’UTR and the number of sites identified on each 
mRNA. Cross species analysis using miRanda found ~2000 human genes contain target 
sites that are conserved among mammals. Of these, ~250 human genes are conserved 
among mammals and fish (Betel et al., 2008; John et al., 2004). 
 
PicTar (http://pictar.mdc-berlin.de/), the probabilistic identification of combinations of 
target site, was developed by Krek and colleagues (2005). This algorithm accounts for 
synergistic effects of multiple binding sites of one miRNA or several miRNAs acting 
together. In this model, miRNAs compete with each other for binding, and the 
synergistic effect of multiple binding sites of one miRNA or several miRNAs acting 
together is taken into consideration. Cross-species comparisons are used to reduce the 
chance of false positives, where candidate target genes are defined as UTRs with a 
minimal (user-defined) number of evolutionarily conserved putative binding sites. 
PicTar then scores the candidate sequences for each species separately. The resulting 
scores are combined to obtain the final PicTar score for a gene. Estimations using 
published miRNA targets indicated PicTar could have ~30% false discovery rate (Grun 
et al., 2005). 
 
A systematic analysis on miRNA target site accessibility was performed by Kertesz and 
colleagues in 2007 (Kertesz et al., 2007). It was shown, mutations that diminish target 
accessibility reduce miRNA induced translational repression, and this effect was 
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comparable to mutations that disrupt sequence complementarity. The authors devised a 
model for miRNA-target interaction that computes the difference between the free 
energy gained from the formation of the miRNA-target duplex and the energy lost by 
unpairing the target site nucleotides.  In doing so, the model generates an energy-based 
score for the miRNA-target interaction (∆∆G), which was strongly correlated with the 
experimentally measured degree of repression. Based on this model, a genome wide 
miRNA target prediction program was developed (PITA – Probability of Interaction by 
Target Accessibility; http://genie.weizmann.ac.il/pubs/mir07/index.html). PITA uses 
standardised settings based on sequence complementarity to identify initial seeds for 
each miRNA in 3' UTRs, then applies the free-energy model to each putative site, and 
finally combines sites for the same miRNA to obtain a total interaction score for the 
miRNA and UTR. Different to other programs described above, PITA allow user 
defined settings for seed size and wobble base pairing. In addition to the pre-defined 
3’UTR sequences, users can also upload cDNA sequences to predict potential miRNA 
binding.   
 
Apart from the freely available web-based programs described here, many more 
programs for miRNA target prediction have been developed. However, due to the 
complexity and limited knowledge of miRNA binding motifs, computational 
predictions based on sequence alignments are not as straight forward as formerly 
anticipated and different algorithms identify disparate targets (Baek et al., 2008; Kertesz 
et al., 2007). Thus, experimental validation of the predicated targets is essential for 
identifying the true mRNA target and determining the function of the miRNA (Wang, 
2006). 
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1.1.6 Experimental detection of miRNAs 
As a result of the physical properties of miRNAs, several methods have been developed 
to purify and detect miRNAs. These include: small RNA purification methods; PCR-
based techniques which can detect low copy number with high sensitivity and 
specificity for both the precursor and the mature form (Chen et al., 2005; Schmittgen et 
al., 2004); and hybridization techniques such as Northern Blotting, in situ hybridization, 
bead-based flowcytometry and microarray expression profiling (Kloosterman et al., 
2006; Liu et al., 2004; Lu et al., 2005). 
1.1.6.1 Purification of small RNAs 
Mature miRNA sequences are around 22nt in length. Conventional RNA purification 
methods using spin columns (e.g. QIAGEN RNeasy Kit) predominantly isolate RNA 
species larger than 200nt, and most small RNAs are lost during the purification process. 
Methods for the enrichment of small RNA specifies that are less than 200nt were 
therefore developed. Similar to conventional RNA extraction procedures, the sample 
(tissue or cultured cells) is homogenised in a lysis buffer, followed by acid phenol based 
organic extraction step to separate DNA and protein from total RNA (Boom et al., 1990; 
Chomczynski and Sacchi, 1987). To isolate RNA that is highly enriched for small RNA 
species, the large RNA species is first precipitated and immobilised, then, small RNA 
are precipitated from the filtrate using a higher ethanol concentration. A number of 
small RNA purification kits have been developed based on this principle (e.g. 
Ambion/Applied Biosystems, mirVana miRNA Isolation kit; QIAGEN, miRNeasy Mini 
Kit).    
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1.1.6.2 miRNA detection using quantitative reverse transcriptase-
PCR  
The stem-loop quantitative reverse transcriptase PCR (qRT-PCR; Applied Biosystems) 
assay is designed specifically for the quantification of mature miRNAs. It is a 
TaqMan® based two-step procedure (reverse transcription and real time quantitative 
PCR) where the RT primer has a stem-loop structure (Figure 1.3). Stem-loop RT 
primers are thought to be better than conventional primers in terms of RT efficiency and 
specificity. The assays are highly specific for individual miRNAs and are not affected 
by genomic DNA contamination. The manufacturer claims that precise quantification 
can be achieved with as little as 25 pg of total RNA. Compared to more traditional 
methods such as Northern Blotting, this method enables fast and sensitive miRNA 
expression profiling. In addition, stem-loop RT-PCR can be used for the quantification 
of other small RNA molecules such as siRNAs (Chen et al., 2005). The stem-loop qRT-
PCR method was developed by Applied Biosystems. An early access assay kit 
containing a 180-assay panel was released in early 2005 (TaqMan
®
 miRNA Assays – 
Human Panel Early Access Kit, PN 4365381), which contained assays for most of the 
known human miRNAs at the time.  
1.1.6.3 miRNA detection using locked nucleic acid 
Locked nucleic acid (LNA) is a class of nucleic acid analogues that exhibit high affinity 
for hybridization towards complementary DNA and RNA. The ribose ring of a LNA is 
“locked” by a methylene bridge connecting the 2’-O atom with the 4’-C atom (Figure 
1.4). LNA nucleosides consists six common bases (T, C, G, A, U and mC), which 
enables Watson-Crick base pairing with complementary DNA and RNA nucleotides. 
Because the molecule is ‘locked’ by the methylene bridge, the LNA is constrained in 
the ideal conformation for Watson-Crick base pairing, this improves mismatch 
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Figure 1.3 Two-step stem-loop quantitative reverse transcription PCR (qRT-PCR; 
Chen et al., 2005). 
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Figure 1.4 Molecular structures of DNA, LNA (Locked Nucleic Acid) and RNA  
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discrimination and increases the thermal stability of the resulting duplex (Petersen and 
Wengel, 2003). Since the early application of LNAs for Northern Blotting (Valoczi et 
al., 2004), LNA probes have been widely used for miRNA detection procedures such as 
in situ hybridisation (Bak et al., 2008; Moschos et al., 2007; Schratt et al., 2006; 
Wienholds et al., 2005) and LNA based miRNA microarray expression profiling (da 
Costa Martins et al., 2008; Valadi et al., 2007).    
1.1.7 Modulation of endogenous miRNA function using synthetic 
oligonucleotides  
Applying the advances of RNA interference (RNAi) approaches, miRNA function can 
now be modulated using single stranded antisense oligonucleotides (ASOs). During 
RNAi, small interfering RNA (siRNA) molecules bind to target mRNA by full sequence 
complementarity, which induces endogenous sequence-specific degradation of the 
target mRNA.  Using a similar approach, synthetic miRNA-specific reverse 
complement oligonucleotides can down-regulate the expression of endogenous miRNA 
(Krutzfeldt et al., 2005) or competitively bind to miRNA and prevent the association of 
miRISC (van Rooij et al., 2008a).  
 
To date, a number of anti-miRNA ASOs have been successfully used to inhibit miRNA 
activity in vitro and in vivo. Antagomirs were one of the first such ASOs described. 
They are synthesised with 2’-O-methoxyethyl modified nucleotides on a 
phosphorothioate backbone and contain hydroxyprolinol-linked cholesterol at the 3’ end 
(Krutzfeldt et al., 2005). These modifications reduce RNase-mediated degradation and 
facilitate cellular uptake of the oligonucleotide. Krutzfeldt and colleagues showed the 
intravenous administration of antagomirs to mice significantly decreased targeted 
miRNA levels (Krutzfeldt et al., 2005). 2’O-Methoxyethyl phosphorothioate modified 
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nucleotides without 3’ cholesterol conjugation have also been used to efficiently inhibit 
miRNA in liver (Esau et al., 2006). In addition, oligonucleotides consisting of locked-
nucleic-acid (LNA) modified bases were also used to target and inhibit miRNAs. Elmen 
and colleagues (Elmen et al., 2008) showed mature miR-122, important for lipid 
metabolism, was depleted in non-human primates upon intravenous injections of anti-
miR-122 LNA oligonucleotides, and this led to a significant decrease of plasma 
cholesterol level. LNA modified oligonucleotides are now been evaluated for human 
clinical trials of miRNA inhibition (van Rooij et al., 2008a). These findings suggest 
ASOs are good resources for miRNA functional studies in vitro and in vivo, and as for 
siRNAs, may be important for therapeutic applications. 
1.2 Role of miRNA in the heart 
Heart disease is a major cause of mortality and morbidity world wide. It is a significant 
health burden, one of the largest problems faced by the National Health Service in the 
United Kingdom, accounting for a substantial proportion of healthcare resources 
(Luengo-Fernandez et al., 2006). Common forms of heart disease such as 
cardiomyopathy, hypertensive heart disease, heart failure and ischemic heart disease, 
are caused by a combination of genetic and environmental factors. Much effort has been 
invested into the study of heart diseases at the cellular level, but the molecular 
mechanisms underlying these common diseases remain poorly defined.  
 
The role of miRNAs in the heart was poorly understood at the outset of this study. 
However, over the last few years, studies of miRNAs in the developing and adult heart 
have identified critical roles for miRNAs in normal cardiac function and pathological 
conditions. Heart-specific Dicer knockout mice showed disrupted expression of cardiac 
contractile proteins and profound sarcomere disarray, which leads to dilated 
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cardiomyopathy, left ventricular dysfunction (LVD) and post-natal lethality. 
Intriguingly, Dicer expression is decreased in end-stage human dilated cardiomyopathy 
and LVD (Chen et al., 2008). In other studies, expression profiling revealed miRNA 
expression patterns of foetal heart and that of the adult are different. Interestingly, in 
both human and animal models of cardiac hypertrophy and heart failure, miRNAs that 
are normally only expressed in the foetal heart are re-expressed in the failing heart 
(Thum et al., 2007). Over 100 miRNAs have been shown to be differentially regulated 
in both human and animal models of heart disease, but only a small number of miRNAs 
have been studied at a functional level (reviewed in Latronico et al., 2007 and Thum et 
al., 2008a). A few examples of miRNAs that have been shown to have important roles 
in cardiogenesis and disease pathophysiology are described in this section (Table 1.1). 
1.2.1 miR-1 and miR-133 in cardiogenesis and hypertrophy 
miR-1 and miR-133 are muscle specific miRNAs that have important regulatory roles in 
embryonic heart development and post-natal cardiac physiology. Studies in the mouse 
embryo revealed that both miRNAs are directly controlled by muscle differentiation 
transcription factors including MyoD, Mef2 and serum response factor (SRF). Sequence 
analysis of these transcription factor binding sites in the miRNA promoter regions 
showed this regulatory mechanism is highly conserved across species, including 
humans (Zhao et al., 2005). Although miR-1 and miR-133 are expressed together from 
the same genomic locus in a tissue-specific manner, they have different roles in skeletal 
muscle development (Chen et al., 2006). miR-1 promotes myogenesis through 
inhibition of histone deacetylase 4 (HDAC4), a transcriptional repressor of muscle gene 
expression, whereas miR-133 enhances myoblast proliferation by repressing its own 
transcription factor SRF via a negative regulatory loop. miR-1 is also involved in 
cardiac differentiation, by targeting and inhibiting Hand2, a transcription factor  
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Table 1.1: miRNA functions in the heart.  
 
 
 
*Gene names: Hand2, heart and neural crest derivatives expressed 2; HDAC4, histone 
deacetylase 4; SRF, serum response factor; HERG, potassium voltage-gated channel, 
subfamily H, member 2; RhoA, ras homolog gene family, member A; Cdc-42, cell 
division cycle 42; WHSC2, Wolf-Hirschhorn syndrome candidate 2; SPRY1, sprouty 
homolog 1; COL1A1, collagen type I, alpha 1; COL1A2, collagen type I, alpha 2; 
COL3A1, collagen type III, alpha 2; FBN1, fibrillin 1; THRAP1, thyroid hormone 
receptor associated protein 1 
miRNA Function 
Validated 
target(s)* 
Inhibition of proliferation Hand2 
miR-1 
 
Myogenesis HDAC4 
Promotion of proliferation SRF 
Control of cardiac conductance HERG miR-133 
Inhibition of cardiac hypertrophy 
RhoA, Cdc-42, 
WHSC2 
miR-21 
Reduce cardiac ERK-MAPK and inhibit 
cardiac fibrosis 
SPRY1 
miR-29 Inhibits cardiac fibrosis 
COL1A1, 
COL1A2, 
COL3A1, FBN1 
Stress-dependent cardiac remodelling THRAP1 
miR-208 
Regulation of β-MHC expression  
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important for ventricular cardiac myocyte hyperplasia (Zhao et al., 2005). In addition, a 
study by Lim and colleagues using microarray technology showed overexpression of 
miR-1 in HeLa cells caused a shift in gene expression profile towards the heart and 
skeletal muscle (Lim et al., 2005), indicating miRNAs can down-regulate a large 
number of target mRNA transcripts and define tissue-specific gene expression. 
 
Both miR-1 and miR-133 are also involved in the development of post-natal cardiac 
myocyte pathophysiology. Care et al. (2007) showed a decrease in miR-1 and miR-133 
expression in cultured cardiac myocytes treated with phenylephrine (PE) and in the 
ventricular tissue of mice induced with transverse aortic constriction (TAC), a widely 
used in vivo model of cardiac hypertrophy. Interestingly, expression levels of these 
miRNAs are also decreased in the ventricles of exercise-trained wild type mice and in 
the cardiac-specific Akt transgenic mouse (Care et al., 2007). Therefore, miR-1 and 
miR-133 are implicated in cardiac myocyte hypertrophy irrespective of the nature of 
underlying cause. Further studies of miR-133 have shown overexpression of miR-133a-
2 in cultured cardiac myocytes abolishes the hypertrophic response to PE stimulation, 
and in vivo administration of antagomir-133 via osmotic pump in mice induced 
hypertrophy. In silico and experimental target analyses of miR-133 revealed that RhoA, 
a GDP-GTP exchange protein regulating cardiac hypertrophy, Cdc42, a signal 
transduction kinase implicated in hypertrophy, and Nelf-A/WHSC2, a nuclear factor 
involved in cardiogenesis, are all targets of miR-133 (Care et al., 2007).  
 
In a time course study performed by Sayed et al., more than 50 miRNAs were 
differentially regulated during the development of pressure overload-induced cardiac 
hypertrophy (Sayed et al., 2007). Amongst these miRNAs, miR-1 was downregulated 
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soon after TAC (day 1), and its expression was at the lowest at day 7, following which it 
recovered and was normal by day 14 post-TAC. Viral overexpression of miR-1 
inhibited serum-induced hypertrophic growth and growth-related target genes, including 
Ras GTPase-activating protein (RasGAP), cyclin-dependent kinase 9 (Cdk9), 
fibronectin, and Ras homolog enriched in brain (Rheb) in cultured neonatal cardiac 
myocytes. In separate studies by Yang et al. and Luo et al., miR-1 and miR-133 were 
shown to have an important role in arrhythmogenesis through inhibition of HCN2 and 
HCN4, which encode the hyperpolarization-activated channels in the heart (Luo et al., 
2008; Yang et al., 2007). HCN2 and HCN4 proteins are upregulated during hypertrophy, 
and this was accompanied by pronounced reduction of miR-1 and miR-133 levels. 
Forced expression of both miRNAs prevented the overexpression of HCN2 and HCN4 
in hypertrophied cardiac myocytes (Luo et al., 2008), suggesting a causal relationship 
between miR-1 and miR-133 and HCN2/HCN4.      
1.2.2  A role for miR-208 following hypertrophic stimulation in vivo 
Cardiac hypertrophy is associated with upregulation of the foetal genes such as atrial 
natriuretic factor (ANF), brain natriuretic factor (BNF) and β-myosin heavy chain (β-
MHC). In the heart, the genes encoding the two isoforms of MHC (α and β) are located 
in tandem, separated by 4.5kb of intergenic sequence, with β-MHC gene located 5’ 
upstream of the α-MHC gene (Mahdavi et al., 1984). miR-208 is encoded in intron 27 
of the human and mouse α-MHC genes, and controls regulation of β-MHC only in 
conditions of stress, not during normal cardiac development (van Rooij et al., 2007). 
The miR-208 knockout mouse is viable without an obvious cardiac phenotype at 
baseline apart from the upregulation of fast skeletal muscle contractile proteins and 
‘stress proteins’ (ANF and BNF) at baseline. These genes are not direct targets of miR-
208. When the knockout animals were subjected to TAC, they failed to produce 
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hypertrophic and fibrotic responses to pressure overload. In addition, apart from the 
expected upregulation of stress markers (such as ANF and BNP), an increase in β-MHC 
was not observed. In contrast, α-MHC was increased, rather than reduced. The protein 
product of a predicted miR-208 target, thyroid hormone receptor (TR)-associated 
protein 1 (THRAP1), the TR coregulator, was increased in miR-208 knockout mice. 
Treating the knockout animals with stress stimuli that cause reduction of α-MHC 
transcription also reduced the level of the pri-miR-208, which in turn relieves 
transcriptional repression on its target mRNA, thrap1. The resulting increase in 
THRAP1 protein influences the TR-regulated expression of both α- and β-MHC. 
Therefore, at least in mouse heart, miR-208 appears to mediate the switch from the 
expression of α-MHC to that of β-MHC during stress or thyroid hormone induced 
cardiac growth.  
1.2.3 A Role for miR-29 in cardiac fibrosis 
The expression patterns of miRNAs in mice and humans after myocardial infarction 
(MI) were examined by van Rooij et al. (2008b), which revealed dynamic regulation of 
miRNA expression during post-MI remodelling in both humans and mouse. Five 
miRNAs were found to have altered expression levels (miR-21, miR214 and miR-223 
were upregulated; miR-29b and miR-149 were downregulated). Among the 
differentially regulated miRNAs, all members of the miR-29 family were 
downregulated. In vitro experiments confirmed miR-29 targets a group of key mRNA 
that encode fibrosis related proteins such as collagens and fibrillins, and the expression 
level of miR-29 in cardiac fibroblasts were considerably (5- to 12-fold) higher than in 
the cardiac myocytes. Systemic in vivo silencing of miR-29b using miR-29b specific 
antagomirs led to the induction of collagen mRNA expression in the heart. These data 
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suggest miR-29 functions as a negative regulator of collagen gene expression in the 
heart. 
1.2.4 Gene regulation by miR-21 in cardiac fibroblasts 
In addition to miR-29, miR-21 also has an important role in cardiac fibroblast 
function/activity of the failing heart. Thum and colleagues investigated the expression 
profile of miRNAs in a transgenic mouse model of heart failure (β1-adrenergic receptor 
transgenic mice; Engelhardt et al., 1999), and identified that miR-21 expression is the 
most differentially regulated out of all miRNAs studied. Further experiments confirmed 
miR-21 to be significantly upregulated in other animal models of heart disease as well 
as in human heart failure (Thum et al., 2008b). Expression analysis across cell types 
using quantitative-PCR (q-PCR) showed miR-21 to be most highly expressed in cardiac 
fibroblasts and with low levels of expression in cardiac myocytes. While miR-21 levels 
increased in fibroblasts during heart failure, it was unchanged in cardiac myocytes. In 
functional studies, miR-21 regulated fibroblast survival and growth factor secretion via 
the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) 
pathway, which is implicated in interstitial fibrosis. This control is mediated through the 
direct inhibition of a potent inhibitor of the ERK pathway, SPRY1 (sprouty homologue 
1) by miR-21. In vivo silencing of miR-21 in a mouse pressure-overload-induced 
disease model (TAC) reduced cardiac ERK/MAPK activity and inhibited interstitial 
fibrosis and attenuated cardiac dysfunction.  
1.3 Role for miRNAs in Type 2 Diabetes and diabetic heart  
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterised by whole body 
insulin resistance, relative insulin deficiency and hyperglycaemia. In insulin resistant 
conditions, tissues fail to respond to insulin stimulation, there is a decrease in glucose 
uptake in skeletal muscle and blood glucose levels are increased (hyperglycaemia; 
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Shulman, 2000). As an insulin sensitive organ, the heart is affected by insulin resistance 
states. Patients with T2DM are at increased risk of developing heart diseases such as 
coronary artery disease (CAD) and LVD (Grundy et al., 1999; Nathan et al., 1997). As 
mentioned in the previous section, miRNAs have shown to have important functions in 
cardiac development and cardiac hypertrophy, however, their involvement in the 
diabetic heart and insulin resistance related LVD is still largely unknown. A number of 
miRNAs have recently been implicated in the regulation of insulin secretion and 
glucose homeostasis, suggesting their possible roles in T2DM and insulin resistance.  
1.3.1 miR-375 regulates exocytosis of insulin in the pancreas 
miR-375 is an important regulator of insulin exocytosis in the pancreatic islet. Poy and 
colleagues discovered that overexpression of miR-375 in pancreatic cell lines decreased 
glucose-induced insulin secretion with no alterations in glucose-mediated production of 
ATP. Furthermore, repression of miR-375 increased glucose-stimulated secretion of 
insulin. Myotrophin, a protein implicated in exocytosis, was identified as a direct target 
of miR-375. Interaction of miR-375 and the 3’UTR of myotrophin resulted in the 
repression of myotrophin translocation and inhibited insulin secretion (Poy et al., 2004). 
In addition to exocytosis, myotrophin also activate nuclear factor-κB (NFκB, p65) in 
cardiac myocytes (Gupta et al., 2002), which is associated with cardiac hypertrophy. 
NFκB activity in the pancreatic beta cells also associates with cytoskeleton remodelling, 
which results in increased glucose-stimulated insulin secretion (Hammar et al., 2005). 
Further investigations on the interaction of miR-375 or other miRNAs with myotrophin 
and NFκB in other systems such as the heart may provide insights to the function of 
miRNA in the insulin resistant heart.    
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1.3.2 miR-29 and insulin resistance 
Two members of miR-29 family (miR-29a and miR-29b) were identified as upregulated 
in muscle, fat and liver of Goto–Kakizaki (GK) rats, a non-obese model of type 2 
diabetes, as compared to control animals (He et al., 2007). Overexpression of miR-
29a/b/c in 3T3-L1 adipocytes, a murine insulin-responsive fat cell line, inhibited 
insulin-stimulated glucose uptake. High levels of miR-29 led to insulin resistance 
mimicking the insulin resistance in cells incubated with high glucose and high insulin. 
miR-29a and miR-29b levels were upregulated in the presence of high glucose 
(hyperglycemia) and high insulin (hyperinsulinemia) in 3T3-L1 adipocytes. Insig1 
(insulin-induced gene 1), an ER membrane protein that is involved in the control of 
cholesterol biosynthesis and Cav2 (caveolin 2) have been validated as targets of miR-
29a/b/c (He et al., 2007).  
1.3.3 miR-133 in diabetic heart 
Apart from its role in cardiac hypertrophy, miR-133 was also identified to be 
differentially expressed in diabetic hearts (Xiao et al., 2007b). The upregulation of miR-
133 in diabetic rabbit hearts was induced by the serum response factor (SRF), which 
was robustly activated in the diabetic heart.  Delivery of exogenous miR-133 into the 
rabbit myocytes and cell lines led to post-transcriptional repression of HERG, the ether-
a-go-go-related gene that encodes cardiac potassium channel responsible for rapid 
delayed rectifier K
+
 current (I(Kr)). This caused substantial depression of I(Kr), and the 
effect was abrogated by inhibition of miR-133. Silencing of SRF downregulated miR-
133 expression and increased I(Kr) density. Repression of ERG by miR-133 is likely to 
be reflected by the differential changes of ERG protein and transcript, and thereby 
depresses I(Kr), which contributes to repolarization and the associated arrhythmias in 
diabetic hearts (Xiao et al., 2007b). 
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Collectively, these findings suggest the importance of miRNA mediated gene regulation 
in insulin resistance and possibly type 2 diabetes. However the role of miRNA in insulin 
signalling and glucose metabolism in the heart is still to be identified.   
1.4 Insulin resistance and diabetic heart disease  
Type 2 diabetic patients can develop cardiac function abnormalities even in the absence 
of predisposing conditions such as hypertension and CAD (Shishehbor et al., 2003). 
One of the earliest cardiac abnormalities that these patients develop is left ventricular 
diastolic dysfunction, which has been reported in 60% of patients with well-controlled 
T2DM (Poirier et al., 2001). In insulin resistant conditions, cardiac energy metabolism 
is impaired, left ventricular hypertrophy may develop and fibrosis is common, which 
causes increase in stiffness of the ventricular wall and impaired relaxation, leading to 
diastolic dysfunction (Gonzalez-Vilchez et al., 2005; Zarich et al., 1988). Additionally, 
systolic abnormalities may develop, these include, shortened systolic ejection time, 
diminished ejection fraction (EF) and increased systolic dimension and mass (Gonzalez-
Vilchez et al., 2005; Sykes et al., 1977). If insulin resistance and the symptoms of LVD 
are left untreated, heart function can deteriorate further and heart failure symptoms and 
signs worsen. This section reviews current findings on insulin signalling in the heart and 
the molecular effects of insulin resistance on cardiac metabolism.     
1.4.1 Insulin signalling in the heart 
Insulin plays a key role in regulating glucose uptake and utilisation in the heart. Under 
normal physiological conditions, when blood glucose levels are high, insulin induces 
cardiac myocyte glucose uptake by binding to the tetrameric insulin receptor (IR), 
which consists of two extracellular α-subunits and two transmembrane β-subunits. The 
binding of insulin to the extracellular subunits of the receptor induces the activation of 
the tyrosine kinase activity of the β-subunits (Ottensmeyer et al., 2000), triggering the 
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autotransphosphorylation of the receptor where one β-subunit phosphorylates the other 
on several tyrosine residues. Once activated, the IR recruits and phosphorylates a 
number of downstream targets including the IR substrate (IRS) family, which in turn 
recruits and activates the phosphoinositide 3-kinases (PI3K) at the plasma membrane 
(Bertrand et al., 2008; Hirsch et al., 2007). PI3K is a heterodimeric protein composed of 
a p110 catalytic and a p85 regulatory subunit; it phosphorylates PI phosphates at the 3’ 
position. The main product of PI3K is PI3,4,5P3 (PIP3) produced from the PI4,5P2. 
Increase in PIP3 concentration in the plasma membrane induces the translocation of 
phosphoinositide-dependent kinase 1 (PDK1) and Akt (also known as Protein Kinase B, 
PKB) to the plasma membrane. PDK1 phosphorylates and activates Akt (Thr 308), 
which in turn, promotes the translocation of insulin sensitive glucose transporter 
(GLUT4) from the cytoplasm to the sarcolemmal membrane, to allow glucose entry into 
the myocyte (Zorzano et al., 1997; Figure 1.5).  
 
Although the IR/PI3K/Akt pathway is well defined, in the heart, the downstream 
elements regulating glucose uptake are less well understood. Indeed, it was only 
recently shown that the Rab GTPase-activating protein (GAP) Akt substrate 160 
(AS160) is required for membrane trafficking of the GLUT4 containing vesicles. 
Insulin induces phosphorylation of AS160, which leads to its inactivation, this prevents 
Rab GAP function and promotes GLUT4 translocation to the plasma membrane 
(Kramer et al., 2006; Miinea et al., 2005). Apart from signalling through Akt, insulin 
can also regulate glucose uptake via other PDK1 substrates, including the atypical 
protein kinase C (PKC) λ/ζ family, which has been implicated in GLUT4 membrane 
translocation (Farese et al., 2005). Other signalling pathways regulating GLUT4 
translocation following insulin stimulation have also been described (Chang et al., 2004,  
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Figure 1.5 The insulin signalling pathway 
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2007; Watson and Pessin, 2007), however these mechanisms have not been studied in 
detail in the heart. 
 
Apart from regulating glucose uptake, insulin signalling also controls protein synthesis 
in cardiac myocytes through modulation of several key translation factors and ribosomal 
proteins. Upon activation, Akt phosphorylates and inactivates the tuberous sclerosis 
factor (TSC2), a GAP of the G protein Rheb, which induces the activation of Rheb and 
in turn induces the phosphorylation and activation of mTOR (Inoki et al., 2002; Potter 
et al., 2002). The 4E-binding protein-1 (4E-BP1) and p70 ribosomal S6 protein kinase 
(p70S6K) are the main downstream targets of mTOR, where phosphorylation of both 
elements promotes protein translation (Pham et al., 2000; Proud and Denton, 1997; 
Rolfe et al., 2005). In addition, Akt can also inhibit GSK-3β (by phosphorylation of 
serine 9; Cross et al., 1995), which in turn activates eIF2B (eukaryotic initiation factor 
2B), and thus induces protein synthesis (Welsh et al., 1997). GSK-3β and mTOR also 
play key roles in the development of cardiac hypertrophy (Frey and Olson, 2003) and 
this emphasises the central role for insulin in the regulation of cardiac hypertrophy.  
1.4.1.1 Altered signalling in insulin resistant states 
Insulin resistance is characterised by perturbed insulin-induced activation of the 
PI3K/Akt signalling pathway. Dysregulated insulin signalling can be mediated through 
diacylglycerol accumulation, which activates PKCs that in turn provoke serine 
phosphorylation of IRS1, as a result inhibiting the PI3K/Akt pathway (Savage et al., 
2005). Or, insulin signalling by itself can activate negative feedback, where Ser/Thr 
kinases including mTOR and PKCλζ mediate phosphorylation (at serine/threonine  
residues) and inhibition of IRS proteins (Liu et al., 2001; Zick, 2005). Abnormal fatty 
acid metabolism also plays a major role in cellular insulin resistance (Shulman, 2000).   
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1.4.2 Glucose uptake and cardiac metabolism 
The heart requires large amount of energy and oxygen to sustain its uninterrupted 
contraction/relaxation cycle. About 2% of total cellular ATP is consumed in each heart 
beat in the rat (Jacobus, 1985). In the normal heart, ATP generation comes from 
mitochondrial oxidation of different substrates, consisting 60-70% fatty acid (FA), 20% 
glucose and 10% lactate (Neely et al., 1972; Saddik and Lopaschuk, 1991). However, 
when circulating glucose and insulin concentrations rise, glucose becomes the favoured 
oxidised substrate of the heart. In T2DM, glucose uptake, glycolysis and pyruvate 
oxidation are impaired, lack of insulin function augments lipolysis and release of FA 
from the adipose tissue. The heart rapidly adapts to use FA exclusively for ATP 
production; this adaptation has a major role in the chronic development of diabetic 
cardiomyopathy. 
 
Under normal physiological conditions, glucose is one of the major carbohydrates 
utilised by the heart. Cardiac glucose uptake is dependent on the transmembrane 
glucose gradient and the content of sarcolemmal glucose transporters (GLUT1 and 
GLUT4). GLUT1 is mostly localised in the sarcolemmal membrane and is responsible 
for basal cardiac glucose uptake. GLUT4 is the insulin-sensitive adult glucose 
transporter, and the majority of this isoform is located in an intracellular compartment 
under basal conditions. The translocation of GLUT4 from the cytosol to the plasma 
membrane requires insulin stimulation (Luiken et al., 2004b). Independent of insulin 
stimulation, GLUT4-mediated glucose uptake can also be induced by AMPK, which 
promotes GLUT4 redistribution to the sarcolemmal membrane (Li et al., 2004; Yang 
and Holman, 2005). Following translocation, glucose is converted to pyruvate through 
glycolysis, and the pyruvate produced is converted to acetyl-CoA by decarboxylation, 
Chapter One 
46 
which enters the Citric Acid Cycle to be broken down into H2O and CO2 for ATP 
generation. Oxidation of one glucose molecule provides 30 ATP with 6 oxygen 
consumed.  
1.4.2.1 Altered cardiac metabolism during insulin resistance 
As compared with glucose, FA is the preferred substrate for ATP production in the 
normal heart. The ability to metabolise glucose provides an alternative energy source 
for the heart, especially under stressed conditions such as ischemia and pressure 
overload.  However, in insulin resistant states, cardiac myocytes fail to take up 
circulating glucose due to the diminished response to insulin stimulation and the heart 
remains dependent on FA metabolism for energy generation. In patients with T2DM, 
enhanced lipolysis in adipose tissue and higher lipoprotein synthesis by the liver 
increases circulating free FA and triglycerides, this results in increased FA delivery to 
the cardiac myocytes. Although the heart adapts to utilise FA, when FA supply exceeds 
the oxidative capacity, the FA is converted to triglycerides or ceramide, which may 
worsen myocardial insulin resistance (Hajduch et al., 2008).  
 
The reliance on lipid metabolism in insulin resistant states increases the intracellular 
glycogen pool through increased glycogen synthesis and/or impaired glycogenolysis 
(Higuchi et al., 1995; Laughlin et al., 1990). If glycogen accumulation persists, it may 
also directly impair insulin signalling (Jensen et al., 2006). The identification of a 
glycogen binding domain in AMPK suggests a possible role for the kinase in the 
regulation of glycogen metabolism (Hudson et al., 2003). Indeed, additional studies 
show that AMPK mutations can affect glycogen metabolism (Arad et al., 2002), 
whereas
 
primary defects in glycogen metabolism activate AMPK while decreasing 
glycogen synthase activity (Nielsen et al., 2002)..      
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1.4.3 Regulation of GLUT4 translocation and expression 
As a result of its hydrophilic properties, glucose cannot pass through a lipid bilayer by 
diffusion. Instead, glucose enters the cell through glucose transporter-mediated import. 
Like many other inducible substrate transporters in the heart (e.g. long-chain fatty acids 
transporter fatty acid translocase FAT/CD36; Luiken et al., 2004a), GLUT4 is located in 
both sarcolemma and intracellular compartments. Following insulin stimulation, 
GLUT4 located in the intracellular pool is activated and translocated to the sarcolemma. 
In cardiac myocytes, GLUT4 is stored in two distinct compartments, the non-endosomal 
compartment (mainly for storage) and the endosomal compartment within the recycling 
endosomes (Fischer et al., 1997). Most GLUT4 molecules are stored in the non-
endosomal compartment. Following insulin stimulation, GLUT4 vesicles translocate 
from the non-endosomal compartment to the recycling endosome and from there to the 
plasma membrane.  
1.4.3.1 Translocation of GLUT4 
Translocation of GLUT4 from the cytoplasm to the plasma membrane is a vesicle-
mediated process. Irrespective of the specific signal transduction pathways required, 
they must impinge upon the GLUT4 storage compartments to induce GLUT4 
trafficking. Thus, regulation of substrate uptake can occur via vesicle biogenesis, and its 
translocation to the cell membrane or exocytosis. Glucose transporter vesicles form the 
major part of insulin-responsive compartments (IRC).  Although the mechanisms of 
GLUT4 vesicle biogenesis in the heart remain unclear, studies in adipocytes and muscle 
cells have shown these compartments are enriched for GLUT4, IRAP (insulin-regulated 
aminopeptidase) and VAMP2 (vesicle-associated membrane protein-2), but are absent 
of the small vesicle transport marker cellugyrin and endosome markers EEA1 and 
transferring receptor (Martin et al., 1996; Zeigerer et al., 2002). Coat and adaptor 
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proteins (e.g AP1) are recruited during vesicle formation, which drive the formation of 
the budding compartments on the donor membranes of the Golgi apparatus.  In turn, the 
coat and adaptor proteins associate with donor membranes through interactions with 
cytoplasmic tails of cargo proteins (Gillingham et al., 1999; Li and Kandror, 2005). In 
addition, Golgi-localised γ-ear-containing Arf-binding protein (GGA) of coat adaptor 
proteins has been identified as a requirement for the sorting of GLUT4 protein from the 
Golgi to the IRC, but not from the IRC to the plasma membrane under the stimulation 
of insulin (Hou et al., 2006; Li and Kandror, 2005). 
 
Despite intense investigation, the precise sub-cellular location and trafficking pathway 
of GLUT4 containing vesicles are still largely unclear. Studies in cultured adipocytes 
using GLUT4-GFP (green fluorescent protein) fusion proteins suggested the GLUT4 
pool is peri-nuclear localised, and undergoes enhanced exocytosis and trafficking to the 
plasma membrane by insulin regulation (Zeigerer et al., 2002). A more recent study 
suggests GLUT4 vesicles are continuously trafficking to and from plasma membrane in 
absence of insulin. During insulin stimulation, these vesicles have increased pausing at 
the plasma membrane with higher probability of membrane fusion (Lizunov et al., 
2005). The processes of docking, pausing (or tethering) and fusion of vesicles is again 
poorly understood. The docking of GLUT4 vesicles by the plasma membrane appears to 
require the exocytosis complex, where three components, Exo70, Sec6 and Sec8, 
redistributes to the plasma membrane in response to insulin (Ewart et al., 2005). Once at 
the membrane, SNARE (SNAP and NSF attachment receptors) complex proteins are 
required for the fusion of the vesicles. (Hong, 2005), of which VAMP2 is the 
predominant SNARE required for insulin stimulated GLUT4 translocation (Randhawa 
et al., 2000).  
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1.4.3.2 Expression of GLUT4 
In addition to GLUT4 translocation, glucose uptake can also be regulated by controlling 
the expression of the GLUT4 protein. Regulation of GLUT4 gene transcription is 
conferred within a 2.4kb promoter region of the DNA. This region contains a MEF2 
binding domain at position between -466 and -457, relative to transcription initiation 
site, which are essential for regulation of tissue specific expression of the gene (Thai et 
al., 1998). Two other regulatory factor binding sites have also been identified: thyroid 
hormone receptor binding site located between -457 and -426, and MyoD binding site, 
which is located next to the MEF2 site. It was found in rat cardiac muscle that full 
activation of GLUT4 transcription required the cooperation of these three elements and 
the presence a 82bp enhancer (at -502/-420) (Santalucia et al., 2001).       
 
Insulin increases glucose uptake by stimulating GLUT4 translocation. In insulin 
resistant states, insulin-stimulated glucose uptake is decreased. GLUT4 protein and 
mRNA levels are decreased in adipose tissue during insulin resistance, however, 
regulation of GLUT4 expression by insulin is only observed in certain muscle cell types 
(Camps et al., 1992), suggesting insulin is only able to regulate GLUT4 gene expression 
in specific cell types/states. Insulin resistance associated with T2DM does not appear to 
be linked to changes in GLUT4 expression in skeletal muscle (Dohm et al., 1991; 
Handberg et al., 1990; Pedersen et al., 1990), and reduction in glucose uptake in the 
skeletal muscle in diabetic patients is not solely a result of deficient expression of 
GLUT4 (Friedman et al., 1992), but predominantly due to the failure of insulin 
stimulated recruitment of GLUT4 to the cell surface. In the heart however, studies in 
cultured rat cardiac myocytes revealed an increase in glut4 transcription and mRNA 
levels following insulin stimulation (Petersen et al., 1995). Promoter studies in human 
Glut4 have identified a fragment of DNA located in the promoter region (between -1154 
Chapter One 
50 
and -730) that allows insulin dependent regulation in adipose tissue and cardiac muscle 
(Olson and Pessin, 1995). Indeed, members of nuclear factor I (NFI) family of 
transcription factors have been identified to mediate GLUT4 expression in adipocytes 
by binding to the insulin response element in the presence of insulin stimulation (Cooke 
and Lane, 1999b). However, transcription factors and enhancers involved in insulin 
mediated transcription of GLUT4 in the heart are still yet to be identified.   
1.5 Aims of the Study 
 
Previous studies have shown that miRNAs have important role(s) in heart development, 
cardiac hypertrophy and the development of metabolic disease. This PhD thesis 
characterises miRNAs in the insulin resistant heart, and determines a role of miRNAs in 
the pathophysiology of cardiac insulin resistance using in vitro and in vivo 
methodologies.  
 
The specific aims of the study were: 
1. To establish the experimental methodologies for miRNA studies in the host 
laboratory  
2. To determine the expression of miRNAs in the normal human heart  
3. To identify differentially expressed miRNAs in the insulin resistant human 
heart.  
4. To prioritise miRNA(s) of interest and characterise their role in the heart. 
5. To validate mRNA targets of miRNA(s) of interest using bioinformatic and 
experimental approaches.  
6. To determine the function of miRNA(s) of interest using in vitro and in vivo 
methodologies 
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CHAPTER TWO 
General materials and methods 
Details of buffers and media used in this dissertation can be found in Appendix A. 
Maps of all plasmids can be found in Appendix B. Sequence information on primers 
can be found in Appendix C.  
2.1 RNA isolation, quantification and quality check 
2.1.1 RNA isolation 
Total RNA was extracted using Trizol reagent (Invitrogen, Paisley, UK), and small 
RNA samples were then purified using mirVana™ miRNA Isolation kit (Ambion, 
Applied Biosystems, Austin, Texas, USA). This procedure isolated total small RNA 
species (<200nt) from large RNAs as separate samples, in accordance with the 
manufacturer’s protocol. In all instances, RNA was extracted from 20 – 50 mg of 
human or rodent tissue. Tissue samples were first homogenised in 1ml of Trizol, then 
treated with chloroform (200µl). The Phenol-chloroform phase and the aqueous phases 
were separated by centrifugation (12 000 × g, 4°C, 20 min). Total RNA was precipitated 
from the aqueous phase using isopropyl alcohol (0.5ml, Sigma) and washed with 75% 
ethanol (v/v; 1ml). After air-drying, the pellet was dissolved in RNase free water 
(Sigma). To extract RNA from cultured cells, 1ml of Trizol agent was added directly to 
the cells that were washed in cold phosphate buffered saline (PBS). For preparation of 
RNA samples enriched with small RNA and large RNA respectively, total RNA 
samples from the Trizol extraction were mixed with the Lysis/Binding Buffer and 
miRNA Homogenate Additive, then mixed with 100% ethanol (1/3 volume for large 
RNA and 2/3 volume for small RNA) to precipitate RNAs of difference sizes using two 
glass fibre filters. While attached to the filters, each RNA sample was washed with 
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Washing Buffers 1, 2 and 3. Each RNA sample was then eluted in 60µl of Elution 
Solution.   
 
For preliminary assessment, sample concentration were measured by spectrophotometry 
(NanoDrop Technology, Delaware, USA) and the RNA quality was determined by the 
260/280 absorbance ratio (acceptable ratio >1.9). For the initial study of miRNA 
expression in human heart samples, RNA integrity was assessed using both the RNA 
6000 Nano (for total RNA samples) and the Picochip (for small RNA samples; Agilent 
2100 Bioanalyser; Agilent Technologies) according to the manufacture’s protocols. 
250ng (Nanochip) or 2.5ng (Picochip) of each sample was used for the analyses. In 
preparation for qRT-PCR analysis, RNA concentrations of human samples were also 
determined using RiboGreen (Invitrogen) based on standard curve analysis (Section 
2.1.2). Quantified samples were diluted with RNase free water accordingly. 
2.1.2 RNA quantification using RiboGreen® 
RiboGreen
® 
RNA quantitation reagent (Invitrogen) is a fluorescent RNA stain used for 
RNA quantification. The quantification was carried out following the manufacturer’s 
protocol. In brief, RiboGreen reagent and RNA samples were diluted in nuclease free 
1×TE (Tris-EDTA, Invitrogen) buffer respectively. The standard curve samples were 
also prepared in 1×TE buffer consisting 7 concentration points ranging from 3µg/ml to 
47ng/ml (Figure 2.1). Small RNA and large RNA stock samples were used for the 
standard curve accordingly for small RNA and large RNA quantifications. For each 
sample 100µl of diluted RNA was mixed with 100µl of diluted RiboGreen
®
. Mixtures 
were incubated for 5 min at room temperature before analysing on the fluorescent plate 
reader (FLUOStar OPTIMA, BMG Labtech, Aylebury UK). RNA sample 
concentrations were calculated from the standard curve based on the equation: 
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Figure 2.1 Standard curve of small RNA concentration in relation to RiboGreen 
fluorescent level. The graph plots the mean fluorescent level (determined by optical 
density) against the RNA concentration of each sample. Small RNAs were purified 
using mirVana miRNA Isolation Kit (Ambion) and concentrations of 47, 94, 187, 375, 
750, 1500 and 3000ng/ml were used for the standard curve. 100µl of diluted RNA 
samples were mixed with 100µl of Ribogreen (1×). Levels of flourscence were read in 
duplicate. Fluorescent level of both the standard curve samples and RNA samples for 
quantification were read on one plate using FLUOstar OPTIMA spectrophotometer. 
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y = mx + c, where y = fluorescence, m = slope of standard curve, x = concentration in 
ng/ml, and c = y intercept.  
2.1.3 Agilent Bioanalyser 
The Agilent 2100 Bioanalyzer (Agilent Technology) is a microfluidics-based platform 
that can be used for the analysis of DNA, RNA, protein and cells. It performs capillary 
electrophoresis on a microchip, which uses microchannels (Ogura et al., 1998; Woolley 
and Mathies, 1994). The Bioanalyzer applies electrophoretic and electro-osmotic forces 
to drive fluids through capillaries to produce a virtual gel image and an 
electropherogram of the sample. Total RNA integrity check is one of the major 
applications of the Bioanalyzer. Using the RNA 6000 Chip, a high quality total RNA 
sample produces two dominating but distinct bands representing the 18S and 28S 
ribosomal RNA (rRNA), with a ratio 28S/18S of 2. However, a degraded total RNA 
sample produces more fragmented bands with a much lower 28S/18S ratio (Auer et al., 
2003). In addition to total RNAs, the RNA 6000 chip can also be used to detect the 
integrity of samples enriched with small RNAs (Goff et al., 2005). Indeed, a RNA Chip 
designed for small RNA analysis was developed in 2007 (Agilent Technology). This 
allows the separation of various species of small RNA, including miRNAs, thus enables 
the user to identify small RNAs in total RNA extracts as well as optimising miRNA 
extraction procedures.  
 
In this study, to assess RNA quality, 1µl of RNA (2.5ng or 250ng) from each sample 
was tested using the Agilent Bioanalyser RNA 6000 pico or nano assay. Before use, the 
Bioanalyser electrodes were cleaned by applying 350µl of RNAZap (Ambion, 
Huntington, UK) for one min followed by 350µl of water for 10 seconds. The electrodes 
were then allowed to dry. Filtered gel matrix was prepared by pipetting 550µl of RNA 
matrix into a spin filter and centrifuging at 1500 × g for 10 min. This was aliquoted into 
Chapter Two 
55 
65µl aliquots for use. Immediately prior to running the Bioanalyser assay 1µl of 
vortexed RNA dye concentrate was added to a 65µl aliquot of filtered gel matrix and 
centrifuged at 13,000 × g for 10 min. 9µl of this gel dye mix was used to prepare the 
RNA 6000 nanochip in the chip priming station. Once the chip was primed another 9µl 
was pipetted into each well of the chip marked with a G. 5µl of RNA 6000 Nano 
Marker was added to the remaining 13 wells of the chip. 1µl of each sample and 1µl of 
RNA 6000 Ladder were denatured at 70
o
C for 2 min and placed on ice before being 
added to the wells on the chip. The chip was then vortexed for 1 min and using the 
Eukaryotic total RNA Nano assay. Procedures for using the RNA 6000 Pico assay are 
the same as the Nano assay, except Pico Assay specific reagents and settings were used 
and only 2.5ng of each RNA sample were tested. 
2.2 qRT-PCR 
2.2.1 TaqMan based qRT-PCR for miRNA using stem-loop RT 
primers  
Specific mature miRNA expression levels were quantified by TaqMan
®
 MicroRNA 
Assays (Applied Biosystems) using stem-loop primers for reverse transcription (RT) 
followed by q-PCR. For RT, each reaction contained 1mM dNTPs, 50U of 
MultiScibe™ Reverse Transcriptase, 3.76U of RNase Inhibitor, 3µl of RT-primer (5× 
concentration) and 5ng of small RNA sample, quantified by the standard curve method 
using RiboGreen (Section 2.1.2). Reactions were incubated for 30 min at 16°C, 30 min 
at 42°C and 3 min at 85°C. The q-PCR reaction was set up based on the concentrations 
and volumes recommended in the TaqMan 2× Universal PCR Master Mix (No 
AmpErase UNG) and TaqMan MicroRNA Assay protocols (Applied Biosystems). The 
reaction was performed on the 7500 Fast Real Time PCR Sequence Detection machine 
(Applied Biosystems) under the following conditions: 10 min at 95°C followed by 40 
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cycles of 15 seconds at 95°C, 60 seconds at 60°C, with data collection at end of each 
cycle. Each RT step was performed in duplicate, and for each RT reaction, the q-PCR 
step was performed twice. For qRT-PCR performed for validation and subsequent 
functional analyses, individual TaqMan MicroRNA Assays (purchased from Applied 
Biosystems) were used (Table 2.1). 5ng of small RNA sample was used in each 
reaction. All TaqMan probes were FAM labelled. 
2.2.2 Two-step qRT-PCR mRNA assays 
Total RNA was extracted, purified and quantified as described in Section 2.1. Samples 
were DNase treated by mixing 1µg of total RNA with 1µl of DNase I (Invitrogen), 1µl 
of 10×DNase I Reaction Buffer (Invitrogen) in a 10µl reaction and incubating at room 
temperature for 15 min. cDNA were synthesised using iScript™ cDNA Synthesis Kit 
(Bio-Rad) following manufacturer’s protocol. In brief, each 20µl reaction contained 1µg 
of total RNA, 4µl of 5×iScript Reaction Mix, 1µl of iScript Reverse transcriptase. The 
reaction mix was incubated at 25°C for 5 min, 42°C for 30 min and 85°C for 5 min. For 
SYBR
®
 Green based q-PCR, the 25µl reaction contained 12.5µl of SYBR
®
 Green 
JumpStart Taq Ready Mix (Sigma), 200nM of each primer and 10ng cDNA (from 
iScript cDNA synthesis). Cycling conditions were: 94°C for 2 min followed by 40 
cycles of 94°C for 15 seconds, 60°C for 1 min and 72°C for 1 min, with data collection 
at the end of each cycle. Dissociation analysis (melt curve) was performed at the end of 
each SYBR PCR run to verify the presence of a single amplification product. PCR 
primers were designed by using Primer 3 (http http://frodo.wi.mit.edu; Misener and 
Krawetz, 2000). Primer pair selection criteria were: 17-22 nucleotides (nt) in length, at 
least one GC clamp on the 3’ end; GC content between 40 and 60%; non- 
complementary 3' ends in primer pairs; and the difference of melting temperatures (Tm) 
is < 1°C. Primers were designed using mRNA transcript sequences, with primers 
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Table 2.1 List of Individual TaqMan MicroRNA Assays used* 
 
miRNA ID Product Number Target Sequence 
Let-7a 4373169 UGAGGUAGUAGGUUGUAUAGUU 
miR-16 4365552 UGUCAGUUUGUCAAAUACCCC 
miR-29b 4373288 UAGCACCAUUUGAAAUCAGUGUU 
miR-30b 4373290 UGUAAACAUCCUACACUCAGCU 
miR-34a 4395168 UGGCAGUGUCUUAGCUGGUUGU 
miR-125b 4373148 UCCCUGAGACCCUAACUUGUGA 
miR-187 4373307 UCGUGUCUUGUGUUGCAGCCGG 
miR-199a 4373272 CCCAGUGUUCAGACUACCUGUUC 
miR-214 4373085 ACAGCAGGCACAGACAGGCAG 
miR-218 4373081 UUGUGCUUGAUCUAACCAUGU 
miR-223 4373075 CGUGUAUUUGACAAGCUGAGUU 
miR-296 4373066 AGGGCCCCCCCUCAAUCCUGU 
miR-335 4373045 UCAAGAGCAAUAACGAAAAAUGU 
miR342 4395371 UCUCACACAGAAAUCGCACCCGU 
*At the time of thesis preparation, target sequences of each miRNA were conserved 
across human, mice and rat.   
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 annealing to sites flanking exon-exon boundaries. Oligonucleotide primers were 
synthesised by Sigma-Genosys (Dorset, UK). 
Primers used for SYBR q-PCR:  
Glut4 (ENSRNOT00000023256):    
Forward: 5’-GATTCTGCTGCCCTTCTGTC-3’ (bind to positions 792 to 811) 
Reverse: 5’-CAGCTCAGCTAGTGCGTCAG-3’ (binds to positions 917 to 936) 
Amplicon size: 145bp 
 
For TaqMan based q-PCR, reactions were set up as per the product information sheets 
(2× Universal PCR Master Mix, No AmpErase UNG; Applied Biosystems). Primer and 
TaqMan
®
 probe mix was manufactured by Applied Biosystems (pre-made, TaqMan
®
 
Gene Expression Assays). Each reaction contained 10µl of TaqMan 2× Universal PCR 
Master Mix (No AmpErase UNG), 1µl of 20× Primer and TaqMan
®
 probe mix, 2µl of 
cDNA sample (5ng/ul), and made up to 20µl volume with nuclease free water 
Incubation conditions were: 95°C for 10 min, followed by 40 cycles of 30 seconds at 
95°C and 1 min at 60°C, with data collection at the end of each cycle. For each q-PCR 
run, reactions containing no cDNA sample were used as no template control. All 
reactions were performed in duplicate, including negative controls. All TaqMan probes 
were 5’-FAM labelled, and all reagents and enzymes used for TaqMan based q-PCR 
analysis were supplied by Applied Biosystems.  
TaqMan primer and probe sets used:  
DICER1 (Assay ID: Hs00229023_ml)  
Mef2c (Assay ID: Rn01494042_gl)  
2.2.3 Data analysis  
QRT-PCR results were analysed using the 7500 Fast System Software version 1.3.0 
(Applied Biosystems). The threshold Cycle number (Ct) was determined for each 
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reaction at an appropriate threshold level (above baseline, within the exponential growth 
region of the amplification region of the amplification curve) and a baseline selected 
automatically by the software. Expression fold changes were determined by the ∆Ct 
method (Pfaffl, 2001). The analysis was performed based on the assumption of equal 
amplification efficiency among all miRNA species detected. Statistical analyses were 
performed using MS Office Excel and GraphPad Prism.  
2.3 Northern Blotting for miRNA detection 
Given that miRNAs are considerably shorter than other RNA species such as mRNAs, 
modifications has been made to the traditional Northern Blotting procedure for effective 
detection of miRNAs, however, overall the same principles apply.   
 
Total RNA was extracted using Trizol (Section 2.1.1) and 10~30µg of RNA sample in a 
volume less than 10µl were mixed with equal volumes of bromophenol blue/xylene 
cyanol loading buffer (Gel loading buffer II, Ambion) and denatured for 10 min at 80°C. 
SpeedVac was used to concentrate the sample if the samples exceeded 10µl. Samples 
were loaded on 15% denaturing acrylamide gel with 8M urea (Sigma) and resolved at 
150 volts until the bromophenol blue dye front reaches the bottom of the gel. The 
position of bromophenol blue and xylene cyanol in 15% gels corresponds to 
approximately 10 to 30nt respectively. The gel was then stained in 1× TBE buffer 
containing 4µg/ml of ethidium bromide for 10 min, and viewed under UV to verify 
equal loading using the 5S rRNA bands (121nt). After destaining, the RNA was 
transferred to positively charged nylon membrane (BrightStart, Applied Biosystems – 
Ambion) using a semi-dry transfer cell (Bio-Rad), and the membrane was UV-cross 
linked at 1200uJ (×100) for 30 seconds using the Stratalinker
®
 UV Crosslinker 
(Stratagene, La Jolla, CA, USA). Membranes were prehybridised in Ultrahyb Oligo 
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solution (Applied Biosystems – Ambion) for 1 hour at 42ºC. DNA oligonucleotides, 
complementary to the mature miRNAs were obtained from Sigma-Genosys (Dorset, 
UK), were 5'-end labelled with Redivue adenosine 5'-[-32P] triphosphate, 
triethylammonium salt (PerkinElmer, Waltham, Massachusetts, USA) using mirVana 
Probe and Marker Kit (Ambion, see Section 2.3.1) and added to the hybridization buffer. 
The blot was hybridized overnight at 42ºC and then washed twice with 2× sodium 
chloride sodium citrate buffer (SSC) containing 0.5% sodium dodecyl sulfate (w/v, SDS) 
and exposed to X-ray film (Sigma) between intensifying screens for 18-24 hours at -
80°C. Blots were stripped using 0.5% (w/v) SDS for 1 hour at 60°C and reprobed for 5S 
rRNA after prehybridization as loading controls.  
Denaturing acrylamide gel was prepared with components listed below: 
 ×1 
Urea 7.2g 
10x TBE 1.5ml 
40% Acrylamide (acry:bis acry=19:1) 5.6ml 
DEPC treated water To 15ml 
Mix well until urea is dissolved, then add  
10% APS 75ul 
TEMED 15ul 
Mix well and pour gel immediately   
 
2.3.1 Probe Labelling 
DNA oligonucleotides probes were 5’-labelled with Redivue adenosine 5'-[-32P] 
triphosphate, triethylammonium salt (#EG502Z250UC PerkinElmer, Waltham, 
Massachusetts, USA) using mirVana Probe and Marker Kit (Ambion) according to the 
following recipe: 
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 miRNA probe (µl) 5S rRNA probe (µl) 
DNA oligo (5pmol/µl) 2 1  
[γ32p]ATP  
(1.67pmol/ul, 10µCi/µl) 
6 5 
10×Kinase Buffer 1 1 
T4 Polynucletide Kinase 
(10U/µl) 
1 1 
Nuclease-free water - 2 
Total Volume 10 10 
 
The mixture was then incubated at 37°C for 1 hour, and kept on ice or stored at -20°C 
until needed.   
Sequence for miR-223 probe: 5’-GGGGTATTTGACAAACTGACA-3’  
Sequence for miR-296 probe: 5’-GGAGAGCCTCCACCCAACCCTC-3’ 
Sequence for 5S rRNA: 5’-TTAGCTTCCGAGATCA-3’ 
2.4 Cloning 
All restriction endonucleases used in this study were purchased from New England 
Biolabs. 
2.4.1 DNA amplification (PCR) and agarose gel electrophoresis 
PCR primers were designed by using Primer 3 (http http://frodo.wi.mit.edu; Misener 
and Krawetz, 2000). Primer pair selection criteria were: 17-22 nucleotides (nt) in length, 
at least one GC clamp on the 3’ end; GC content between 40 and 60%; non-
complementary 3' ends in primer pairs; and the difference of melting temperatures (Tm) 
is < 1°C. Oligonucleotide primers were synthesised by Sigma-Genosys (Dorset, UK). 
PCR reactions were performed in 10µl volumes and contained a final concentration of 
1× reaction buffer, 5mM of MgCl2, 0.2mM dNTPs, 1 mM of each oligonucleotide 
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primer and 0.75U of Taq polymerase (Bioline, London, UK). Genomic DNA was used 
at a final concentration of 5ng/µl. Reactions containing water instead of DNA were set 
as negative controls. PCR was carried out using Tetrad thermal cycler (MJ Research, 
Rayne, UK). Standard amplification conditions were 94°C for 3 min, followed by 30 
cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds and 
extension at 72°C for 30 seconds. For PCR using Amplitaq Gold (Applied Biosystems, 
Warrington, UK), the initial denaturation step was increased to 12 min. DNA products 
were resolved by agarose gel electrophoresis. For sequence information on all primers 
used for DNA amplification, please refer to Appendix C. 
 
Agarose gel electrophoresis was carried out using horizontal submarine agarose gels. 
Gels were made by dissolving agarose powder (Invitrogen, Paisley, UK) in 1× TAE 
(Tris-acetate-EDTA, 80°C) buffer. Agarose was cooled to 60°C before pouring. For 
agarose gels used for DNA gel purification, 1% to 2% (w/v) standard agarose and 
NuSieve agarose (Cambrex BioScience, Rockland, ME, USA) was combined in a ratio 
of 1:1. Ethidium bromide was added to the gel and running buffer at the final 
concentration of 10µg per 100ml of gel or running buffer. DNA samples were loaded 
with 1/5 volume of loading buffer (Orange G) and electrophoresis carried out at 100 
volts for 35 min. Quick-Load 2-Log DNA Ladder (New England Biolabs) was used as 
DNA size markers. DNA was visualised using the InGenius gel documentation and 
analysis system (Syngene, Cambridge, UK). 
2.4.2 TA cloning 
PCR products amplied by Taq polymerase have a single deoxyadenosine (A) at 3’ ends 
due to Taq’s non-template-dependent terminal transferase activity. This can be used to 
clone the product into a plasmid vector that has a single overhanging 3’ deoxythymidine 
Chapter Two 
63 
(T). For cloning into the pCR 2.1-TOPO
®
 vector (Invitrogen, Appendix B), 2µl of PCR 
product was mixed with 1µl of Salt Solution, 1µl of pCR 2.1-TOPO
®
 vector and 2µl of 
water in a final volume of 6µl. The mixture was incubated at room temperature for 5 
min. Then 2µl of this ligation mixture was transformed into chemically competent E. 
coli cells. For cloning into pTargeT™ Vector (Promega, Madison, WI, USA; Appendix 
B) the 10µl ligation mixture consisted 1µl of 10×ligation buffer, 3U of T4 DNA ligase 
(Promega), 1µl (60ng) of pTargeT™ Vector, and the appropriate amount of PCR 
product calculated according to the insert/vector molar ratio of 3:1 using the equation: 
insertofng
vectorofsizekb
insertofsizekbvectorofng
=×
×
1
3
. The ligation mix was then incubated 
at 4°C overnight. 2µl of the ligation reaction was then transformed into chemically 
competent E. coli cells 
2.4.3 Transformation of chemically competent E. coli cells 
Chemically competent ONE SHOT
®
 TOP10 E. coli were purchased from Invitrogen. 
For each transformation, one vial (~50µl) of cells was allowed to thaw on ice for 5 min. 
2µl of ligation mixture was added to the competent cells, and incubated on ice for 20 
min. The cells were then heat shocked at 42°C for 30 seconds and returned on ice 
immediately. 250µl of room temperature SOC medium (super optimal broth with 
catabolite; Invitrogen) was added to the transformed cells, and incubated at 37°C with 
shaking (~200rpm) for 1 hour. 50µl of each transformation was plated onto pre-warmed 
LB (Lysogeny Broth) agar plate containing ampicillin (50µg/ml) and x-gal (5-bromo-4-
chloro-3-indolyl beta-galactoside, 40mg/ml), and incubated at 37°C overnight. Cells 
were plated onto pre-warmed LB agar plate containing ampicillin (50µg/ml) or 
kanamycin (50µg/ml), if blue/white colony selection is required, IPTG (0.5mM) and x-
gal (5-bromo-4-chloro-3-indolyl beta-galactoside, 80µg/ml) are also added to the agar 
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plate. Plates were then incubated at 37°C overnight. For both pCR2.1-TOPO
®
 and 
pTargeT™ vector transformations, white colonies were picked for screening of the 
insert; colonies were screened by PCR using forward primer binding to the T7 promoter 
(5’-TAATACGACTCACTATAGG-3’) and the reverse primer of the PCR product. 
Clones positive for the insert were sequenced to confirm the insert sequence and 
orientation.  
2.4.4 Restriction digests 
All restriction digests were performed using restriction endonucleases supplied by New 
England Biolabs (Hitchin, UK). All reactions were carried out in a 20µl reaction volume 
consisting 20U of each restriction enzyme used, 0.5-2µg of DNA, 2µg of Bovine Serum 
Albumin (BSA), and 2µl of 10× reaction buffer that is recommended for the enzymes 
used in the reaction. For double digests, the compatibility of restriction enzymes was 
determined using NEBcutter V2.0 (http://tools.neb.com/NEBcutter2/index.php). All 
reactions were incubated for 2 hours at 37°C, and enzymes were denatured at 65°C for 
15 min. Digested products were resolved by agarose gel electrophoresis.  
2.4.5 Standard protocol for directional cloning 
Both the vector and the TA plasmid containing the inserts were cut with two different 
restriction enzymes that generated non-complementary sticky ends at either end of each 
restriction fragment. Both fragments were resolved on an agarose gel and DNA bands 
representing the fragments were excised out of the gel and DNA was purified using 
Wizard
®
 SV Gel and PCR Clean-Up System (Promega, Madison, WI, USA). The insert 
was ligated to the vector in a 20µl reaction containing 400 Units of T4 DNA ligase 
(New England Biolabs), 2µl of 10× buffer, 200-300ng of cut vector, and the appropriate 
amount of insert DNA according to the 3:1 insert to vector molar ratio (calculated using 
the equation in Section 2.4.2). The ligation mix was incubated at room temperature for 
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12 min and kept at 16°C until use. 2µl of the ligation mix were transformed into TOP10 
chemically competent cells (Invitrogen) as described in Section 2.4.3. Positive clones 
were screened by PCR using primers that was originally used for insert amplification. 
Clones positive for the insert were sequenced to confirm the insert sequence and 
orientation. 
2.4.6 DNA Sequencing 
For sequencing of PCR products, DNA from 50µl reactions were purified using the 
Wizard
®
 SV Gel and PCR Clean-Up System (Promega, Madison, WI, USA). For 
sequencing of plasmid DNA, plasmids were prepared using Wizard Plus SV Minipreps 
DNA Purification System (Promega). Purified DNA samples were quantified by 
Spectrophotometry (Nanodrop Technology). Each sequencing template reaction 
contained ~200ng of DNA, 3.2pmol of primers and water in a total volume of 10µl. 
Samples were sent to the Genomics Core Laboratory (Clinical Sciences Centre, MRC) 
for cycle sequencing, purification and electrophoresis according to the protocols below:  
Samples are cycle sequenced using Big Dye v3.1 chemistry (Applied Biosystems, 
Warrington, UK). 5µl of the template reaction was added to 0.9µl of BigDye, 2µl of 
water and 2µl of 5× buffer. Reactions were cycled under the following PCR conditions: 
95°C for 1 min, followed by 30 cycles of 95°C for 10 seconds, 55°C for 15 seconds and 
60°C for 4 min, then hold at 4°C. The PCR reactions were then cleaned up using an 
EDTA-Ethanol precipitation: 5µl of 125mM EDTA and 30µl of 100% Ethanol was 
added to 10µl of sequencing reaction and incubated at room temperature for 15mins 
before centrifugation at 3,000g for 30mins. The pellets are washed once with 100% 
ethanol and then twice with 70% ethanol. DNA was resuspended in 10-12µl of HiDi 
Formamide, and run on the Applied Biosystems Ltd 3730xl DNA Analyzer.  
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All DNA templates were sequenced in the sense and anti-sense strand. DNA sequences 
were analysed using the Sequencher software (Gene Codes Corporation, An Arbor, MI, 
USA). 
2.4.7 Mini plasmid preparation 
All mini plasmid preparations (miniprep) were carried out using the Wizard Plus SV 
Minipreps DNA Purification System (Promega) following manufacturer’s protocol. 1 to 
5ml of LB culture containing the appropriate antibiotics were inoculated with a single 
colony containing the plasmid of interest, and incubated overnight at 37°C with shaking 
(~200rpm). Bacteria were harvested by centrifugation for 5 min at 10 000 × g at room 
temperature. Each cell pellet was resuspended with 250µl of Cell Resuspension Solution 
by vortexing, and cells were lysed with 250µl of Cell Lysis Solution and incubation at 
room temperature for 5 min. After treatment with 10µl Alkaline Phosphatase Solution, 
the mixture was neutralised with 350µl of Neutralization Solution and centrifuged at 14 
000 × g at room temperature for 10 min. The cleared supernatant was then applied to a 
spin column for DNA binding. The bound DNA was then washed twice with Column 
Wash Solution, then plasmid DNA is eluted from the column with water. Plasmid DNA 
was then quantified by spectrophotometry (Nanodrop).  
2.4.8 Maxi plasmids preparation 
Plasmids required for further experiment purposes in large quantities were prepared 
using the QIAfilter Plasmid Maxi Purification Kit (QIAGEN, Crawley, UK) following 
manufacturer’s protocol. 250ml of LB medium was inoculated with miniprep culture of 
the plasmid of interest, and incubated at 37°C overnight with shaking (~300rpm). 
Bacterial cells were harvested by centrifugation at 6000 × g for 15 min at 4°C. Bacterial 
pellet was resuspended in 10ml of Buffer P1 (containing RNase A), and mixed with 
10ml of Buffer P2 and incubated at room temperature for 5 min to allow lysis of the 
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cells. 10ml of chilled Buffer P3 was then added to the lysate and the mixture was 
filtered through the QIAfilter Cartridge to remove the precipitate that contains protein, 
genomic DNA and detergent. The cleared lysate was then applied to pre-equilibrated 
QIAGEN-tip 500 to allow DNA binding to the resin by gravity flow. The QIAGEN-tip 
was then washed twice with 30ml of Buffer QC before the plasmid DNA was eluted in 
15ml of Buffer QF, and DNA was precipitated with 0.7 volumes (10.5ml) of room 
temperature isopropanol, and centrifuged at 15 000 × g for 10 min. The DNA pellet was 
then washed with 5ml of room temperature 70% ethanol and centrifuged again at 15 
000 × g for 10 min. After 10 min of the air-drying, the plasmid DNA was dissolved in 
TE buffer. DNA was quantified by spectrophotometry (Nanodrop).  
2.5 Cell culture 
2.5.1 Preparation of Neonatal Rat Ventricular Myocytes 
The neonatal rat ventricular myocyte (NRVM) culture was first described by Harary 
and Farley (Harary and Farley, 1963a, b); since then, they have been widely used as an 
in vitro model system. The non-dividing and spontaneously beating NRVMs enable the 
study of the morphological, biochemical and electrophysiological characteristics of the 
heart for studies of hypertrophy, ischaemia, hypoxia etc (Bahi et al., 2006; Long et al., 
1992; Yamashita et al., 1994).  
 
NRVM cultures were prepared by an adaptation of the method of (Iwaki et al., 1990). 
One to two day old neonatal Sprague-Dawley rats (Harlan, Oxford, UK) were sacrificed 
by decapitation. Hearts were removed and collected in ADS buffer (Appendix A) kept 
on ice. Once all dissections were complete, the atria were removed. Hearts were then 
minced in ADS buffer, and then the minced tissue pieces were transferred to a 100ml 
bottle. For the initial digest, 10ml of enzyme mix (collagenase type 2, 115U/ml, 
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Worthington Biochemical Corp #CLS-2, and Pancreatin, 0.6mg/ml, Sigma-Aldrich 
#P3292 , dissolved in ADS buffer and filtered through 20µm syringe filter) was added 
to the tissue and the mixture was incubated with shaking (160 strokes per min) for 5 
min at 37°C. The supernatant was discarded. The tissues were then digested for 5 more 
times with 6-10ml of enzyme mix at shaking speed of 130-140 strokes per min. At the 
end of each digest, the supernatant was collected and centrifuged at 1000rpm for 5 min. 
The cell pellet were resuspended with foetal calf serum (FCS) and kept at 37°C. Cells 
from all digest were pooled in one tube after the last digest, and this was centrifuged at 
1000rpm for 7 min. To remove the fibroblasts, cells were then resuspended in plating 
media (Appendix A) and pre-plated onto non-gelatin coated Primaria dishes (BD 
Biosciences, San Jose, CA, USA) and incubated for 1 hour at 37°C. After pre-plating, 
un-attached cells were washed off the plate surface with plating media, and cells were 
plated onto gelatin coated Primaria dishes at a density of 1.5 ×10
3
 cells per mm
2
 and 
incubated at 37°C with 5% CO2 overnight. After incubation, cells were treated with 
serum free maintenance media (80% Dulbecco's Modified Eagle's Medium, 20% Media 
199) supplemented with 1% penicillin and streptomycin (pen/strep) solution (Sigma) 24 
hours prior to further experiments.  
2.5.2 COS7 cells 
COS7 cells were maintained using DMEM (Dulbecco’s Modified Eagle Medium, 
Invitrogen) supplemented with 10% (v/v) FCS and 1% (v/v) pen/strep solution at 37°C, 
5% CO2. Cells were seeded onto appropriate culture plates at the density of ~500 
cells/mm
2 
18 hours prior to transfection. Cells were passaged at the ratio of 1 to 10 
when density reached 80% confluency. 
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2.5.3 Transfection protocol 
All transfections were performed using lipid based transfection reagent 
Lipofectamine™ 2000 (Invitrogen) following the manufacturer’s protocol. In brief, 
cells were seeded and serum-starved 24 hours before transfection. For each transfection,  
the specified amount of DNA or RNA oligonucleotides was mixed with Opti-MEM 
(Invitrogen), and separately, Lipofectamine was diluted in Opti-MEM (Table 2.2). The 
mixtures were incubated at room temperature for 5 min, and then combined together by 
adding the DNA/RNA mix to the Lipofectamine solution; this was mixed gently and 
incubated at room temperature for 20 min. This transfection mixture was then added to 
the cells. Cells were then incubated for 4 hours under normal maintenance conditions, 
and cell culture media changed where necessary. Cells were harvested 24-48 hours after 
transfection. 
2.6 Protein extraction and quantification 
For isolation of whole cell protein extracts from human or animal tissue, ~50mg of 
tissue was homogenised in 1ml of 1×cell lysis buffer (Cell Signaling Technology, 
Danvers, MA, USA) supplemented with 1mM PMSF (phenylmethylesulphonylfluoride) 
and 1×protease inhibitor cocktail (Complete Mini, Roche Diagnostics, Mannheim, 
Germany). Lysates were centrifuged at 14 000 × g for 10 min at 4°C. Supernatant was 
collected and protein concentration was determined by Bradford assay using Protein 
Assay Dye Reagent Concentrate (Bio-Rad, Hercules, CA, USA) against BSA standard 
curve (5µg/ml ~ 40µg/ml). For protein extraction from cultured cells, cells were washed 
with cold PBS and treated with 200µl of 1×cell lysis buffer with PMSF. Collected 
Lysates were centrifuged as above.  
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Table 2.2 Amount of transfection reaction reagents used for various culture vessels 
 
 
Culture Vessel 
Volume of 
plating media 
Volume of  
Opti-MEM 
Volume of 
Lipofectamine 
2000 
96-well plate 100µl 2×25µl 0.5µl 
24-well plate 500µl 2×50µl 
2µl for DNA 
1µl for RNA 
6-well plate/ 
35mm dish 
2ml 2×250µl 8µl 
60mm dish 4ml 2×500µl 16µl 
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For membrane protein extraction (P1), whole mouse LV was homogenised in a buffer 
containing 20mM Hepes, 250mM sucrose, 1mM EDTA, 1mM PMSF and a cocktail of 
protease inhibitors (5mM benzamidine, 1µM aprotinin, 1µM pepstatin, 1µM leupeptin). 
The homogenate was centrifuged at 2000 × g for 10 min (4°C), and pellet was discarded  
and the supernatant was centrifuged again at 9000 × g for 20 min at 4°C. The pellet 
(membrane protein) was resuspended PBS supplemented protease inhibitor cocktail.    
2.7 Immunoblotting 
Protein samples were resolved by sodium dodecyl sulfate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) using mini PROTEAN 3 system (Bio-Rad). Gels were 
prepared with components listed below: 
For two gels: 
Resolving Gel 
(10%) 
Stacking Gel  
(4%) 
40% acrylamide (w/v) 3.75ml 0.75ml 
2% bis (w/v) 2.00ml 0.41ml 
20% (w/v) SDS  75µl 37.5µl 
1M Tris pH8.8 5.63ml - 
1M Tris pH6.8 - 0.95ml 
10% (w/v) Ammonium Persulphate 
(APS) 
113µl 112.5µl 
TEMED 15µl 7.5µl 
Distilled De-ionised Water 3.42ml 5.23ml 
Total Volume 15ml 7.5ml 
 
Protein samples were prepared to 1~3µg/µl with NuPage LD Sample Buffer and 
NuPage Reducing Reagent (Invitrogen) and boiled for 5 min at 95°C before loading 
onto the gel. 10µg~30µg of protein were loaded in each lane. Gels were run in Tris-
Glycine-SDS Buffer (Bio-Rad) for 30 min at 100V then at 150V for 60-80 min, 
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depending on the molecular weight of protein. Precision Plus Protein Standards were 
used as molecular size marker (Bio-Rad).  
 
When SDS-PAGE was complete, resolved proteins were transferred (wet) to Protran
®
 
Nitrocellulose Transfer Membrane (Whatman, Maidstone, UK) by electrophoresis using 
Bio-Rad mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) at 60V for 1 to 2 
hours, depending on the molecular weight of protein. Membranes were blocked in 
hybridisation buffer at room temperature for 20 min, and hybridised with specified 
primary antibody in hybridisation buffer at 4°C overnight. Membrane was washed three 
times in Tris buffered saline (TBS) supplemented with 0.05% (v/v) Tween 20 (Sigma), 
then probed with secondary antibody at room temperature for 1 hour in TBS 
supplemented with 1% (w/v) milk and 0.05% (v/v) Tween 20. The membrane was 
washed three times again in TBS with Tween 20. Proteins were visualised using 
chemiluminescence (20× LumiGLO Reagent and 20× Peroxide, Cell Signaling). Signals 
were detected by exposing X-ray film (Kodak Scientific Imaging) to the membrane for 
30 seconds to 10 min, depending on the intensity of the signal. List of antibodies used 
can be found in Table 2.3.  Details of buffers can be found in Appendix A. 
2.8 Statistics 
All data are represented as means ± SEM and statistical significance were tested by 
Student’s t-Test or ANOVA using MS Excel or GraphPad Prism 4, unless otherwise stated. 
Specific statistical analyses are described in detail in the relevant Chapter where the test is 
applied.    
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Table 2.3 List of antibodies used. 
 
Antibody Working dilution Host 
Supplier &  
catalogue number 
Anti-Akt 1 in 1000 Rabbit Cell Signaling 9272 
Anti-phospho-Akt 
(ser473) 
1 in 1000 Rabbit Cell Signaling 9271 
Anti-GSK3β 1 in 1000 Rabbit Cell Signaling 9315 
Anti-phospho-GSK3β 
(ser9) 
1 in 1000 Rabbit Cell Signaling 9336 
Anti-insulin receptorβ 1 in 1000 Rabbit 
Upstate (Millipore) 
33460 
Anti-Glut4 1 in 2500 Rabbit Abcam ab645 
Anti-Glut1 1 in 1000 Rabbit Abcam ab32551 
Anti-NFIA 1 in 1000 Rabbit Abcam ab11988 
Anti-Mef2c 1 in 500 Goat Santa Cruz sc-13266 
Anti-IRS1 1 in 1000 Rabbit 
Upstate (Millipore)  
06-248 
Anti-β-actin 1 in 5000 Mouse Abcam ab8226 
Anti-Gapdh  1 in 1 000 000 Mouse 
Fitzgerald Industries 
RDI-TRK5G4-6C5 
Anti-mouse-HRP 1 in 5000 Goat Dako P0447 
Anti-rabbit-HRP 1 in 5000 Goat Dako P0448 
Anti-rabbit-Alexa 488 
(FITC) 
1 in 400 Goat Invitrogen A11034 
Anti-Goat-HRP 1 in 2000 Donkey Santa Cruz sc-2020 
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CHAPTER THREE 
Expression profiling of miRNAs in the human heart 
3.1 Introduction 
At the outset of this study, miRNAs had been shown to have a major role in gene 
expression control during many biological processes, and when dysregulated, could 
contribute to disease pathophysiology (Alvarez-Garcia and Miska, 2005). Several 
expression profiling studies of miRNAs in animal models of heart disease and end-stage 
heart failure have been reported since 2006, and a number of miRNAs are dysregulated 
in the diseased heart (reviewed by Latronico et al., 2007). However, miRNA expression 
studies of the insulin resistant human heart have not been reported, to date. In this 
Chapter, the expression levels of 155 miRNAs in left ventricular biopsy samples from 
patients with T2DM and control samples are examined using TaqMan-based stem-loop 
qRT-PCR. As LVD is also associated with insulin resistance independent of T2DM, 
biopsy samples from patients with LVD were also collected and levels of miRNAs 
differentially regulated in the T2DM group were further assayed in the LVD group.   
3.2 Materials and Methods 
3.2.1 Study population and sample procurement 
Left ventricular biopsies were obtained from patients undergoing coronary artery bypass 
graft surgery who were suitable for inclusion (in collaboration with Prof PG Camici and 
Mr Punjabi; approved by Research Ethics Committee, Hammersmith Hospital; 
reference number: LREC 2003/6699). Inclusion criteria: listed for coronary bypass 
surgery, age 35-75 years, creatinine < 200 µmol/l, an echocardiogram and coronary 
angiogram within 3 months. Exclusion criteria were myocardial infarction within 3 
months, left ventricular ejection fraction <15%, claustrophobia, viability in less than 
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35% of the left ventricle as determined by cardiac MRI or positron emission 
tomography (PET), coincident left ventricular dysfunction and T2DM, or an estimated 
operative mortality of >15%. Patients were assigned to one of three groups: control, 
T2DM or LVD. Patients were considered to have LVD, if their ejection fraction was 
less than 40%; biopsies were taken from normally contracting regions with no evidence 
of infarction. All patients with T2DM had previously been diagnosed with the condition 
and all had normal systolic left ventricular function (Table 3.1). All patients were 
managed with optimal medical therapy which was discontinued the evening prior to 
surgery. The study protocol was approved by the Administration of Radioactive 
Substances Advisory Committee in compliance with guidelines. Written consent was 
obtained from all patients. 
3.2.2 RNA isolation, quantification and quality check 
Tissues samples were processed and RNA was extracted as described in detail in 
Chapter 2, Section 2.1. RNA samples were quantified using NanoDrop (Section 2.1.1) 
and the RiboGreen (Section 2.1.2). Sample quality was assessed using the Bioanalyser 
(Section 2.1.3).  
3.2.3 qRT-PCR 
3.2.3.1 miRNA specific qRT-PCR with stem-loop RT primers  
For the initial miRNA expression profiling of the human biopsy samples, specific 
mature miRNA expression levels were quantified by TaqMan
®
 
 
MicroRNA Assays 
Human Panel Early Access kit (Applied Biosystems) using stem-loop primers for 
reverse transcription (RT) followed by real-time PCR. Hsa-let-7a and hsa-miR-16 
served as positive, ubiquitously expressed controls, and non-human cel-miR-2, cel-lin-4 
and ath-miR159a were used as negative controls. For each 96-well reaction plate, the 
expression of miR-16 (TaqMan MicroRNA Assay, Applied Biosystems, Table 2.1) was  
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Table 3.1 Patient characteristics (n=6 per condition). Data are represented as mean ± 
SD. ** P<0.001, relative to control. T2DM, type 2 diabetes mellitus; LVD, left 
ventricular dysfunction; BMI, body mass index; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; HR, heart rate; EF, ejection fraction; BG, blood glucose; Hb, 
haemoglobin; HbA1c, glycated haemoglobin; WBC, white blood count; BUN, blood 
urea nitrogen 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control T2DM LVD 
Age 58 ± 14 59 ± 7 63 ± 14 
Gender M/F 6/0 6/0 5/1 
Height (m) 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 
Weight (kg) 81 ± 8.2 82 ± 13.0 77 ± 11.3 
BMI 27.0 ± 2.5 27.7 ± 4.3 25.8 ± 3.8 
SBP (mmHg) 129 ± 3 140 ± 24 120 ± 12.7 
DBP (mmHg) 75 ± 4.5 83 ± 7.7 75 ± 9.8 
HR (bpm) 61 ± 6.2 68 ± 4.6 60 ± 7.7 
EF (%) 60 ± 9.5 70 ± 10.7 30 ± 9.0** 
BG (mol/L) 4.9 ± 0.6 5.9 ± 1.7 5.6 ± 1.5 
Insulin (mU/l) 8.8 ± 1.8 13.9 ± 7.2 7.3 ± 2.8 
Hb (g/L) 14.6 ± 1.4 14.3 ± 1.1 13.1 ± 1.5 
HbA1C 5.5 ± 0.2 6.6 ± 1.0 5.8 ± 0.2 
WBC 7.1 ± 2.2 7.5 ± 1.8 7.4 ± 1.0 
BUN 6.3 ± 2.6 6.2 ± 1.4 7.2 ± 3.8 
Creatinine 105 ± 29 108 ± 29 103 ± 26 
Triglycerides 1.5 ± 0.2 1.4 ± 0.8 1.3 ± 0.3 
Total Cholesterol 4.5 ± 0.7 3.3 ± 1.0 5.0 ± 1.1 
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measured in triplicate in a rat RNA sample, which is used as an amplification efficiency 
control. For RT, each reaction contained 1mM dNTPs, 50U of MultiScibe™ Reverse 
Transcriptase, 3.76U of RNase Inhibitor, 3µl of RT-primer (5×) and 5ng of RNA 
sample. Reactions were incubated for 30 min at 16°C, 30 min at 42°C and 3 min at 
85°C. The q-PCR reaction was set up based on the recommended concentrations and 
volumes from the TaqMan 2× Universal PCR Master Mix (No AmpErase UNG) and 
TaqMan miRNA Assays protocol (Applied Biosystems). The reaction was performed 
using the 7500 Fast Real Time PCR Sequence Detection machine (10 min at 95°C 
followed by 40 cycles of 15 seconds at 95°C, 60 seconds at 60°C), with data collection 
at end of each cycle. For the Human LV miRNA expression screen, biopsy sample size 
and technical complexity of the assay required pooling of the RNA samples of each 
patient group. Each RT step were performed in duplicate, and for each RT reaction, the 
q-PCR step was performed twice. For qRT-PCR validation experiments, 5ng of RNA 
sample was used in each reaction, and each RT step were performed once and the q-
PCR step was performed twice. All TaqMan probes used were FAM labelled. 
3.2.3.2 U6 snRNA and 5S rRNA levels 
Levels of U6 small nuclear RNA (snRNA) and 5S ribosomal RNA (rRNA, mirVana™ 
qRT-PCR Primer Set for Normalization, Ambion) selected for data normalisation were 
determined using mirVana qRT-PCR miRNA Detection Kit (Ambion/Applied 
Biosystems) in small RNA samples (20ng/reaction). Reagents were supplied as part of 
the Detection Kit, apart from SYBR Green I (10,000×) and Taq polymerase (5U/µl), 
which were obtained from Invitrogen. The two-step qRT-PCR was performed according 
to manufacturer’s protocol. In brief, each RT reaction contained 2µl of 5× mirVana RT 
buffer, 1µl of 1× mirVana RT primer, 2µl of small RNA (10ng/µl), 0.4µl of ArrayScript 
Enzyme Mix, made up to 10µl total volume with nuclease free water. The reaction was 
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incubated (37°C, 30 min; 95°C, 10 min), followed by q-PCR using 5µl of 5× mirVana 
PCR buffer (contains 1.5× SYBR Green I), 0.2µl of Taq polymerase (5U/µl, Invitrogen), 
0.5µl of 1× PCR primers, 10µl of the RT reaction, and nuclease free water (25µl final 
reaction volume). The reaction was performed using the 7500 Fast Real Time PCR 
Sequence Detection machine (Applied Biosystems) under the following conditions: 
95°C for 3min, followed by 40 cycles of 95°C for 15 seconds and 60°C for 30 seconds, 
with data collection at end of each cycle. Dissociation analysis (melt curve) was 
performed immediately following the amplification cycles (95°C for 15 seconds, 60°C 
for 15 seconds, followed by a slow ramp to 95°C) to verify the presence of a single 
amplification product.  
3.2.3.3 Data analysis  
QRT-PCR results were analysed with the 7500 Fast System Software version 1.3.0 
(Applied Biosystems). The threshold Cycle number (Ct) was determined for each 
reaction at a baseline selected automatically by the software and a threshold level where 
the line intercepts the linear phase of amplification curve of all samples. Expression fold 
changes were determined by the ∆Ct method (Pfaffl, 2001). For the initial human LV 
miRNA expression profiling data, the mean of Ct values of miR-16 levels in the rat 
sample was used as internal control for amplification efficiency to normalise Ct values 
obtained from all human miRNAs. Fold change (FC) of each miRNA was calculated 
using average ∆Ct values of the four technical replicates between control and T2DM 
groups. Amplification efficiency was determined by the Ct values of three randomly 
selected miRNAs at RNA concentrations from 0.008ng/µl to 5ng/µl. The analysis was 
performed based on the assumption of equal amplification efficiency among all miRNA 
species detected. Statistical analyses were performed using MS Office Excel and 
GraphPad Prism. Unsupervised hierarchical clustering was performed using Cluster 3.0 
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software (Eisen et al., 1998), a heatmap was generated using TreeView 1.60 
(http://rana.lbl.gov/EisenSoftware.htm).  
3.3 Results 
3.3.1 Small RNA Sample preparation and quality control 
Human LV biopsy samples were collected at the time of coronary artory bypass surgery 
(ethics approval reference, LREC 2003/6699, Mr Punjabi). Large and small RNA was 
extracted from the biopsy samples using the mirVana miRNA isolation kit (Ambion). 
Samples were divided into three groups: control (n=6), diabetic group (T2DM, n=6) and 
LVD (n=6). RNA samples were quantified and normalised against small or large RNA 
standard curves using RiboGreen (Invitrogen). On average, 263±86ng of large RNA and 
170±38ng of small RNA were recovered from 1mg of heart tissue. The quality of small 
RNA extracted was assessed using the Agilent Bioanalyser (Figure 3.1). Three samples 
from each patient group were analysed, and ~2.5ng of each RNA sample was used. As a 
result of the RNA extraction method used, the samples are enriched with small RNA 
species that are <200 nt, as indicated by the predominant peak, compared with the low 
levels of carryover 18s rRNA (Figure 3.1). When the small RNA peaks were examined 
at higher resolution, all samples showed similar profiles, indicating no global distortion 
of the small RNA species in patient subgroups.  
3.3.2 Expression of non-coding small RNAs in the heart 
Small non-coding RNA species such as 5s rRNA and U6 snRNA have been used as 
‘house-keeping’ controls in small RNA qRT-PCR studies (Pineles et al., 2007; 
Takamizawa et al., 2004). However, analyses of the expression of 5s rRNA and U6 
snRNA in the human heart small RNA samples revealed these RNA species were 
differentially expressed among patient groups (Figure 3.2). Expression levels of U6 
snRNA and 5S rRNA were determined in the human biopsy samples (control n = 6,  
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Figure 3.1 Electropherogram of small RNA samples extracted from human heart biopsies. 
Small RNA species were extracted using mirVana microRNA Isolation Kit (Ambion); ~2.5ng 
used from each sample for the analyses; samples were analysed with Agilent RNA 6000 Pico 
Chip with RNA 6000 ladder, which is shown in red (2100 Bioanalyser, Agilent) a. The 
predominant small RNA peaks and small amount of retained 18s rRNA peaks are detected. b. 
High resolution view of small RNA peaks. Three samples from each patient group are shown. 
T2DM, type 2 diabetes mellitus; LVD, left ventricular dysfunction.  
18s rRNA 
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Figure 3.2 Optimizing qRT-PCR normalization. In some studies of miRNA 
expression, qRT-PCR data were normalized to 5S rRNA or U6 snRNA expression 
levels. However, in this study, these small RNA species were found to be differentially 
regulated between patient groups. Fold change (FC) was calculated by comparing the 
mean Ct value of the diseased groups with that of the control (Control = 6, LVD = 6, 
T2DM = 6). Data are represented as means ± SEM. Statistical analysis revealed 
significant variation between the patient groups (p = 0.021, two-way ANOVA). 
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T2DM n = 6, LVD n = 6; 20ng small RNA per reaction) by qRT-PCR (SYBRGreen, 
Ambion). Compared to controls, the expression of both 5S and U6 small RNAs were 
increased in patients with T2DM (1.7 fold and 2.6 fold respectively; p = 0.021, two-way 
ANOVA). In patients with LVD there was a similar pattern as observed for the T2DM 
group, with both small RNAs upregulated (1.2 fold, 5s rRNA; 2.3 fold, U6 snRNA; p= 
non-significant for both). There was statistically significant variation between the 
patient groups (p = 0.021; Two-way ANOVA). This finding was somewhat unexpected, 
as 5S and U6 genes have been widely used as internal ‘house keeping’ controls. Based 
on these observations, 5S rRNA and U6 snRNA were not used for data normalisation 
and all subsequent qRT-PCR analyses were normalised to total small RNA 
concentrations.  
3.3.3 miRNA expression profiling in control and T2DM patients 
The miRNA expression profiles of heart samples from control and T2DM patients were 
then assayed. Samples from each group were pooled, and expression of 155 miRNAs 
were assayed using stem-loop qRT-PCR. For each patient group, the expression of each 
miRNA was determined using 4 technical replicates. Given expression of negative 
controls were detectable at PCR cycle number 35, only miRNAs with Ct values <35 
were considered to be expressed. Based on this criteria, out of 155 miRNAs represented 
in the qRT-PCR panel 115 miRNAs were expressed (Table 3.2). As shown by the 
analysis of three representative miRNAs of high, intermediate and low expression levels, 
the amplification efficiencies of the qRT-PCR reactions were equal (Figure 3.3). This 
enabled the relative quantification of relative miRNA expression levels in the control 
group over a range of ~4 orders of magnitude (Table 3.2). The most highly expressed 
miRNAs detected were miR-133a and b, which are known to be highly expressed in 
skeletal muscle and the heart (Care et al., 2007; Rao et al., 2006).  
  
Table 3.2 miRNA expression in the human heart. Levels of 115 miRNAs are shown in raw Ct values and relative expression levels, where 
relative expression levels of miRNA were determined in relation to the expression level of the miRNA with the lowest detectable miRNA (hsa-
miR-215). miRNAs are ranked based on their Ct values in the control group (the higher the Ct value, the lower the expression level). miRNAs 
with Ct > 35 were excluded as negative controls were detectable at this level. 
 
miRNA Ct 
Standard 
Deviation 
Relative 
expression 
levels 
miRNA Ct 
Standard 
Deviation 
Relative 
expression 
levels 
miRNA Ct 
Standard 
Deviation 
Relative 
expression 
levels 
miRNA Ct 
Standard 
Deviation 
Relative 
expression 
levels 
hsa-miR-215 35.0 1.0 1 hsa-miR-185 31.1 0.1 15 hsa-miR-151 28.3 0.4 98 hsa-miR-195 26.2 0.7 436 
hsa-miR-135b 34.7 0.5 1 hsa-miR-302d 30.7 0.6 20 hsa-miR-218 28.3 2.1 104 hsa-miR-320 25.8 0.5 574 
hsa-miR-203 34.5 0.9 1 hsa-miR-335 30.7 0.4 20 hsa-miR-25 28.3 0.2 104 hsa-miR-100 25.8 0.4 578 
hsa-miR-368 34.5 1.4 1 hsa-miR-339 30.6 0.3 20 hsa-miR-146 28.2 0.3 106 hsa-miR-29b 25.7 0.6 592 
hsa-miR-370 34.4 1.0 1 hsa-miR-127 30.6 0.4 20 hsa-miR-148a 28.2 0.1 111 hsa-miR-130a 25.7 0.5 607 
hsa-miR-154* 34.3 0.4 2 hsa-miR-194 30.6 1.2 21 hsa-miR-331 28.1 0.6 117 hsa-miR-221 25.7 0.3 620 
hsa-miR-204 34.1 1.6 2 hsa-miR-296 30.6 0.7 21 hsa-miR-199b 28.0 0.8 127 hsa-miR-99a 25.7 0.7 630 
hsa-miR-182 34.1 1.2 2 hsa-miR-107 30.5 0.6 21 hsa-miR-181a 27.9 1.1 137 hsa-miR-103 25.6 0.4 654 
hsa-miR-134 33.8 0.7 2 hsa-miR-302b 30.5 1.0 22 hsa-miR-181b 27.8 0.9 146 hsa-miR-26b 25.1 0.4 898 
hsa-miR-155 33.8 1.3 2 hsa-miR-139 30.2 0.4 26 hsa-miR-21 27.7 0.8 149 hsa-miR-23a 25.0 0.2 986 
hsa-miR-187 33.6 1.2 2 hsa-miR-95 30.2 0.4 26 hsa-miR-130b 27.7 0.4 153 hsa-miR-30d 24.9 0.1 1041 
hsa-miR-189 33.5 0.8 3 hsa-miR-135a 30.2 0.5 27 hsa-miR-34a 27.6 0.2 162 hsa-miR-29a 24.9 0.5 1077 
hsa-miR-299 33.5 0.5 3 hsa-miR-223 29.9 1.3 33 hsa-let-7i 27.5 1.2 176 hsa-miR-27b 24.8 0.6 1106 
hsa-miR-213 33.4 1.3 3 hsa-miR-149 29.8 0.4 35 hsa-miR-199a 27.5 1.3 177 hsa-let-7g 24.7 1.0 1213 
hsa-miR-154 33.3 0.9 3 hsa-miR-132 29.7 0.2 37 hsa-miR-210 27.5 0.6 179 hsa-miR-199a* 24.6 0.5 1311 
hsa-miR-338 33.3 0.4 3 hsa-miR-301 29.7 0.5 38 hsa-miR-342 27.4 0.3 189 hsa-miR-125a 24.4 0.2 1531 
hsa-miR-128a 33.3 0.4 3 hsa-miR-15a 29.5 0.3 43 hsa-miR-152 27.4 0.3 190 hsa-let-7d 24.3 0.6 1636 
hsa-miR-17-3p 33.2 0.2 3 hsa-miR-374 29.5 0.6 43 hsa-miR-19a 27.3 0.3 201 hsa-miR-23b 24.2 0.3 1738 
hsa-miR-190 33.1 1.2 4 hsa-miR-328 29.5 0.6 45 hsa-miR-27a 27.3 0.3 202 hsa-miR-126 24.1 0.3 1838 
hsa-miR-302c 32.8 0.9 4 hsa-miR-324-5p 29.4 0.9 48 hsa-miR-191 27.3 0.5 207 hsa-miR-30c 24.0 0.6 1977 
hsa-miR-367 32.8 0.7 4 hsa-miR-197 29.3 0.7 49 hsa-miR-140 27.2 0.2 221 hsa-miR-29c 23.9 0.2 2093 
hsa-miR-340 32.6 1.1 5 hsa-miR-142-3p 29.3 0.6 49 hsa-miR-222 26.8 0.7 287 hsa-miR-125b 23.7 0.4 2406 
hsa-miR-142-5p 32.6 0.5 5 hsa-miR-106a 29.2 0.4 55 hsa-miR-150 26.7 0.4 312 hsa-let-7b 23.5 0.4 2771 
hsa-miR-181c 32.0 0.6 8 hsa-miR-98 29.0 0.7 61 hsa-miR-214 26.6 0.4 319 hsa-miR-26a 23.1 0.3 3754 
hsa-miR-193 32.0 1.1 8 hsa-miR-15b 29.0 0.9 62 hsa-miR-199-s 26.4 0.4 382 hsa-miR-30b 22.8 0.5 4506 
hsa-miR-9 31.8 0.2 9 hsa-miR-28 28.9 0.2 67 hsa-miR-92 26.4 0.4 386 hsa-miR-145 22.8 0.4 4689 
hsa-miR-302a 31.5 0.6 11 hsa-let-7e 28.5 1.1 88 hsa-miR-30e 26.3 0.5 410 hsa-miR-133b 21.2 0.4 13945 
hsa-miR-224 31.5 0.8 11 hsa-miR-20 28.5 0.4 90 hsa-miR-30a-3p 26.3 0.7 411 hsa-miR-133a 21.2 0.4 14103 
hsa-miR-10a 31.3 0.7 13 hsa-miR-17-5p 28.4 0.6 96 hsa-miR-186 26.2 0.4 429     
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Figure 3.3 Amplification efficiencies of mature miRNA qRT-PCR assays A, 
Standard curves of miR-30b, miR-187 and miR-223 were produced using human LV 
small RNA samples at concentrations 5, 1, 0.2, 0.04, 0.008ng/ul. Linear regression is 
each line is shown (R
2
). B, Derived amplification efficiencies (E = 10
-1/slope
; % 
efficiency = (E-1) ×100%; see Section 3.2.3.3).  
miRNA ID Slope 
Amplification 
efficiency (%) 
Hsa-miR-30b -3.210 105 
Hsa-miR-187 -3.122 109 
Hsa-miR-223 -3.153 107 
B 
A 
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3.3.4 Differential expression of miRNAs between control and T2DM 
patients 
Expression levels of miRNAs were then compared between control patients and patients 
with T2DM based on the ∆Ct method (expression levels were normalised against total 
RNA concentrations). Figure 3.4 shows the heatmap of unsupervised hierarchical 
clustering analysis on the fold change (log2 transformed) in miRNA expressions in the 
T2DM group compared to the control. Differentially expressed miRNAs are highlighted 
in clusters A and B, with A showing upregulated miRNAs (e.g. hsa-miR-342, hsa-miR-
223) and B showing downregulated miRNAs (e.g. hsa-miR-214, hsa-miR-199a) in the 
T2DM group compared to the control. The significance of the changes of individual 
miRNA levels were tested by t-test, assuming unequal variance between two samples. 
Figure 3.5 plots the p-value against the FC observed in T2DM samples compared to the 
controls. To prioritise robustly expressed miRNAs with fold changes that are likely to 
have biologically relevant effects, a filtering cut-off was set as Ct<35 and FC < -2 or > 2. 
This revealed that, out of the 115 miRNAs that had Ct values less than 35, 10% 
miRNAs were differentially regulated by these criteria as compared with the control 
group (p≤0.05). Out of these 11 miRNAs, seven were upregulated and four were 
downregulated. However, the shortcomings of pooled sample analysis are widely 
recognised, thus fold changes in pooled samples were validated by direct biological 
validation in individual samples. Owing to the small sample size and limited statistical 
power, multiple testing was not performed on preliminary data obtained from the pooled 
samples.   
 
To examine the expression of the 11 miRNAs identified as differentially regulated in 
the pooled screen in more detail, the expression of these miRNAs were analysed in 
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Figure 3.4 Heatmap of miRNA expression levels in hearts of control and T2DM 
patients. Unsupervised hierarchical clustering analysis was performed using log2 
transformed fold-change in expression of T2DM group compared to the control (4 
technical replicates in each group). Low expressions are shown in blue and yellow 
indicate high expression. Four technical replicates were obtained in each group. 
Clustering was performed using Cluster 3.0, heatmap was generated using TreeView 
1.60 (see Section 3.2.3.3).  
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A 
B 
-2.5        1:1         2.5 
Chapter Three 
 87 
 
  
 
 
 
 
 
 
 
Figure 3.5 Plot of nominal p-value against fold change for miRNAs in T2DM 
patients vs. control. miRNAs that lie in the shaded areas have fold changes of 2 or 
more, and nominal p<0.01. p-values were calculated using two-tailed t-test, assuming 
unequal variance between two samples. Multiple testing was not used. Instead, fold 
changes in pooled samples presented here were validated by direct biological validation 
in individual samples.   
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patients vs. control. miRNAs that lie in the shaded areas have fold changes of 2 or 
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Table 3.3 Expression levels of miRNAs prioritised in pooled sample studies in 
individual patient samples. qRT-PCR were performed in individual patient samples, 
fold change (FC) of the diabetic group (n = 6) compared to the control samples (n = 6) 
were determined by the ∆Ct method. p-values were obtained by t-test (see Appendix D).    
 
 
 
 
FC p- value FC p-value
hsa-miR-367 4.38 0.001 2.04 0.093
hsa-miR-223 3.73 0.012 1.99 0.021
hsa-miR-342 2.83 0.000 1.37 0.101
hsa-miR-187 2.47 0.050 5.01 0.030
hsa-miR-34a 2.16 0.038 2.04 0.001
hsa-let-7a 2.08 0.015 1.15 0.252
hsa-miR-302a 2.05 0.012 2.05 0.011
hsa-miR-125b -2.04 0.025 1.57 0.032
hsa-miR-335 -2.31 0.031 -1.02 0.477
hsa-miR-214 -2.64 0.000 1.12 0.329
hsa-miR-199a -3.88 0.026 1.66 0.096
Pooled sample 
analysis
Individual sample 
analysis
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individual patient samples by qRT-PCR (Table 3.3, Appendix D). Out of the 11 
miRNAs, fold changes of four miRNAs (miR-34a, miR-187, miR-223 and miR-302a) 
were confirmed in the independent samples. Although hsa-miR-125b was found to be 
downregulated in the pooled analysis, it was significantly upregulated in the individual 
sample study.  
3.3.5 Expression levels of miRNAs differentially regulated in T2DM 
patients in patients with LVD 
Similar to diabetic cardiomyopathy, LVD is characterized by myocardial insulin 
resistance (Dutka et al., 2006; Paternostro et al., 1996). To explore further miRNA 
expression in the insulin resistant heart, the study was extended to samples from 
patients with LVD. Expression levels of the miRNAs confirmed as differentially 
regulated in the T2DM group were examined in individual LVD samples by qRT-PCR 
(Figure 3.6). Levels of miR-34a and miR-187 were unchanged, whereas expression of 
miR-302a was 2.0 fold lower in LVD group samples than the controls (p=ns, Figure 
3.6C) and miR-125b was 1.4 fold higher in LVD (p=ns; Figure 3.6E). miR-223 was the 
only consistently differentially expressed miRNA in the insulin resistant heart with 2.2-
fold and 2.0-fold increase in LVD and T2DM patient groups respectively (LVD: 
p=0.056; T2DM: p=0.021; Figure 3.6D).   
3.3.6 Expression of DICER1 in the human LV 
DICER, the ribonuclease essential for the processing of mature miRNAs has an 
important role in the development of dilated cardiomyopathy and LVD (Chen et al., 
2008; da Costa Martins et al., 2008; Zhao et al., 2007). The expression level of DICER1, 
the gene that encodes for the RNase III DICER protein, was determined in the human 
samples. Gene expression was determined by qRT-PCR. Compared to the control group, 
DICER1 expression is down-regulated in LVD (FC=-2.15, p= 0.071) but unchanged in  
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Figure 3.6 Differential miRNA expression in T2DM and LVD compared with 
control in individual samples. Expression levels of a. hsa-miR-34a; b. hsa-miR-187; c. 
hsa-miR-223; d. hsa-miR-302a and e. hsa-miR-125b were determined in individual 
patient samples by qRT-PCR. Fold changes compared to the control group were 
calculated based on the ∆Ct method. Data represented as means of biological replicate 
of each patient group ± SEM (Control: n=6; T2DM: n=6; LVD: n=6), ** p = 0.001; * p 
< 0.05 and
 ∆
 p = 0.056 (one-tailed student’s t-test). 
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Figure 3.7 qRT-PCR analysis of Dicer 1 mRNA expression in human LV. 150ng of 
large RNA samples extracted from biopsy samples were used for each reaction. Gene 
expression of each group was detected from each sample individually (Control = 6, 
LVD = 6, T2DM = 6). Fold changes were calculated by comparing the mean Ct values 
of diseased groups with that of the control. Data represented as means ± SEM. 
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diabetic hearts (FC=1.09; Figure 3.7).  DICER protein analysis by immunoblotting was 
not possible due to the limited amount of biopsy samples for protein preparation and the 
poor quality of the DICER antibody (data not shown).     
3.4 Discussion 
In cardiac hypertrophy and heart failure there is profound dysregulation of miRNAs and 
a causative role of some specific miRNAs have been confirmed in these pathologies 
(Sayed et al., 2007; Thum et al., 2008a; van Rooij et al., 2008b). However the 
regulation of miRNAs in the insulin resistant heart, has not been characterised. In order 
to determine the expression of mature miRNAs in the insulin resistant human heart, 
small RNAs were isolated from LV biopsy samples collected from control patients and 
from two patient groups characterised by myocardial insulin resistance (T2DM and 
LVD) at the time of cardiac surgery.  
 
Microarray-based, large scale miRNA expression analysis technologies were not 
available at the onset of the study and hence a 96-well-plate format qRT-PCR method 
was used to determine miRNA expression levels in the human heart. To control for 
amplification variation between reaction plates, three internal control reactions 
amplifying rno-miR-16 from a common rat heart small RNA sample were included on 
each plate. A scaling factor was calculated based on the averages of the three control 
reactions on each plate. Ct values of the rest of the plate was then normalised using this 
scaling factor, this allows for the comparison of expression levels among reaction plates.  
Similar to observations of mRNA studies, finding a ‘housekeeping’ gene that is 
expressed at a constant level is also difficult for small RNA studies. Here, the ‘house 
keeping’ genes (5s rRNA and U6 snRNA, Figure 3.2) were differentially expressed 
among patient groups. Therefore, to calculate the relative expression levels (fold 
Chapter Three 
 93 
change), Ct values were normalised to total small RNA concentrations, using a standard 
curve method (Cook et al., 2002; Pfaffl, 2001). This method allows for more accurate 
correction of the amount of template in each reaction (Bustin, 2002).  
Expression levels of 115 miRNAs in the non-diabetic human heart with normal 
ventricular function were detected over 4 magnitudes of expression (Table 3.2). Based 
on the initial screen of pooled samples, ~10% of the miRNAs assayed exhibited changes 
in expression between the diabetic group as compared to the expression in the normal 
LV (Figure 3.4 and 3.5). For the initial pooled screen, because of small sample size and 
limited statistical power multiple testing was not used. If the multiple testing is applied, 
all variation would be lost. To control for this, differential expression detected in the 
pooled screen were validated by direct biological validation in individual samples. Not 
all differences could be validated in individual samples (Table 3.3 and Figure 3.6), 
indicating, as expected, expression profiling of pooled samples requires validation in 
individual samples. However, the preliminary pooled screen was unavoidable in this 
study as human heart biopsy samples are of limited amount and did not provide 
sufficient RNA to perform the initial analysis in individual samples.        
 
Compared to previous studies of end-stage LVD in humans (Thum et al., 2008a), there 
were less pronounced changes in miRNA levels and no change in DICER in the diabetic 
heart (Figure 3.7). Downregulation of DICER (FC=-2.15, P = 0.071) in the LVD group 
is in agreement with a previous report, where DICER protein levels were found to be 
significantly lower in the failing heart compared to the non-failure control. Interestingly, 
Dicer1 deletion in mice has severe structural and functional abnormalities in the heart 
(Chen et al., 2008). Decrease in Dicer1 may lead to a global down-regulation of mature 
miRNAs and this could be coupled with an increase in accumulation of pre-miRNA 
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sequences. Further large scale expression profiling studies on both pre- and mature 
miRNAs in LVD or heart failure samples could shed more light on the role of DICER in 
gene expression control via regulation of miRNA processing.    
Four miRNAs were confirmed as significantly upregulated in the diabetic heart. Among 
these, miR-34a, miR-125b, miR-187 and miR-223 have been reported to be involved in 
carcinogenesis (Johnnidis et al., 2008; Nikiforova et al., 2008; Scott et al., 2007; 
Yamakuchi et al., 2008), whereas miR-302a may have a role in stem-cell differentiation 
(Card et al., 2008; Greco and Rameshwar, 2007). None of these miRNAs have been 
previously implicated in insulin resistance. A recent study in a mouse model of 
myocardial infarction revealed that miR-223 is the most highly upregulated miRNA 
species in both border zone and remote myocardium 14 days after infarction (van Rooij 
et al., 2008b).  
 
In this chapter, miR-223 was the only miRNA identified as differentially regulated in 
both T2DM and LVD. As both LVD and diabetic patients are insulin resistant at the 
myocardial level and diabetic hearts are prone to heart failure (Cook et al., 2005), the 
potential role for miR-223 in cardiac insulin resistance was explored further. 
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CHAPTER FOUR 
Expression of miR-223 in the heart and its role in insulin 
signalling 
 
4.1 Introduction 
The diabetic and failing heart are both associated with myocardial insulin resistance and 
perturbed cardiac glucose metabolism. The insulin signalling pathway is the major 
regulator of cardiac glucose metabolism. Under normal physiological conditions, insulin 
induces cardiac myocyte glucose uptake through binding to the insulin receptor (IR) and 
activating the phosphatidylinositol 3-kinase (PI3K) pathway (Bertrand et al., 2008; 
Hirsch et al., 2007), which leads to the activation of protein kinase B (Akt) and 
translocation of insulin sensitive glucose transporter (GLUT4) from the cytosol to the 
sarcolemmal membrane (Pham et al., 2000; Zorzano et al., 1997). However, in insulin 
resistant states cardiac myocytes have a diminished response to insulin stimulation and 
reduced glucose uptake. Although the detailed mechanisms underlying insulin 
resistance remain to be fully characterised, miRNAs have already been implicated in 
glucose metabolism and insulin signalling in non-cardiac tissues. In the pancreas, miR-
375 was described to suppress glucose-induced insulin secretion (Poy et al., 2004); and 
members of the miR-29 family were upregulated in the skeletal muscle of the diabetic 
rat, and their overexpression induced insulin resistance in the cultured adipocytes (He et 
al., 2007). 
 
In chapter three, miR-223 was identified as the only miRNA upregulated in both 
diabetic and failing hearts, suggesting a possible role for this miRNA in the 
pathophysiology of myocardial insulin resistance. Previous studies of miR-223 have 
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focused on the role of this miRNA in establishing and maintaining the cell lineage of 
immune cells. The expression of miR-223 was first described in murine bone marrow, 
where it was found to be expressed in myeloid cell lineages (Chen et al., 2004). It was 
subsequently shown to be an essential modulator of myeloid differentiation in human 
(Fazi et al., 2005). In humans, the gene expressing miR-223 is located on the X 
chromosome, and in immune cells, its expression is regulated by two transcription 
factors C/EBPα and NFI-A. In addition to mammalian myelopoiesis, miR-223 is also 
involved in triggering the innate immune response in the lung (Moschos et al., 2007). 
To date, a functional role for miR-223 in the heart has not been reported, although it 
was found to be upregulated following myocardial infarction (van Rooij et al., 2008b). 
This chapter describes the effect of miR-223 on cardiac glucose metabolism and insulin 
signalling in vitro. 
4.2 Materials and Methods 
For descriptions of materials and methods used for PCR, standard cloning, qRT-PCR, 
Northern Blotting, tissue culture, protein extraction and quantification, immunoblotting 
and antibody used in this chapter, please refer to Chapter 2. For maps of all plasmids 
used, please refer to Appendix B. 
4.2.1 Histology and in situ hybridisation 
In situ hybridisation was performed as previously described (Moschos et al., 2007). In 
Brief, 10 µm thick cryosections were cut from OCT (Tissue-Tek, Surrey UK) embedded 
murine heart tissue, fixed in 4% (w/v) paraformaldehyde (Sigma; 10 min) and washed 
in Dulbecco’s Phosphate Buffered Saline (DPBS, Sigma). Sections were incubated with 
10 µg/ml proteinase K (Sigma) and re-fixed in 4% (w/v) paraformaldehyde. After 
washing in DPBS, sections were pre-hybridised in hybridisation buffer (50% formamide 
(Sigma), 5× SSC buffer (Sigma), 250 µg/ml yeast RNA (Ambion), 1× Denhardt's 
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solution (Sigma) in DEPC (Sigma) treated water) in a humidifying chamber. Sections 
were then incubated with 2 µM miRNA-specific Locked nucleic acid (LNA) probe or 
scrambled probe (Exiqon, Denmark) labelled with digoxygenin (DIG) in hybridisation 
buffer and incubated in a humidifying chamber at 50°C for 18h. Sections were washed 
twice in buffer (50% (v/v) formamide, 5× SSC buffer in DEPC-treated water) and in 
DPBS. Sections were incubated in blocking buffer (10% (v/v) sheep serum; Sigma; 1h) 
and then with sheep anti-DIG fAb fragments (Roche Diagnostics) labelled with alkaline 
phosphotase (AP) diluted in 10% (v/v) sheep serum (2h at room temperature). Sections 
were incubated with AP-substrate BCIP/NBT substrate kit (Vector Laboratories, 
Peterborough, UK; 12h) in a humidifying chamber, and then mounted with aqueous 
mounting media (Hydromount, National Diagnostics, Hull, UK). For routine 
histological staining, frozen tissue sections were cut at 10 µm thickness and fixed in 
95% ethanol (Fisher Scientific, Loughborough UK) for 10 min and stained with 
haematoxylin and eosin. Sequences of LNA-enhanced probes:  
Anti-rno-miR-223: GGGGTATTTGACAAACTGACA  
Scrambled control: TTCACAATGCGTTATCGGATGT 
4.2.2 Adenoviral-mediated overexpression of miRNAs in vitro  
4.2.2.1 Generation of adenovirus 
Primary miRNA sequences for miR-223 and miR-296 were amplified by PCR from 
Brown Norway (BN) rat genomic DNA.  
Primers used for miR-223 were: 
Forward: 5’actggaattcGGTGTCTTAGCCAGTCATGT3’  
Reverse: 5’actggcggccgcCTCTGAAGGATTGCTATAGTT3’  
Primers used for miR-296 were:  
Forward: 5’actggaattcTTGTGTTGGGGAGACAGAGG3’ 
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Reverse:  5’ actggcggccgcACCCCAAGAGCACTAACTGG3’ 
All primers were tagged with restriction enzyme site sequences at the 5’ end to allow 
for directional cloning. EcoRI sites (GAATTC) were added to the forward primers, and 
NotI sites (GCGGCCGC) to the reverse primer. PCR products were digested with 
EcoRI and NotI, and cloned into the EcoRI/NotI site of VQ Ad5CMV K-NpA plasmid 
(Appendix 3), supplied by ViraQuest Inc (North Liberty, IA, USA). Positive clones 
were screened by antibiotic selection and DNA sequencing. Viral particles were 
generated and titrated commercially by ViraQuest Inc (North Liberty, IA, USA). 
Method used by ViraQuest Inc for the viral generation was based on the technology 
described in (Anderson et al., 2000). All viral particles were stored in A195 buffer 
(Evans et al., 2004). 
4.2.2.2 Adenovirus infection 
For infection of cells, the indicated amount of virus (MOI, multiplicity of infection) was 
pre-diluted in maintenance media then added directly to the cell culture. For COS7 cells 
and NRVMs, cells were infected with virus 24 hours after serum starvation. For 
negative controls, cells were infected with equal concentrations of adenovirus carrying 
an empty construct (purchased from ViraQuest Inc). All viral expression experiments 
were performed 24~46 hours after infection. For insulin stimulation experiments, 
100nM of insulin was added to the cells for 1hour.  
4.2.3 Glucose uptake assay 
NRVMs were isolated and serum starved for 24 hours before being infected with 
adenovirus encoding miR-223 (Ad-miR-223), miR-296 (Ad-miR-296) or control virus 
at the specified concentrations. Glucose uptake was measured with minor adaptation to 
the method described by (Moyers et al., 1996). As a positive control for the assay, cells 
were treated with insulin (10
-7
M) or vehicle control for 30 min 46 hours after infection. 
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At the end of stimulation, cells were washed twice with PBS, and incubated for 10 min 
in glucose free media (Appendix A) containing [
3
H]2-deoxyglucose (0.2µCi/ml); for 
detection of non-specific incorporation, 10µM of cytochalasin B was added together 
with [
3
H]2-deoxyglucose. Cells were then washed 3× in cold PBS to remove 
unincorporated [
3
H]2-deoxyglucose, and permeablized with 0.1N NaOH. Incorporated 
radioactivity was measured by scintillation counting (Tri-Carb Liquid Scintillation 
Analyzer, Perkin Elmer, Waltham, Massachusetts, USA) with correction for non-
specific glucose uptake and protein levels. For wortmannin experiments, cells were 
treated with 100nM of wortmannin 15 min prior to insulin stimulation.  
4.2.4 AMPK activity assay 
NRVMs were cultured as described in Section 2.5.1. Cells were washed once with ice-
cold PBS then quickly harvested in lysis buffer specific for the assay following the ‘fast 
extraction’ protocol (50mM HEPES pH7.4/7.5, 10% (v/v) glycerol, 1mM EDTA pH8, 
1% (v/v) Triton, 0.1mM PMSF, 1mM dithiothreitol, 5mM sodium pyrophosphate, 
50mM sodium fluoride). Lysed cells were centrifuged for 20 min at 13 000 × g at 4°C, 
and the supernatant containing the solubilised fraction was stored at -80°C.  Total 
AMPK activity was measured by incorporation of 32p to SAMS peptide (His-Met-Arg-
Ser-A&-Met-Ser-Gly-Leu-His-Leu-Val-Lys-Arg-Arg). This AMPK activity was 
assayed by Dr N Marty (Cell Stress Group, Clinical Sciences Centre, MRC) as 
previously described (Cheung et al., 2000; Davies et al., 1989; Woods et al., 1996). In 
brief, total AMPK was purified from protein lysates by immunoprecipitation using anti-
AMPK antibody (rabbit, anti b1 and b2 subunit, produced by Prof Carling’s laboratory, 
Clinical Sciences Centre MRC; Thornton et al., 1998). Total AMPK activity was 
measured by incubating the immunoprecipitant with SAMS in a 
32
P containing buffer 
(Davies et al., 1989). Incorporation of 
32
P was measured by scintillation counting. Level 
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of phospho-acetyl-CoA carboxylase was analysed by immunoblotting using Phospho-
Acetyl CoA Carboxylase (serine 79) antibody at 1 in 1000 dilution (3661, Cell 
Signalling). Detailed materials and methods for immunoblotting are described in 
Section 2.7, Chapter 2.  
4.2.5 Immunofluorescence  
NRVMs were plated onto gelatine coated 8-well chamber slides at a density of 75 000 
cells per well. Cells were treated with serum free maintenance media before infection 
with adenovirus for 48 hours. For staining, cells were washed twice with ice-cold PBS 
then treated with 4% (w/v) paraformaldehyde for 15 min at 4°C. Cells were then 
incubated with 0.1% (v/v) triton X-100 (Sigma) in for 15 min at 4°C. After three washes 
in PBS, cells were blocked with 10% (v/v) FCS (in PBS) at room temperature for 20 
min, then incubated with Glut4-specific antibody (at 1 in 500 dilution in PBS; Abcam, 
Cambridge, UK) for 1 hour. Cells were then washed twice with PBS and incubated with 
FITC (Fluorescein isothiocyanate) conjugated anti-rabbit antibody (Invitrogen; 1 in 400) 
for 1 hour at room temperature. Cells were then stained with DAPI (VECTASHIELD 
Mounting Medium with DAPI ) and viewed using Leica TCS SP1 DM IRB confocal 
fluorescent microscope.  
4.3 Results  
4.3.1 Expression of miR-223 in the heart  
Previous studies have shown miR-223 to be highly expressed in the bone marrow (Chen 
et al., 2004). To determine the expression level of miR-223 in the heart as compared 
with other organs, miR-223 expression level was examined across mouse tissues by 
qRT-PCR and Northern blot analyses (Figure 4.1). Small RNA samples were prepared 
from 8 organs harvested from 8-week old C57Bl6 mice. For qRT-PCR, 5ng of small 
RNA was used in each reaction, and relative expression was determined based on the 
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Figure 4.1 Expression of miR-223 across tissues in the mouse. A, qRT-PCR analysis 
of miR-223 expression across tissues. Data are presented as FC in relation to the 
expression level observed in the lowest expressing tissue, the pancreas. Relative 
expression (FC) were calculated against the pancreatic expression (FC=1). Data are 
presented as means ± SD, n=2 for each tissue. B, Northern blot of miR-223 expression 
across tissues.  5S rRNAs are shown to indicate equal loading.  
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lowest expressing organ (the pancreas, Figure 4.1A). For Northern Blotting, 30µg of 
RNA sample was used from each tissue, 5’end-
32
P-labelled DNA oligonucleotides 
consisting complementary sequences to mmu-miR-223 was used as probe (Figure 
4.1B). Both methods showed miR-223 to be most highly expressed in the spleen and 
lung, moderately expressed in the heart and skeletal muscle, and expressed at low levels 
in pancreas and brain. To localise miR-223 to a specific cell type in the heart, rat heart 
cryosections were analysed by in situ hybridization using DIG-labelled LNA enhanced 
probes (Figure 4.2). This localized miR-223 expression to cardiac myocytes, with 
prominent peri-nuclear staining, and also in non-myocytes (interstitial and pericardial 
cells).  
4.3.2 Adenoviral expression vectors for miRNA overexpression 
studies 
In order to carry out functional studies of miR-223 in vitro, adenoviral vectors 
expressing miRNA sequences under the control of a CMV promoter were constructed. 
Pri-miR-233 and pri-miR-296 sequences were cloned into the VQ Ad5CMV K-NpA 
plasmid following standard cloning methods (Section 2.4, Chapter 2; Figure 4.3). 
Adenoviral vectors were generated for miR-223 (Ad-miR-223) and a miRNA that is not 
differentially expressed in the patient groups, miR-296, as control (Ad-miR-296). Viral 
stock concentrations were 4.0 × 10
10
 and 3.0 × 10
10
 plaque forming units per millilitre 
(pfu/ml) respectively for Ad-miR-223 and Ad-miR-296. Adenoviral particles carrying 
empty constructs were used as negative controls for the infection (purchased from 
ViraQuest Inc, USA). Negative E1 glycoprotein detection confirmed all viral stocks 
contained no detectable replication competent adenoviral particles (performed by 
ViraQuest Inc.).  
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Figure 4.2 In situ hybridization analysis of miR-223 expression in the rat heart. A 
and C, in situ hybridization at 20× and 40× magnification respectively. B and D, 
haematoxylin and eosin stain of contiguous sections at 20× and 40× magnification 
respectively. E, In situ hybridization with negative control (20×). Bar = 50µm (A, B and 
E); Bar = 25µm (C and D). In situ hybridization was performed using DIG labeled 
miRCURY™ LNA enhanced probes (Exiqon, Denmark) specific for rat miR-223; 
negative control contained scrambled sequence.   
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Figure 4.3 Maps of plasmids used for making miRNA expressing adenovirous.  Pri-miRNA sequences were amplified from rat cDNA and 
cloned into EcoRI and NotI sites of the pVQ-Ad5CMV K-NpA plasmid.  Sequence information of insert fragment are presented below the 
plasmid map. A. for miR-223 B. for miR-296. Pre-miRNA sequences are shown in bold, mature miRNA sequences are underlined. 
>pri-rno-miR-223 
GGTGTCTTAGCCAGTCATGTTAGTGTCTGCCATTTGTCTCACTCCCAGAGTA
AGGTATAATCAGCCCATTTTTTTTCCTTTCAGGTGCATATCTTCCAGCATGT
TCTTGCTGCTCATCCAAGGCTCCTGATCTGGCCTTCTGCAGTGTTACGCTCC
GTGTATTTGACAAGCTGAGTTGGACACTCTGTGTGGTAGAGTGTCAGTTTGT
CAAATACCCCAAGTGTGGCTCATGCTTATCAGCTCCAGGTCCAGGACTGAGC
AGATAGCCTGCTGTCTTCATATGAGTGCTTATGAAACATGAAGCTCTCTGGA
GTTATTCTATGGCTTTTTGAGGGAACTATAGCAATCCTTCAGAGG 
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Figure 4.4 Adenoviral-mediated overexpression of miR-223 and miR-296 in NRVMs. Cultured NRVMs were infected with Ad-miR-223, 
Ad-miR-296 or control virus (Ctrl) at indicated concentrations for 48 hours. Control virus expresses an ‘empty vector’ which does not carry any 
transgene. Increase in miR-223 and miR-296 levels were determined by qRT-PCR (A and B) and northern blot (C and D). 5S rRNAs are shown 
as loading control. Data are shown as mean ± SD, n=2. 
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To assess the degree of overexpression and to determine the virus concentration to use 
for in vitro functional studies, cultured NRVMs were infected with Ad-miR-223, Ad-
miR-296 or control virus at concentrations of 5, 10, 50, 100 MOI (multiplicity of 
infection) for 48 hours. Small RNA was extracted from the cells, and expression of 
mature miR-223 was analysed by qRT-PCR and Northern Blotting (Figure 4.4). Fold 
changes in miR-223 and miR-296 expressions were calculated by comparing the 
amount of the miRNA in the infected cells to that of the uninfected cells (0MOI). 
Detectable overexpression was achieved for both miRNAs, even at the lowest viral 
concentration tested (5 MOI; 17-fold for miR-223 and 50-fold for miR-296). Compared 
to uninfected cells, infection with the control virus at concentrations greater than 
10MOI downregulated the expression of endogenous miR-223 and miR-296 (Figure 
4.4). Since control viruses had the minimum effect on endogenous miRNA expression 
at 5 MOI and both vectors achieved sufficient levels of overexpression at this 
concentration, 5MOI of virus was used for all subsequent overexpression experiments.   
4.3.3 Overexpression of miR-223 increases glucose uptake in 
NRVMs  
Based on the observations in the insulin resistant human heart, the hypothesis that miR-
223 may play a role in cardiac insulin signalling and/or glucose metabolism was tested. 
To test this effect, rno-miR-223 was overexpressed in cultured NRVMs using 
adenovirus, and glucose uptake was determined by incubating the cells with [
3
H]2-
deoxyglucose containing media (Section 4.2.3). In the absence of insulin stimulation, 
Ad-miR-223 infection significantly increased (1.3-fold, p<0.05) glucose uptake, as 
compared to control virus infected cells (Figure 4.5A). The increase in glucose uptake 
in unstimulated Ad-miR-223 infected cells was of a similar magnitude to that observed 
for insulin stimulation of control virus infected cells (1.3 fold, p<0.01). No further  
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Figure 4.5 Glucose uptake assay in cardiac myocytes infected with Ad-miR-223 or 
control viruses in the presence or absence of insulin (A) or wortmannin (B). 
NRVMs were infected with Ad-miR-223, Ad-miR-296 or control viral (5 MOI each) 
vector for 46 hours, then stimulated with insulin (100nM) for 30 min (A) or with 
wortmannin (100nM) for 15 min (B). Cells were first treated with wortmannin if both 
stimuli were used. Glucose uptake was then assessed by incubating cells with [
3
H]2-
deoxyglucose containing media, incorporated tritium activity was measured by 
scintillation counting with correction for non-specific glucose uptake and protein levels. 
All data are represented as means ± SEMs, n=4. *p<0.05; **p<0.01 
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increase in glucose uptake was detected in cells treated with miR-223 virus and insulin. 
Overexpression of miR-296 was used as an additional control and had no effect on 
glucose uptake in cardiac myocytes. These data shows miR-223 affects glucose uptake 
at baseline, independent of insulin stimulation. To examine whether these effects were 
dependent on PI3K activity, the glucose uptake assay was repeated with the presence of 
wortmannin, the PI3K inhibitor (Figure 4.5B). A significant increase in glucose uptake 
(1.4-fold, p<0.05) with miR-223 overexpression remained after inhibition of the PI3K 
pathway, although total uptake was reduced in all cells treated with wortmannin.   
4.3.4 Overexpression of miR-223 inhibits insulin stimulated 
Akt/Gsk3β activation  
To dissect the mechanism underlying miR-223-induced glucose uptake, the insulin 
signalling pathway was examined in NRVMs following miR-223 overexpression, with 
or without insulin stimulation. By immunoblotting, at baseline, no detectable changes 
were observed in total levels of AKT, IRβ or IRS1. Similar results were observed for 
phosphorylated levels of AKT (serine 473) and glycogen synthase kinase 3, β subunit 
(GSK3β, serine 9). However, following insulin stimulation, the increase in phospho-Akt 
(serine 473) and Gsk3β (serine 9) was significantly attenuated in Ad-miR-223 infected 
cells as compared with control (38% and 33% reduction respectively, p<0.01; Figure 
4.6). This suggests miR-223 overexpression inhibits insulin stimulated Akt/Gsk3β 
phosphorylation in NRVMs. 
4.3.5 Effects of miR-223 expression on AMPK activity 
In addition to the insulin signalling pathway, AMPK activation in response to stress also 
increases glucose uptake in the heart (Russell et al., 2004). To investigate the effect of 
miR-223 on AMPK in cardiac myocytes, the beta subunit of AMPK was purified from 
NRVMs treated with Ad-miR-223, and the phosphorylation activity of the kinase was
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Figure 4.6 Immunoblots of insulin signalling proteins in samples from 
cardiomyocytes infected with Ad-miR-223 or control virus in the presence or 
absence of insulin. A. Representative immunoblots from three independent 
experiments with similar results. B and C. Semi-quantitative densitometry of changes in 
phosphorylation of Akt (Ser473, B) and Gsk3β (Ser9, C). All data are presented as 
means ± SEMs, n=3; **p<0.01. 
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Figure 4.7 Effects of miR-223 expression on AMPK activity. Cultured NRVMs were 
infected with Ad-miR-223 or control adenovirus for 48 hours. A. Total AMPK activity 
assay.  Total AMPKβ activity was measured using SAMS peptide. The amount of 
phosphorylation was determined by scintillation counting. Results in DPM were 
normalised against the amount of protein used per assay. B. Immunoblot on phospho-
acetyl-CoA carboxylase (ACC; serine 79).    
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tested using a synthetic peptide (SAMS peptide).  Compared to control, no significant 
change in AMPK activity was found in NRVMs overexpressing miR-223 (Figure 4.7A). 
Immunoblotting analysis on phospho-Acetyl-CoA carboxylase (ACC), a downstream 
target of activated AMPK, revealed no change in phosphorylation of the enzyme at the 
serine 79 residue (Figure 4.7B). Thus, miR-223 overexpression has no detectable effect 
on AMPK activity in cardiac myocytes.   
4.3.6 Overexpression of miR-223 increases total Glut4 protein level 
Given that miR-223 expression neither increases insulin signalling nor changes AMPK 
activity, the role of glucose transporters in miR-223-mediated glucose uptake was 
investigated. In cardiac myocytes, two proteins are primarily responsible for glucose 
transportation, Glut1 (basal uptake) and Glut4 (insulin sensitive glucose uptake). In 
miR-223 overexpressing NRVMs, total Glut1 levels were unchanged, whereas the total 
Glut4 levels were increased (1.3 fold, p<0.001; Figure 4.8A). To determine whether 
this increase is caused by changes in transcription, the level of Glut4 mRNA was 
analysed by qRT-PCR (Figure 4.8B). No difference in Glut4 mRNA was detected in 
cells overexpressing miR-223 as compared with control. This suggests that the increase 
in Glut4 protein induced by miR-223 overexpression is caused through post-
transcriptional mechanisms.   
4.3.7 Effects of miR-223 expression on Glut4 vesicle proteins and 
Glut4 localisation 
Glucose uptake can be regulated via GLUT4 carrying vesicle biogenesis in addition to 
changes in insulin signalling and Glut translocation. Levels of two proteins found in 
GLUT4 vesicles were therefore analysed by immunoblotting: SCAMPs, secretory 
carrier membrane proteins largely found in GLUT4 carrying vesicles in insulin-
sensitive cells (Fischer et al., 1997; Laurie et al., 1993), and UBC9, the small ubiquitin- 
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Figure 4.8 Levels of Glut4 in miR-223-overexpressing cardiac myocytes. A. 
Immunoblot of total cellular Glut1 and Glut4 levels in cardiac myocytes. Upper panel, 
representative immunoblot from three independent experiments with similar results. 
Lower panel, semi-quantitative densitometry of Glut4 protein levels. B. mRNA level of 
Glut4 by qRT-PCR. Data are represented as means ± SEMs, ***p<0.001. 
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Figure 4.9 Effects of miR-223 expression on GLUT4 vesicle protein levels. NRVMs 
were overexpressed with miR-223 for 46 hours and then stimulated with 100nM of 
insulin for 30 min. Total protein were extracted from cells and the levels of total 
SCAMP3 and Ubc9 were analysed by immunoblotting.   
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Figure 4.10 Cellular localisation of Glut4 in miR-223 overexpressed neonatal rat 
cardiac myocytes.  NRVMs were cultured in chamber slides, infected with Ad-miR-
223 and control virus, and stained with Glut4 specific primary antibody and FITC-
conjugated anti-rabbit secondary antibody. Cells were visualised at 40x magnification, 
bar = 20µm. A. and B, DAPI staining on cell nucleus, C. and D. Glut4, E. and F. 
overlay.  
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related modifier conjugating enzyme that regulates the GLUT4 turnover in adipose cells 
(Liu et al., 2007). In NRVMs, no difference in vesicle proteins levels were observed in 
miR-223 overexpressing cells as compared with control cells (Figure 4.9). Glut4 
cellular localisation was then assessed in neonatal cardiac myocytes. Using a Glut4-
specific antibody with a FITC-conjugated secondary antibody, the localisation of Glut4 
was analysed in miR-223 overexpressing NRVMs by immunofluorescence (Figure 4.10). 
Glut4 was mostly peri-nuclear localised, and the cytoplasmic localisation of Glut4 was 
more diffused in miR-223 overexpressing cells than in the controls.  
4.4 Discussion 
To date, miR-223 has been studied primarily in immune cells. Expression studies have 
previously described miR-223 as highly expressed in the bone marrow (Chen et al., 
2004), however, its levels in other tissues are not well described. In this study, 
expression analysis across tissues in mouse showed that, apart from bone marrow, miR-
223 is most highly expressed in spleen and lung (Figure 4.1), in agreement with a role 
for miR-223 in immune response and inflammation (Johnnidis e t al., 2008; Moschos et 
al., 2007). Among the tissues tested, miR-223 is moderately expressed in the heart, with 
prominent localisation peri-nuclear expression in cardiac myocytes and also expression 
in non-myocytes (Figure 4.2). Levels of intermediate miRNA expression may be 
particularly important for post-transcriptional gene regulation. Intermediately expressed 
miRNAs, such as miR-223, may function as a buffer to regulate genetic noise by fine 
tuning the amount of protein synthesised at the translational level (Hornstein and 
Shomron, 2006).  
 
miR-223 was upregulated in the hearts of patients with LVD or T2DM, conditions 
characterised by myocardial insulin resistance and abnormal glucose metabolism. To 
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investigate whether miR-223 plays a role in glucose metabolism in the heart, the effect 
of adenoviral-mediated miR-223 overexpression on glucose uptake was analysed in 
neonatal cardiac myocytes. This revealed overexpression of miR-223 in vitro 
significantly increases glucose uptake at baseline, independent of PI3K signalling. This 
increase was similar in magnitude to that induced by insulin stimulation (Figure 4.5).  
At the same time, high expression of miR-223 suppresses insulin-mediated induction of 
Akt and Gsk3β (Figure 4.6), suggestive of feedback inhibition of key mediators of 
insulin signalling. In contrast, miR-223 increased Glut4 protein levels through a post-
transcriptional mechanism (Figure 4.8). These data show that miR-223- induced 
glucose uptake is a result of increased Glut4 expression, and Glut4-mediated glucose 
uptake, which is independent of insulin signalling. In addition to changes in glucose 
metabolism, a decrease in Akt phosphorylation suggests miR-223 could cause cells to 
become less responsive to the insulin stimulation, which is similar to the signalling 
pattern found in insulin resistant cardiac myocytes. Collectively, miR-223 appears to 
have dual role of promoting glucose uptake via increase in GLUT4 level and, likely 
secondarily, inhibiting insulin signalling, possibly due to feedback inhibition. 
 
Apart from insulin signalling, glucose uptake can also be induced by AMPK, which 
promotes GLUT4 redistribution to the sarcolemmal membrane (Li et al., 2004; Yang 
and Holman, 2005) in response to stress. To determine if an enhanced AMPK activity is 
the cause of the observed increase in glucose uptake, the AMPK activity of miR-223 
overexpressed NRVMs was measured by the amount of phosphorylation of SAMS 
peptide (Davies et al., 1989). No difference in phosphorylation was observed between 
the miR-223 overexpressed NRVMs and control cells (Figure 4.7A); this result was 
confirmed by immunoblotting on phosphorylated ACC (Figure 4.7B). These data 
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indicates miR-223 induced glucose uptake was not caused by changes in AMPK 
activity, and miR-223 expression does not affect AMPK signalling in vitro. 
 
As discussed in Chapter 1, glucose uptake and metabolism are essential for cardiac 
energy production, especially in ischemic conditions. Previous studies have found that 
during ischemia, insulin signalling is impaired (Beauloye et al., 2001). However, 
glucose uptake is increased through AMPK signalling (Russell et al., 2004). In the 
present study, miR-223 was shown to upregulate glucose uptake at baseline independent 
of insulin and AMPK signalling, this suggests it may have a more pronounced effect on 
glucose uptake during metabolic stress such as ischemia and functions as a backup 
source of glucose supply. Further studies in models (in vivo or ex vivo) of myocardial 
infarction/ischemia could provide more insights into the metabolic function of miR-223. 
 
Since the increase in glucose uptake to NRVMs was independent of insulin and AMPK 
signalling, levels of Glut4 proteins were analysed in miR-223 overexpressing cardiac 
myocytes. Two previously described vesicle proteins that are involved in Glut4 vesicle 
biogenesis and translocation were examined. No detectable changes were observed in 
their expression with miR-223 overexpression (Figure 4.9), suggesting miR-223 
expression does not have an effect on Glut4 vesicle biogenesis. Although slight 
differences in the intracellular distribution of Glut4 were observed by 
immunofluorescence (Figure 4.10), in depth studies on Glut4 carrying vesicles are 
required to draw firm conclusions of the effects of miR-223 on Glut4 sub-cellular 
localisation.  Previous studies of Glut4 trafficking in adipose cells using Total Internal 
Reflectance Fluorescent microscopy suggested Glut4 vesicles are continuously 
trafficking to and from plasma membrane in absence of insulin; whilst following insulin 
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stimulation, the vesicles have increased pausing at the plasma membrane with higher 
probability of membrane fusion (Lizunov et al., 2005). Hence, miR-223 could be 
involved in the regulation and fine-tuning of Glut4 vesicle shuttling to and from the 
plasma membrane. The effect of miR-223 on Glut4 will be discussed further in Chapter 
5.   
 
In this chapter, the potential role of miR-223 in glucose metabolism and insulin 
signalling was examined in neonatal cardiac myocytes. It was found that miR-223 
induces glucose uptake in cardiac myocytes independently of PI3K/Akt activity and 
AMPK signalling, and involves post-transcriptional upregulation of Glut4 protein levels. 
In parallel, miR-223 decreased proximal insulin signalling after insulin stimulation, 
which is similar to the signalling pattern found in insulin resistant cardiac myocytes (He 
et al., 2006).  
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CHAPTER FIVE 
Prediction and validation of miR-223 targets in vitro 
 
5.1 Introduction 
miRNA bind to and inhibit target mRNA translation, therefore an approach for miRNA 
target identification is to use an in silico method. As described in Chapter 1, a number 
of miRNA target prediction program have been developed. However, the interaction 
between a miRNA and its target is more complex than initially expected and different 
algorithms identify disparate targets. Thus experimental validation of predicted target 
genes is essential for identifying true mRNA targets. 
 
Currently, there is no clear consensus as to which experimental approaches should be 
applied to prove a specific mRNA is the target of a miRNA species. A widely accepted 
approach uses the luciferase assay, where the 3’UTR sequence of the target mRNA, 
containing the predicted miRNA target site, is cloned downstream of luciferase, and the 
luciferase construct is then co-expressed with the miRNA in a cell-line. If an interaction 
between the miRNA and mRNA exists, luciferase activity is lower in cells co-
expressing the miRNA than in control cells. To confirm specificity, luciferase activity 
should be reinstated when the predicted miRNA binding site is mutated (Fazi et al., 
2005; Johnnidis et al., 2008; Poy et al., 2004). As a more direct assay, if an mRNA is 
the true target of a specific miRNA, alterations of the miRNA’s concentration should 
correspond with changes in the protein encoded by the mRNA. This can be assayed by 
overexpressing the miRNA (gain-of-function) in the cell type that is known to express 
the putative target protein and analysing protein levels by immunoblotting (Poy et al., 
2004; Zhao et al., 2007).  
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To date, using a combination of in silico and experimental techniques, three mRNA 
targets of miR-223 have been identified in granulocytes: NFI-A (Fazi et al., 2005), 
Mef2c and Igf1r (Johnnidis et al., 2008). During haematopoiesis, NFI-A was found to 
repress miR-223 expression in non-differentiating granulocytes; and in turn, NFI-A 
translation is repressed by miR-223 through a negative feedback loop. In other cell 
types, nuclear factor I is a mediator of insulin and cyclic-AMP stimulated repression of 
GLUT4 expression (Cooke and Lane, 1999a, b). Mef2c is also targeted by miR-223 in 
granulocytes, where it promotes myeloid progenitor proliferation. In skeletal muscle, 
MEF2C regulates GLUT4 expression (Moreno et al., 2003). In the heart, MEF2C is 
required for cardiogenesis, and inactivation of Mef2c in mouse leads to cardiac 
morphogenetic defects, vascular abnormalities and embryonic lethality (Morin et al., 
2000; Zang et al., 2004). Studies have also found MEF2C and MEF2C-regulated genes 
are decreased in the failing hearts of diabetic patients (Razeghi et al., 2002).  If MEF2C 
is a true miR-223 target in heart, miR-223 could influence MEF2C-regulated 
transcription, and establish a role for miR-223 in heart failure patients with diabetes. 
This chapter describes the predicted mRNA targets for miR-223 and presents results 
from experimental validations of selected predicted and previously confirmed targets in 
the cardiac myocytes.   
5.2 Materials and Methods 
For general materials and methods used for tissue culture, adenoviral infection, qRT-
PCR, cloning, transfection, protein extraction, immunoblotting and antibodies used in 
this chapter please refer to Chapter 2. For information on human biopsy samples, please 
refer to Chapter 3, Section 3.2.1  
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5.2.1 In silico miR-223 target prediction  
Five web-based miRNA target prediction programs were used for the prediction of 
miR-223 target genes (see Table 5.1 for URLs). Following program-specific 
instructions, mature hsa-miR-223 sequence was used to screen for human genes for 
potential miR-223 target sites. Where possible, only sites that were conserved across 
species and contain no G:U wobble base pairing were included. To prioritise target 
genes that are involved in insulin signalling and/or glucose metabolism, each predicted 
target was examined in the context of previous data relating to gene function. Targets 
that were predicted by more than one program and are known to be involved in glucose 
metabolism were prioritised for further study. 
5.2.2 Luciferase reporter assays using psiCHECK-2 vector  
The psiCHECK-2 (Promega, Southampton UK; Appendix B) vector enables 
monitoring of changes in expression of a target gene fused downstream of the Renilla 
luciferase gene. In this project, the plasmid was used to validate the authenticity of the 
predicted miRNA targets in luciferase assays. In general, 3’UTR sequences flanking the 
predicted miRNA binding site of potential mRNA targets was amplified by PCR from 
BN rat cDNA (refer to Appendix C for primer sequence information), and TA cloned 
into pTargeT™ vector (Promega) as described in Section 2.4.2. Clones with the 
sequence confirmed 3’UTR sequences were selected and the insert was sub-cloned into 
psiCHECK-2 vector by directional cloning using restriction enzymes NotI and XhoI 
(Section 2.4.5). Clones were screened by PCR and DNA sequencing. Selected clones 
were amplified by maxiprep (Section 2.4.8). For luciferase assay, in each transfection 
reaction, 100ng of plasmids were transfected into COS7 cells that were seeded onto 24-
well plates (1×10
5
 cells per well) the day before (as described in Section 2.5.3). After 
transfection (24 hours), media was removed, cells were washed twice with PBS and 
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lysed with 1× Passive Lysis Buffer (Promega, 30 min at room temperature).  Lysates 
were transferred into 96-well plates and renilla and firefly luciferase activity were 
detected using Dual-Glo™ Luciferase Assay System (Promega) using a FLUOstar 
OPTIMA (BMG Labtech, Aylesbury UK) according to the manufacturer’s instruction. 
In brief, lysates were first treated with equal volume of Dual-Glo™ Luciferase Buffer to 
activate firefly bioluminescence. After firefly luciferase activity had been measured, an 
equal volume of Stop & Glo
®
 buffer was added to allow the detection of Renilla 
luciferase activity. Data were analysed using MS Excel, Renilla luciferase activity was 
normalised against the firefly luciferase activity. Four biological replicates were set up 
for each transfection condition.  
5.2.3 GLUT4 expressing construct and transfection 
A construct expressing full length rat GLUT4 cDNA was purchased from Geneservice 
Ltd (Clone ID: IMAGE: 7192278) and sequence verified by DNA sequencing. COS7 
cells were transfected with 300ng of cDNA construct per well using Lipofectamine 
2000 (Invitrogen), and incubated at 37°C and 5% CO2 for 4 hours. Cells were then 
infected with virus at 5MOI (Ad-miR-223 or control). Cells were harvested 24 hours 
after infection, and total protein lysates were collected as previously described (Section 
2.6).  
5.3 Results 
5.3.1 Predicted targets of miR-223 
In Chapter 4, miR-223 was shown to promote glucose uptake through increased Glut4 
expression in cardiac myocytes. To identify the mechanism underlying this phenotype 
and to investigate the role of miR-223 in the heart, potential targets of miR-223 were 
prioritised using five independent in silico miRNA target prediction programs (Table 
5.1). The number of predicted targets varied greatly between algorithms, with the least  
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Table 5.1. Number of miR-223 target genes identified by miRNA target prediction 
software. The human genome was used for all predictions.  
 
Prediction 
Program 
Seed size 
(nt) 
mismatch 
Site 
conservation 
Number of target 
genes predicted 
Target Scan† 7-8 
 
(only 5’ of 
miRNA) 
 
(Mammals) 
202 
miRanda‡ Minimum 7  
 
(Mammals) 
1415 
miRBase 
version 5* 
Minimum 7 
  
(max. 1 allowed) 
 
(minimum 2 
species) 
999 
PicTar** Minimum 7 x 
 
(vertebrates & 
flies) 
180 
PITA§ Minimum 6 x 
  
(17 vertebrates & 
flies) 
285 
 
†
http://www.targetscan.org (Grimson et al., 2007) 
‡
http://www.microrna.org/microrna/home.do (Betel et al., 2008; John et al., 2004) 
*
http://microrna.sanger.ac.uk/targets/v5 (Griffiths-Jones et al., 2006; Griffiths-Jones et 
al., 2008) 
**
 http://pictar.mdc-berlin.de (Krek et al., 2005) 
§
http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html (Kertesz et al., 2007)  
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amount of targets predicted by TargetScan and the most from Human miRNA Targets. 
Using the prior experimental knowledge of a role for miR-223 in glucose metabolism, 
only candidates previously known to be involved in glucose uptake and/or insulin 
signalling were prioritised for further investigation. In total, 10 genes were selected as 
candidates (Table 5.2).  
5.3.2 Experimental validation of predicted candidates 
Among the predicted target genes, two were selected for further analysis: myotrophin 
(Mtpn) and Rab10. Mtpn is a nuclear factor-κB interacting protein that was found to 
have increased expression in failing human heart (Gupta et al., 2002; Sil et al., 1993), 
and is targeted by miR-375 during the regulation of glucose-stimulated secretion of 
insulin (Poy et al., 2004). Rab10, on the other hand, is a Rab GTPase that promotes 
GLUT4 translocation to the cell membrane in adipocytes (Sano et al., 2007). To verify 
their authenticity as miR-223 targets, both miRNA/mRNA interaction (by luciferase 
assay) and protein expression (by immunoblotting) were analysed (Figure 5.1). As a 
positive control, previously confirmed miR-223 targets, NfIa and Igf1r, were also 
included in the analysis. For protein expression analysis, NRVMs were infected with 
Ad-miR-223 or control virus for 48 hours, cells were then harvested and whole cell 
protein lysates were analysed by immunoblotting. Both myotrophin and Rab10 
exhibited no change in protein expression in miR-223 overexpressed NRVM. 
Surprisingly, neither of the positive controls (NfIa and Igf1r) showed a decrease in 
protein levels (Figure 5.1A). On the contrary, a two-fold increase was observed in 
nuclear factor IA level in cardiac myocytes overexpressing miR-223 (p<0.01).  
 
The interaction between miR-223 and predicted mRNA 3’UTR was further examined 
by luciferase assay (Figure 5.1B). The 3’UTRs of the predicted mRNA transcripts were 
  
1
2
5
 
Table 5.2. Predicted target genes of miR-223 involved in insulin signalling and glucose metabolism. 
 
Gene name Gene ID Gene Function Identified by Effects on insulin/glucose metabolism 
IGF1R ENSG00000140443 tyrosine kinase miRanda, TargetScan  
Induces cardiac growth/hypertrophy,  
previously validated target of miR-223 
(Johnnidis et al., 2008) 
MEF2C ENSG00000081189 Transcription factor miRanda, TargetScan, PicTar 
Regulates cardiac development and many metabolic 
effects, previously validated target of miR-223  
(Johnnidis et al., 2008) 
MTPN ENSG00000105887 
NF-κB interacting 
protein 
TargetScan , PITA, PicTar 
Increases in failing heart (Sil et al., 1993),  
involved in glucose-stimulated secretion of insulin 
(Poy et al., 2004) 
NF1A ENSG00000162599 Transcription factor 
miRanda, TargetScan, PITA, 
PicTar 
Transcriptional repression of GLUT4,   
previously validated target of miR-223 
(Fazi et al., 2005) 
PCK2 ENSG00000100889 carboxykinase miRBase, Target Scan 
Possible candidate for T2DM 
(Beale et al., 2007) 
PKC-έ ENSG00000171132 kinase miRanda 
Insulin exocytosis,  
negative regulation of insulin signalling 
(Mendez et al., 2003) 
RAB10 ENSG00000084733 GTPase 
miRanda, TargetScan, PicTar, 
PITA 
Regulates GLUT4 translocation (Sano et al., 2007) 
RPS6KB1 ENSG00000108443 kinase miRanda, TargetScan 
Component of Insulin signalling pathway 
(Chakraborty et al., 2007) 
SP1 ENSG00000172845 Transcription factor miRanda 
Control glucose transporter expression  
(Copland et al., 2007; Hwang and Ismail-Beigi, 2006) 
VAMP2 ENSG00000179036 Vesicle protein miRanda 
Required for GLUT4 translocation  
(Randhawa et al., 2000) 
  
1
2
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Figure 5.1. Experimental assessment of Rab10 and myotrophin as miR-223 targets A. Immunoblot analysis of protein levels encoded by 
predicted target genes of miR-223. Upper panels, representative immunoblots of Rab10 and Mtpn in Ad-miR-223 and control virus infected 
NRVMs. Previously verified miR-223 targets Nuclear Factor IA and Igf1r are included in the analysis as positive controls. Lower panel, semi-
quantitative densitometry of NFIA protein levels in Ad-miR-223 and control virus infected cells. Data are presented as mean ± SEM. ** p<0.01. 
B. Analysis of miRNA/mRNA interaction by Luciferase assay. 3’UTR sequences flanking the predicted miR-223 target sites were cloned 
immediately downstream of the renilla luciferase gene in the psiCHECK-2 plasmid and transfected into COS7 cells. Cells were infected with 
Ad-miR-223 and control virus 5 hours after transfection, and luciferase activity was measured 24 hours after transfection. Renilla luciferase 
activity was normalized against firefly luciferase activity. 3’UTR of Nuclear factor IA was included in the analysis as a positive control. All data 
are presented as mean ± SEM, n=4; * p=0.012.        
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cloned downstream of the renilla luciferase gene using the psiCHECK-2 plasmid and 
transfected into COS7 cells. Cells were infected with Ad-miR-223 for 24 hours, and 
luciferase activity was determined as described in Section 5.2.2. Consistent with the 
immunoblot results neither Rab10 nor Mtpn 3’UTRs showed changes in renilla 
luciferase activity, thus suggesting no interaction between the 3’UTR and the miRNA. 
In contrast to previous studies, cells transfected with psiCHECK-2 plasmids that contain 
the 3’UTR of NfIa showed a slight, but significant increase in luciferase activity upon 
miR-223 overexpression (10% increase, p=0.012). This result is in accordance with the 
apparent paradoxical increase in NfIa protein levels (Figure 5.1A).  
5.3.3 Is Mef2c a target of miR-223 in cardiac myocytes? 
Previous studies have shown that Mef2c is a target of miR-223 in neutrophils. 
Immunoblot anaylsis of human heart biopsy samples revealed that patients with either  
T2DM or LVD have significantly lower levels of MEF2C than that of the control group 
(Figure 5.2A). However, analysis of Ad-miR-223 infected NRVMs had no effect on 
Mef2c protein or transcript levels (Figure 5.2B), and transfection of NRVMs with a 
MEF2-Luciferase reporter construct confirmed no effect of miR-223 on Mef2c 
(experiment performed by collaborators at the Heart Failure Research Center, Academic 
Medical Center, Amsterdam, the Netherlands; data not shown). These results suggest 
that although miR-223 inhibits Mef2c in granulocytes and Mef2c is downregulated in 
the insulin resistant heart, it is not a direct target of miR-223 in cardiac myocytes in 
vitro.   
5.3.4 Glut4 as a miR-223 target 
As described in Chapter 4, overexpression of miR-223 caused an increase in glucose 
uptake in cardiac myocytes through an increase in total Glut4 protein level. In addition, 
in Section 5.3.2 miR-223 was found to increase the protein levels of NfIa (a known 
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Figure 5.2. Analysis of Mef2c by immunoblotting.  A. MEF2C expression in human 
LV. Biopsies were collected from LV of T2DM, LVD and control group patients as 
discussed in Chapter 2, 30µg of protein were resolved on SDS-PAGE. Blots were 
probed with MEF2C specific antibody. MEF2C is significantly lower in diabetic and 
LVD patients compared to the controls. B. Mef2c expression in Ad-miR-223 infected 
NRVMs by immunoblotting. C. Mef2c transcript level in miR-223 overexpressed 
NRVMs by TaqMan based qRT-PCR. Data are presented as mean ± SEM, n=3.  
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miR-223 target) in NRVMs. These data suggest that Glut4 could be a direct target of 
miR-223. In silico sequence analysis of the Glut4 3’UTR showed no predicted miR-223 
target sites in this region of the transcript. However, whole cDNA sequence analysis 
using free energy based miRNA prediction program PITA 
(http://genie.weizmann.ac.il/pubs/mir07/index.html), revealed 38 potential target sites 
for rno-miR-223 in the rat Glut4 sequence with a combined energic score (ddG) of -9.39 
(Table 5.3), and 47 potential target sites for mmu-miR-223 in mouse Glut4 cDNA with 
a combined ddG of -9.51 (Table 5.4). Analysis in the human GLUT4 cDNA also 
revealed 47 potential target sites for hsa-miR-223 with combined ddG of -11.04 (Table 
5.5).  These computational results suggest Glut4 could be a direct target of miR-223 
across species. To test this experimentally, full-length rat Glut4 cDNA was co-
expressed with miR-223 in COS7 cells (a cell line that does not express endogenous 
Glut4). Immunoblotting analysis of Glut4 showed a 1.6 fold increase (p<0.05) in total 
Glut4 level in cells infected with Ad-miR-223 as compared to control virus (Figure 5.3). 
This supports the hypothesis that miR-223 has a direct effect on Glut4.   
5.4 Discussion 
Identification of a bona fide miRNA target is a challenging task. In this chapter, 
predicted target genes of miR-223 from five miRNA target prediction algorithms were 
screened and targets with a functional role in glucose metabolism were prioritised 
(Table 5.1 and 5.2). As discussed in earlier sections, although most algorithms are 
designed on the six basic principles, various algorithms generate lists of disparate 
targets. Table 5.1 presents the number of mRNA targets of miR-223 predicted by each 
of the five algorithms. Among these, PicTar and TargetScan predicted the least number 
of targets as compared to microRNA.org and miRBase. This difference could be 
explained by the difference in filtering criteria used by the various algorithms.  
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Table 5.3. Predicted miR-223 binding sites in Glut4 cDNA in rat. 
 
 (http://genie.weizmann.ac.il/pubs/mir07/index.html) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 Position of predicted miR-223 binding site on the Glut4 cDNA. Shown in base pairs. 
2 
"X:Y:Z" seed notation: X= size of the seed; Y= number mismatches; Z= number of 
G:U wobble pairs.
 
3
 Energic score, a score of ~ -10 is predicted to be functional, depending on miRNA 
concentration.  
4
 Combined ddG from all predicted sites, indicates overall effect of all sites combined 
on Glut4.  
SITE PREDICTIONS  TARGET PREDICTIONS  
Position
1 
Seed
2
 ddG
3
 microRNA Sites Score
4 
2057  8:0:1 -9.07 rno-miR-223 38 -9.39 
2374  6:1:1 -7.7    
878  6:1:0 -6.87    
908  6:0:1 -4.39    
2212  6:1:0 -3.47    
1208  6:1:1 -2.3    
1592  6:1:0 -1.6    
912  6:1:1 -0.48    
1001  6:1:1 0.34    
1238  6:1:1 0.63    
916  7:1:1 1.76    
2341  6:1:0 1.9    
1335  6:1:1 2.13    
2087  6:1:1 2.23    
900  6:1:1 2.39    
294  6:1:1 2.74    
1565  7:1:1 3.42    
882  6:1:1 4.02    
755  6:1:1 4.61    
991  6:1:1 5.36    
956  6:1:0 5.36    
2112  6:1:1 5.73    
1982  8:1:1 6.04    
2258  6:1:1 6.27    
1419  7:1:1 6.46    
2276  6:1:1 6.73    
636  6:1:1 8.83    
1024  7:1:1 8.91    
551  6:1:1 9    
197  6:1:0 9.06    
1781  7:1:1 9.84    
1187 6:1:0 10.44    
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Table 5.4. Predicted miR-223 binding sites in Glut4 cDNA in mouse. 
(http://genie.weizmann.ac.il/pubs/mir07/index.html) 
 
 
 
 
 
 
 
 
 
SITE PREDICTIONS  TARGET PREDICTIONS 
Position
1
 Seed
2
 ddG
3
 microRNA Sites Score
4
 
2116 8:0:1 -8.46 mmu-miR-223 47 -9.51 
739 7:0:1 -8.38    
2431 6:1:1 -8.2    
947 6:1:0 -6.34    
1649 7:1:1 -4.35    
2267 7:1:0 -3.81    
1735 6:1:0 -3.44    
2130 6:1:0 -3.38    
2487 7:1:1 -3.34    
2619 6:1:0 -3.04    
1661 6:1:0 -3.03    
1729 8:1:1 -0.35    
237 6:1:0 0.16    
980 7:1:1 0.64    
977 6:1:1 1.01    
1277 6:1:1 1.12    
985 7:1:1 1.41    
363 6:1:1 1.47    
2171 6:1:1 1.94    
1256 6:1:0 2.03    
2397 6:1:0 2.26    
1307 6:1:1 2.36    
1070 6:1:1 2.62    
2730 7:1:0 2.65    
866 6:1:1 2.93    
2146 6:1:1 2.96    
1862 8:1:1 3.3    
1404 6:1:1 3.38    
818 6:1:1 3.38    
2556 6:1:1 3.64    
1488 7:1:1 3.68    
1635 6:1:1 3.78    
824 6:1:1 3.99 
659 6:1:1 4.09 
951 6:1:1 4.25 
1093 7:1:1 4.42 
266 6:1:0 4.91 
270 6:1:1 5.36 
1506 6:1:1 6.02 
969 6:1:0 6.59 
2226 6:1:1 6.93 
705 6:1:1 7.12 
2588 7:1:1 7.19 
620 6:1:1 7.93 
1470 6:1:1 8.06 
1060 6:1:1 8.79 
1855 7:1:1 11.04 
1
 Position of predicted miR-223 binding 
site on the Glut4 cDNA. Shown in base 
pairs. 
 
2 
"X:Y:Z" seed notation: X= size of the 
seed; Y= number mismatches; Z= number 
of G:U wobble pairs.
 
 
3
 Energic score, a score of ~ -10 is 
predicted to be functional, depending on 
microRNA concentration.  
 
4
 Combined ddG from all predicted sites, 
indicates overall effect of all sites 
combined on Glut4.  
 
Chapter Five 
132 
 
Table 5.5. Predicted miR-223 binding sites in Glut4 cDNA in man. 
(http://genie.weizmann.ac.il/pubs/mir07/index.html) 
 
 
 
 
 
 
 
 
SITE PREDICTIONS  TARGET PREDICTIONS 
Position
1
 Seed
2
 ddG
3
 microRNA Sites Score
4
 
2794  6:1:1 -11.01 hsa-miR-223 55 -11.04 
1640  7:1:1 -6.74    
752  6:1:1 -6.36    
938  6:1:0 -5.99    
730  7:0:1 -5.42    
2197  6:1:1 -4.24    
2857  6:1:1 -3.6    
2807  6:1:1 -3.43    
1295  6:1:1 -3.1    
511  6:1:1 -2.29    
2695  6:1:1 -2.02    
976  7:1:1 -1.25    
2181  6:1:0 -0.75    
1626  6:1:1 -0.31    
1726  6:1:0 -0.2    
354  6:1:1 -0.17    
2760  6:1:1 -0.0056    
2363  6:1:1 0.013    
650  6:0:1 0.53    
551  6:1:1 0.58    
1298  6:1:1 1.1    
2305  8:1:1 1.43    
2924  6:1:1 1.49    
3114  7:1:1 1.7    
2753  6:1:1 1.88    
972  6:1:1 1.92    
942  6:1:1 2.05    
2965  6:1:1 2.15    
1395  6:1:1 2.17    
1061  6:1:1 2.6    
257  6:1:0 3.32    
3063  6:1:0 3.9    
2560  6:1:0 3.93 
2381  7:1:1 3.94 
2452  6:1:0 4.85 
1268  6:1:1 5.13 
217  7:1:1 5.53 
1479  7:1:1 5.77 
2518  6:1:1 6.15 
2921  6:1:1 6.21 
581  6:1:1 6.27 
1084  7:1:1 6.3 
1101  6:1:1 6.54 
792  6:1:0 6.57 
2538  6:1:1 6.62 
594  6:1:1 6.78 
261  6:1:1 7.27 
1
 Position of predicted miR-223 binding 
site on the Glut4 cDNA. Shown in base 
pairs. 
 
2 
"X:Y:Z" seed notation: X= size of the 
seed; Y= number mismatches; Z= number 
of G:U wobble pairs.
 
 
3
 Energic score, a score of ~ -10 is 
predicted to be functional, depending on 
microRNA concentration.  
 
4
 Combined ddG from all predicted sites, 
indicates overall effect of all sites 
combined on Glut4.  
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Figure 5.3. miR-223 expression directly affects total Glut4 level. COS7 cells 
overexpressing full-length rat Glut4 cDNA were infected with Ad-miR-223 or control 
virus. 24 hours after infection, total Glut4 expression was analysed by immunoblotting 
with Glut4 specific antibody. Upper panel, representative blot of total Glut4. Lower 
panel, semi-quantitative densitometry of Glut4 protein levels in COS7 cells. Cells 
overexpressed with miR-223 showed 1.6-fold increase in total Glut4 level as compared 
to cells expressed with Glut4 but treated with control virus. Data are presented as mean 
± SEM. * p<0.05. 
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Predictions from TargetScan and PicTar preferentially select for transcripts with at least 
one conserved 7- or 8-mer site on the 3’UTR. Whereas algorithms such as miRanda and  
miRBase allow mismatch or wobble base pairing to the seed tend to generate large 
number of target sites/genes. However, a recent study of the impact of miRNAs on 
protein expression levels suggested inclusion of mismatch or wobble base pairing may 
compromise the proportion of true targets of the prediction (Baek et al., 2008).     
 
Among the genes prioritised in this study, Rab10, Mtpn, NfIa, Igf1r and Mef2c were 
chosen for experimental validation in cardiac myocytes. Neither Rab10 nor Mtpn were 
confirmed as miR-223 targets by luciferase assay or immunoblotting analysis (Figure 
5.1), although proteomic analysis in neutrophils cultured from miR-223
-/-
 mice revealed 
1.4 fold increase in Rab10 and Mtpn protein levels with similar fold changes in mRNA 
levels, suggesting Rab10 and Mtpn could be regulated by miR-223, at least in 
neutrophils (Baek et al., 2008). Surprisingly, NfIa, Ifg1r and Mef2c, three previously 
verified miR-223 targets, were not downregulated by miR-223 in cardiac myocytes. 
Strikingly, protein levels of NfIa were actively increased by 2-fold following miR-223 
overexpression (Figure 5.1A). These findings suggest that miRNA-mediated gene 
inhibition is tissue specific, and targets of miRNAs identified in one tissue type may not 
be relevant in another, particularly when one considers that miRNAs can 
‘paradoxically’ increase protein levels of target mRNAs in some cell types (Vasudevan 
et al., 2007). Indeed, studies of the effect of cell cycle and cellular stress have revealed 
that miRNAs can actually activate translation (Vasudevan et al., 2007). This finding 
may be particularly important for cardiac myocytes that are terminally differentiated.  
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MEF2C is a transcription factor that regulates glucose metabolism and promotes Glut4 
expression in the skeletal muscle (Moreno et al., 2003), and was found to be 
downregulated in failing hearts of diabetic patients (Razeghi et al., 2002).  In the present 
study, immunoblotting analysis revealed MEF2C to be significantly downregulated in 
both diabetic and failing heart (Figure 5.2A). This finding confirms a potential role for 
MEF2C in the insulin resistant heart. MEF2C is a known target of miR-223 in myeloid 
cells, however, in vitro studies in cardiac myocytes detected no interaction between 
miR-223 and Mef2c (Figure 5.2B and C), indicating the decrease in MEF2C observed 
in T2DM and LVD patients is likely independent of miR-223.  
   
In Chapter four, miR-223 was shown to increase total Glut4 protein in cardiac myocytes.  
Despite the fact that Glut4 3’UTR is not predicted to have miR-223 target sites, its 
protein levels were increased in COS7 cells overexpressing miR-223 (Figure 5.3). The 
mechanism underlying this effect is still unclear, however target prediction using full-
length cDNA sequence of Glut4 revealed a number of potential target sites in rat, mouse 
and man, reflecting miR-223 binding to functional sites in coding, 5’ or 3’UTR mRNA 
sequence of Glut4 (Tables 5.3, 5.4 and 5.5). Although a large proportion of predicted 
targets consist 6-mer seed sequences, direct interaction between miR-223 and Glut4 
could be enforced by multiple binding to target sites by the miRNA. This is supported 
by findings from the ENCODE (Encyclopedia of DNA Elements) project that identified 
multiple miRNA sites throughout the coding gene sequences (Birney et al., 2007).  
 
What could be the mechanism behind miR-223 mediated upregulation of Glut4? 
Because Glut4 was upregulated in both dividing (COS7 cells) and non-dividing cells 
(NRVMs) upon miR-223 overexpression, the change in Glut4 protein level may not be 
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caused by cell-cycle specific miRNA-mediated translational activation (proposed by 
Vasudevan et al., 2007). Studies in human cell lines and C. elegans have shown 
interaction between the RISC complex and other mRNA binding proteins such as 
ribosomal proteins to suppress translation (Chendrimada et al., 2007), miR-223 
associated RISC factor could be interacting with other RNA binding proteins that acts 
as translational enhancers. On the other hand, miR-223 might not be the direct regulator 
of Glut4, instead, it could be inhibiting the expression of a Glut4-specific repressor, thus 
when miR-223 is overexpressed, the repressor level decreases, and the inhibition of 
Glut4 is then removed.  
 
Findings presented in this Chapter question the utility of miRNA target prediction 
programs, a point highlighted in a recent study that revealed only a third of predicted 
targets were verifiable experimentally, whereas numerous ‘non-targets’ were 
differentially regulated at the protein level following miRNA deletion in the mouse 
(Baek et al 2008). Furthermore, the striking observation of increased NfIa and Glut4 
protein levels with miR-223 overexpression suggests miRNA-mediated gene regulation 
is cell-type specific, and the induced glucose uptake observed in cardiac myocytes could 
be a result of direct induction of Glut4 level by miR-223. 
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CHAPTER SIX 
In vivo studies of miR-223 
 
6.1 Introduction 
In vivo study of gene function is a crucial step for determining a gene’s role in 
physiological processes. Loss- and gain-of-function studies in mouse have revealed 
profound functions of miRNA in many aspects of cardiac physiology, such as cardiac 
hypertrophy, cardiac contraction, arrhythmia and cardiac fibrosis. In this study, to 
examine the effect of miR-223 on Glut4 protein expression, two mouse models were 
developed: in vivo inhibition of miRNA using chemically modified oligonucleotides 
and cardiac-specific overexpression of miR-223.   
 
By adopting the principles of RNAi, chemically synthesised antisense oligonucleotides 
(ASOs) can be used to silence endogenous miRNAs (Krutzfeldt et al., 2005). These 
ASOs contain sequences complementary to the mature sequences of the corresponding 
target miRNAs. To reduce RNase-mediated degradation and to facilitate cell uptake 
upon in vivo administration, these ASOs are often modified with 2’O-Methyl modified 
nucleotides on a phosphorothioate backbone, and contain hydroxyprolinol-linked 
cholesterol on the 3’ end. Krutzfeldt and colleagues (2005) showed that intravenous 
administration of ASOs to mice significantly decreased targeted miRNA levels. Carè 
and colleagues (Care et al., 2007) successfully inhibited miR-133 expression in the 
heart and induced cardiac hypertrophy with single infusion of anti-miR-133 ASO using 
an osmotic gradient pump. More recently, systemic inhibition of miR-29 by direct tail-
vein injection lead to increased collagen mRNA expression in the heart (van Rooij et al., 
2008b).   
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Gain-of-function transgenic (TG) animal models are a powerful tool for the study of the 
molecular and cellular mechanisms of diseases such as cardiac hypertrophy and heart 
failure. Trangenic mice can be generated by microinjection of DNA encoding the gene 
of interest directly into the pronucleus of fertilised mouse oocytes (Gordon and Ruddle, 
1981; Gordon et al., 1980). Post injection, surviving oocytes are implanted into the 
oviducts of a pseudo-pregnant female and allowed to develop. Microinjection of DNA 
leads to the integration of 1 to 50 copies of the transgene at a single site on the 
chromosome. Rarely two sites of integration are found in a single animal. If the 
integration occurs before the embryo divides into the two cell stage, all cells will 
contain the transgene, thus allowing the transgene to be passed on to subsequent 
generations. Once founder mouse carrying the transgene is identified, it can be bred 
with inbred lines of wild-type mice to produce a line of heterozygous transgenic mice. 
Procedures for screening potential founders for the presence of the transgene, include 
PCR or Southern Blot using DNA isolated from tail tip or ear clip biopsies (Hogan, 
1994). A wide range of mouse strains can be used for transgenic studies, and the well-
characterised strain of choice for cardiovascular research, the C57/BL6, is often used. 
To increase transgene insertion, a founder transgenic mouse can be generated using a 
hybrid strain (e.g CBAB6/F1) and backcrossed to C57/BL6 mice (Auerbach et al., 
2003).  
 
Given that the integration of transgene is present in all nucleated cells of the transgenic 
animal, in order to express a gene in an organ-specific manner, a cardiac-specific 
approach relies on the
 
use of a cardiac-specific promoter that is able to
 
drive high levels 
of cardiac-restricted expression. The α-MHC promoter has been the promoter of choice 
to direct cardiac-specific overexpression and a wide range of transgenes have been 
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expressed using this construct (Cook et al., 2008; Molkentin and Robbins, 2008). In the 
heart, there are two isoforms of the myosin heavy chains, α and β-MHC. The genes 
expressing these proteins are located in tandem, separated by 4.5kb of intergenic 
sequence, with β-MHC gene located 5’ upstream of the α-MHC gene (Mahdavi et al., 
1984). In the rodent, α-MHC is expressed continuously in the
 
atria throughout the 
development whereas the expression of β-MHC
 
is restricted to the ventricles during this 
period. While β-MHC is downregulated
 
soon after birth, transcription of α-MHC is 
initiated and continues to be the predominant isoform of MHC in the adult (Lompre et 
al., 1984). The expression of α-MHC is highly specific to the cardiac myocytes 
(Subramaniam et al., 1991), this is enforced by a GATA motif 1.9kb upstream of the 
gene’s transcription start site, which only interact with cardiac myocyte specific GATA 
binding factors (Huang and Liew, 1997), thus the promoter activity of α-MHC is highly 
cardiac specific. Although the expression of α-MHC is at its highest in postnatal mouse 
heart, owing to the changes of α-MHC gene expression through out development and 
the fact that the activity of the α-MHC promoter is suppressed during the development 
of many experimental forms of cardiac hypertrophy and heart failure, it is unlikely that 
the transgene expression can be maintained at a steady state over the prolonged period, 
which may be required for the development of any phenotype. 
 
Magnetic resonance imaging (MRI) is a non-invasive, medical imaging technology used 
to assess the function and structure of the body. MRI technology uses a powerful 
magnetic field to align the nuclear magnetisation of hydrogen atoms in water in the 
body. Radiofrequency fields are used to systematically alter the alignment of this 
magnetization, causing the hydrogen nuclei to produce a rotating magnetic field 
detectable by the scanner. This signal can be manipulated by additional magnetic fields 
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to build up enough information to construct an image of the body. Cardiac MRI is based 
on the principles of whole body MRI with optimisations made in the use of ECG 
(electrocardiogram) gating and rapid imaging techniques, specific for the cardiovascular 
system. Cardiac MRI can provide highly accurate 3-dimentional representations of 
cardiac structure and function (Hoit, 2001). Apart from its clinical applications, cardiac 
MRI technology has also been developed to study phenotypic alterations in research 
animal models such as TG mice.  
 
This chapter describes the molecular and physiological findings observed from both 
gain- and loss-of-function studies on miR-223 in the mouse with respect to earlier in 
vitro findings.   
6.2 Materials and Methods 
This section describes materials and methods used specifically for this chapter. For 
information on general materials and methods such as qRT-PCR and western blotting, 
please refer to Chapter 2.  
6.2.1 miRNA inhibition in vitro by antisense oligonucleotides 
Anti-miRNA oligonucleotides specific for miR-223 were commercially synthesised 
(Thermo Scientific). Each oligonucleotide consists of 2’O-methyl modified nucleotides, 
with phosphorothioate links between nucleotides 1, 2 and 3 and between the last four 
nucleotides. All inhibitors were tagged with a cholesterol molecule at the 3’ end. 
NRVMs were serum starved and transfected with 100nM of anti-miR-223 
oligonucleotides or 100nM of non-targeting oligonucleotides comprising sequences 
antisense to cel-miR-67 (negative control) using Lipofectamine 2000 reagent 
(Invitrogen) following procedures described in Section 2.5.3. Transfections were done 
in triplicates. Cells were incubated at 37°C, 5% CO2 for 48 hours before harvest.  
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Sequences of antisense oligonucleotides were:  
Anti-miR-223: 5’UGUCAGUUUGUCAAAUACCCC3’ 
Anti-cel-miR-67 (negative control): 5’UCACAACCUCCUAGAAAGAGUAGA3’ 
6.2.2 miR-223 silencing in vivo 
All animal related procedures were carried out under the authority of the appropriate 
Home Office (UK) personal and project licences in accordance with the Home Office 
Animals (Scientific Procedures) Act 1986. Mice were maintained on a 12 h light/dark 
cycle and an ad libitum diet of standard mouse chow (RE3, Special Diet Service). 
Synthetic oligonucleotide inhibitors comprising complementary sequence to miR-223 
and cel-miR-67 (negative control) were designed and supplied by Dharmacon Inc. 
(Thermo Scientific, Chicago, IL, USA). Ten-week old C57BL/6 male mice received 
either anti-mmu-miR-223 or anti-cel-miR-67 at a dose of 80mg/kg body weight or a 
comparable volume of buffer (used to solubilise the ASO, supplied by Dharmacon Inc.) 
through tail vein injection. Tissues were harvested 48 hours after treatment.  
 
At the end of the experiment, tissues were harvested from adult animals which were 
humanly killed under the regulation of Schedule 1 of Animal (Scientific Procedures) 
Act 1986. Tissues were dissected, weighed, rinsed in cold PBS, and snap frozen in 
liquid nitrogen then stored at -80°C. Expression of miR-223 was determined by miR-
223 specific qRT-PCR following procedures described in Sections 2.2.1. Blood samples 
were collected from the tail vein, clotted blood was centrifuged at 2000 × g for 15 min 
at 4°C, serum samples were then stored in separate tubes at -80°C. Blood glucose levels 
were measured from tail bleed using OneTouch
®
 Glucose Monitor (LifeScan Canada 
Ltd, Burnaby, Canada) following manufacture’s instruction. Serum insulin level was 
measured by Enzyme-Linked Immuno Sorbent Assay (ELISA) using the Rat/Mouse 
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Insulin ELISA Kit (Linco Research, St Charles, MO, USA) following the 
manufacturer’s protocol.  
6.2.3 Cardiac-specific transgenic mouse 
Primary miR-223 sequence was amplified from BN rat genomic DNA using primers 
with restriction site linkers on the 5’end. SalI sites (GTCGAC) were added to the 
forward primers, and HindIII sites (AAGCTT) on the reverse primer. Primers used for 
the amplification were: 
Forward: 5’cgtagtcgacGGTGTCTTAGCCAGTCATGT3’  
Reverse: 5’cgtaaagcttCTCTGAAGGATTGCTATAGTT3’  
 
PCR products were digested with SalI and HindIII, and inserted into the SalI/HindIII 
site of pBS2/α-MHC vector (gift from Rosenzweig Lab, Harvard Medical School, USA, 
with approval of J Robbins; Appendix B). Positive clones were selected by ampicillin 
and PCR; selected clones were sequenced. Once sequence verified, plasmids were 
amplified by maxi-prep as described in Section 2.4.8. For microinjection, the plasmid 
was digested with restriction enzyme NotI and digested DNA was resolved by agarose 
gel electrophoresis. The DNA band containing the α-MHC promoter and the pri-rno-
miR-223 insert (~6.6kb) was excised out and purified using QIAquick Gel Extraction 
Kit (QIAGEN) according to manufacturer’s protocol. Purified DNA was eluted in 
Water for Embryo Transfer (Sigma), and applied onto a Spin-X 100 column (Sigma) 
and centrifuged at 13 000 × g for 5 min at room temperature. DNA was quantified by 
spectrophotometry (Nanodrop Technology), and diluted to 2ng/µl. Transgenic mice 
were generated by the Transgenics and Embryonic Stem Cell Research Libratory at the 
Clinical Sciences Centre, MRC by pronuclear microinjection of DNA into a F1 
CBA/B6 × CBA/B6 hybrid mouse oocytes using standard technique (Hogan, 1994). 
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Injected oocytes were implanted into a surrogate female. Positive offspring were 
screened by PCR and selected founders were used for backcrossing to C57/BL6 mice. 
All offspring from each generation were genotyped, and positive mice were used for 
backcross. Animals were maintained and bred in the Central Biological Services Unit at 
Hammersmith Hospital Campus, Imperial College. Mice were kept on a 12 hour 
light/dark cycle and an ad libitum diet of standard mouse chow. All procedures were 
carried out under the authority of the appropriate Home Office (UK) personal and 
project licences in accordance with the Home Office Animals (Scientific Procedures) 
Act 1986. 
6.2.3.1 DNA extraction and genotyping   
Tail tip or ear clip biopsies were collected from weaned pups. DNA was extracted 
following the HotSHOT method (Truett et al., 2000). Biopsies were incubated in 75µl 
of alkaline lysis buffer (Appendix A) for 5 min at 100°C, then mixed by vortexing for 
20 seconds, and incubated again at 100°C for 5 min. The samples were then vortexed 
again and kept on ice to cool. Once cooled, 75µl of neutralising buffer (Appendix A) 
was added to each sample. For PCR, 1µl of the DNA sample was used for 10µl reaction. 
PCR was performed following the standard PCR protocol as described in Section 2.4.1. 
Primers used for genotyping were:  
Forward: 5’CCCACACCAGAAATGACAGACA3’ (binding to the α-MHC promoter), 
Reverse: 5’cgtaaagcttCTCTGAAGGATTGCTATAGTT3’ (binding to the miR-223 
insert).  
PCR products were resolved on agarose gel electrophoresis. Samples with a band of 
~0.5kb are selected as positive.    
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6.2.3.2 Phenotypic Studies on the transgenic mice 
Tissues were harvested from adult animals which were humanly killed under the 
regulation of Schedule 1 of Animal (Scientific Procedures) Act 1986. Tissues were 
dissected, weighed, rinsed in cold PBS and snap frozen in liquid nitrogen. Expression of 
the transgene was determined by miR-223 specific qRT-PCR and Northern Blotting 
following procedures described in Sections 2.2.1 and 2.3. For immunoblotting analyses, 
protein lysates were purified as described in Section 2.6. 
6.2.3.3 Functional assessment of the heart by cardiac MRI 
Cardiac function of mice at 10 months of age was assessed by cardiac MRI.  Animals 
were anesthetised with 1.5–2% isoflurane-oxygen mixture, and ventilated using a small 
animal ventilation apparatus. Cardiovascular MRI was performed on a 9.4T horizontal 
MR scanner (Varian, Palo Alto, CA, USA) located in the Biological Imaging Centre 
(Clinical Sciences Centre, MRC, Imperial College London). Electrocardiogram was 
monitored with a monitoring and gating system (SA Instruments, Inc. Stony Brook, NY, 
USA). Scout Gradient echo images were acquired in order to obtain the short-axis plan 
(cross-sectional view) of the heart, transverse sectional view was obtained from the 
short-axis plan. The following parameters were used for image acquisition: RF coil = 
rapid 38; PW/length = 2msec; FLIP angle = 90°; amplification power ratio = 
25.2~27.7dB; shim (line width) = 200~380Hz. All imaging were performed by facility 
staff at the Biological Imaging Centre (in collaboration with Dr W Gsell and Dr M 
Wylezinska-Arridge, Biological Imaging Centre, Clinical Sciences Centre, MRC).      
 
Stroke volume was calculated by capturing consecutive cross section images of 1mm 
thickness from the atrium to the apex, the LV volume was calculated following the 
Simpson’s rule (Niwa et al., 1996) at the end of diastole and systole, and the stroke 
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volume was determined based on the difference between the end diastolic and systolic 
volumes.  
6.3 Results 
6.3.1 Loss-of-function studies  
6.3.1.1 miR-223 inhibition in vitro  
Loss-of-function studies were carried out using Anti-miR-223 ASOs. Prior to in vivo 
administration, the silencing effect of the ASOs on the miRNA in cardiac myocytes was 
tested in vitro. Cultured NRVMs were transfected with anti-rno-miR-223 or anti-cel-
miR-67, a negative control that inhibits miR-67 in Caenorhabditis elegans. Cells were 
harvested 48 hours after transfection, and RNA extracted. Quantitative RT-PCR 
analysis revealed miR-223 level was reduced by 93% compared to the cells treated with 
negative control (Figure 6.1), demonstrating high efficiency of the ASO in silencing 
endogenous mature miR-223.    
6.3.1.2 miR-223 inhibition in vivo 
For in vivo loss-of-function studies of miR-223, chemically modified ASOs were 
administered by direct injection via the mouse tail vein. Ten-week-old C57/BL6 mice 
were treated with single dose (80mg/kg body weight) of Anti-mmu-miR-223, Anti-cel-
miR-67 (negative control) or equal volumes of buffer control with three animals in each 
treatment group. Animals were sacrificed 48 hours after injection; body, heart and LV 
weight were recorded and tibial lengths were measured (Table 6.1). To assess the effect 
of ASOs on the heart, heart and LV weights were indexed to body weights and tibial 
length (Figure 6.2). As experiment was designed to observe acute molecular changes, 
no changes in either heart or LV weight were detected.    
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Figure 6.1. Inhibition of miR-223 in NRVMs by anti-sense oligonucleotides. 
Primary cultures of NRVMs were treated with 30nM of Anti-cel-miR-67 (negative 
control) or anti-rno-miR-223. Expression of miR-223 was measured by stem-loop qRT-
PCR, and its levels in the anti-rno-miR-223 treated cells were compared with cells 
transfected with the non-targeting negative control. Percentage of knock down indicates 
the level of expression in antagomir treated cells in relation to the control cells (data 
presented as means ± SEM; * p=0.0014; n=3). 
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Table 6.1 Measurements of mice treated for loss-of-function studies. 
 
Animal ID Treatment
Body weight    
before injection (g)
Body weight                   
48 hrs after injection (g)
Heart Weight 
(mg)
LV weight 
(mg)
Tibial Length 
(mm)
LV weight/ 
heart weight
LV weight/ 
tibial length
1 Saline Control 23.0 24.5 131.2 81.3 18.0 0.62 4.52
2 Saline Control 25.0 22.1 114.5 69.8 17.5 0.61 3.99
3 Saline Control 24.2 24.5 124.9 79.7 17.0 0.64 4.69
4 Anti-cel-miR-67 22.3 21.4 108.0 70.5 17.0 0.65 4.15
5 Anti-cel-miR-67 23.8 22.8 110.1 73.8 17.0 0.67 4.34
6 Anti-cel-miR-67 23.1 22.3 121.8 73.5 17.0 0.60 4.32
7 Anti-mmu-miR-223 23.6 21.6 106.0 74.3 16.5 0.70 4.50
8 Anti-mmu-miR-223 21.3 20.4 101.8 65.6 16.5 0.64 3.98
9 Anti-mmu-miR-223 24.9 23.6 125.6 80.4 18.0 0.64 4.47
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Figure 6.2 Indexed heart and LV weight of ASO treated mice.  Ten-week-old mice were administered with 80mg/kg of anti-mmu-miR-223, 
anti-cel-miR-67 or equal volumes of buffer. Animals were sacrificed 48 hours after treatment, and body, heart, LV weights and tibial length were 
measured before tissues were harvested. No difference in heart and LV weights were observed in mice treated with anti-mmu-miR-223. Data are 
presented as mean ±SEM, n=3.   
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Figure 6.3 Expression of miR-223 across tissues. Animals administered with ASOs 
were sacrificed 48 hours after treatment, tissues were harvested, and RNA was extracted. 
Expression of mmu-miR-223 were analysed by stem-loop qRT-PCR. Data are presented 
as mean ±SEM, n=3. *p< 0.05; **p<0.01.  
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6.3.1.3 Inhibition of miR-223 levels across tissues 
At end of the 48-hour treatment, mice were sacrificed and tissues were harvested. RNA 
samples were purified from LV, skeletal muscle (SM), liver, kidney, spleen, lung and 
brain. The expression of miR-223 was analysed by stem-loop qRT-PCR (Figure 6.3). In 
anti-mmu-miR-223 treated mice, the expression of miR-223 was decreased significantly 
by 48% in the LV and 30% in the SM. miR-223 level were dramatically decreased in 
liver and kidney (84% and 94% respectively), the route (hepatorenal) through which 
ASOs are excreted.  
6.3.1.4 Blood glucose level is lower in anti-mmu-miR-223 treated mice 
In chapter 4, in vitro studies on miR-223 identified its involvement in regulation of 
glucose uptake. Therefore, non-fasted blood glucose were measured to determine the 
effect of systemic miR-223 inhibition. Glucose levels in anti-mmu-miR-223 treated 
animals were significantly reduced by 40% (p<0.001; Figure 6.4A), while serum 
insulin levels remained unchanged (Figure 6.4B). Hence the reduced blood glucose 
level is not a result of alteration in serum insulin level.  
6.3.1.5 Alterations in Glut4 expression in LV and SM 
The expression of Glut4 levels were assessed in the LV and SM at the protein and 
mRNA levels. In the LV, immunoblotting analysis revealed Glut4 protein levels were 
significantly reduced (33%, p<0.05) compared to mice treated with buffer control and 
21% compared to mice treated with anti-cel-miR-67. Surprisingly, total Glut4 levels in 
skeletal muscle were increased in anti-miR-223 treated mice (3 fold, p<0.001) as 
compared to buffer control or anti-cel-miR-67 treated animals (Figure 6.5). No 
significant changes in Glut4 mRNA were observed in either LV or SM samples (Figure 
6.6). Collectively, alterations observed in this study in the LV appear to complement the  
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Figure 6.4 Non-fasted blood glucose level and serum insulin level in ASO treated 
mice.  Ten-week-old mice were administered with 80mg/kg of anti-mmu-miR-223, 
anti-cel-miR-67 or equal volumes of buffer. 48 hours after treatment, prior to sacrificing 
the animal, venous blood glucose level was measured using a glucometer (A), and blood 
serum were collected from the tail vein, and serum insulin levels were determined by 
ELISA (B). Data are presented as mean ± SEM, n=3. Statistical significance was 
analysed by one-way ANOVA; *** p<0.001.  
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Figure 6.5 Alterations in total Glut4 protein levels in LV and skeletal muscle. Ten-
week-old mice were administered with ASOs as previously described. Whole cell 
protein lysates were harvested from LV and SM, total Glut4 protein level was 
determined by immunoblotting using Glut4 specific antibody. Upper panels, 
immunoblot of total Glut4 in LV. Gapdh are presented as loading control. Lower panels, 
semi-quantitative densitometry of Glut4 protein levels normalised against loading 
control. A=LV and B=SM. Data are presented as mean ± SEM, * p<0.05; *** p<0.001. 
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Figure 6.6 mRNA level of Glut4 by qRT-PCR in LV and SM. Total RNA were 
extracted from LV and SM of mice treated with Anti-mmu-miR-223 or controls. Glut4 
mRNA levels were determined by SYBR Green based qRT-PCR. Fold change in 
expression was calculated using the ∆Ct method, and the level of expression was 
normalised to total RNA concentration.  Data are represented as means ± SEMs, n=3. 
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in vitro observations described in Chapter 4; however, the effects of miR-223 
expression on Glut4 in SM are paradoxical.   
6.3.2 Gain-of-function studies 
To determine the effects of miR-223 overexpression in vivo, a cardiac-specific miR-223 
gain-of-function mouse model was generated. As described in Section 6.2.3, pri-rno-
miR-223 sequence was PCR amplified from the genomic DNA of BN rat and cloned 
into pBS2/α-MHC vector, downstream of the α-MHC promoter. The plasmid was then 
linearised and injected into CBA × C57/BL6 hybrid mouse oocytes. Injected oocytes 
were implanted into a surrogate female. Positive offspring were screened by PCR. 
Among the 10 offspring generated from the injected oocytes, two were positive for the 
transgene (Figure 6.7), and were selected for breeding. Founder mice were repeatedly 
back-crossed with C57/BL6 mice (Charles River) to obtain offspring on a C57/BL6 
genetic background. Mice generated from each cross with the wildtype C57/BL6 mouse 
were genotyped by PCR, and positive animals were used for the next backcross. Two 
transgenic lines were established, and four backcrosses were achieved for each line at 
the time of submission of this dissertation. 
6.3.2.1 Expression of miR-223 in the transgenic heart 
To assess the specificity of transgene expression in the heart and the level of 
overexpression, tissues from TG mice at the second backcross were harvested, and the 
level of mature miR-223 was assessed by qRT-PCR and Northern Blotting. Figure 6.8 
summarises miR-223 expression detected by qRT-PCR in the TG mice compared to the 
WT littermates, where expression of the miRNA is 64 folds higher in the TG compared 
to the WT (p<0.0001; Figure 6.8A and B). In addition, unvarying levels of miR-223 in 
the TG and WT spleen demonstrate the overexpression is heart specific (Figure 6.8C). 
Results from qRT-PCR analyses were further validated by northern blotting (Figure 
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Figure 6.7 Genotyping for founder animals. Tail tip biopsies were collected from 
founder animals. DNA was extracted using the HotSHot method. PCR were performed 
using forward primers binding to the MHC promoter and reverse primers binding to the 
transgene. PCR amplicons were resolved on 2% (w/v) agarose gel. Bands were 
visualised with ethidium bromide, and visualised under UV light. Expected band size: 
~420bp. A. Initial genotyping. B. Confirmation of initial genotyping result. Animals 3 
and 7 were identified as founder animals. 
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Figure 6.8 Analysis of miR-223 expression in transgenic mice by qRT-PCR. Heart and spleen were harvested from wildtype (WT) and 
transgenic (TG) littermates. Expression of mature miR-223 was analysed by qRT-PCR. A. Expression of miR-223 in heart and spleen of TG and 
WT presented in Ct values. B Expression of miR-223 in the heart of TG mice compared to WT (p<0.0001). C Expression of miR-223 in the 
spleen of TG mice compared to WT.  
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Figure 6.9 Northern Blot on miR-223 in TG mice. A. miR-223 expression in the LV 
of TG and WT mice. B. Expression of miR-223 across tissues in TG mice. 5S rRNAs 
are shown to indicate equal loading.  
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6.9). Comparing the expression of miR-223 across tissues in TG mice (Figure 6.9B), 
the expression was only elevated in the LV, as compared to the WT distribution (Figure 
4.1, Chapter 4) 
6.3.2.2 Expression of miR-223 targets in transgenic heart  
As described in Chapter 5, in the attempt to identify targets of miR-223, the expression 
levels of several proteins were tested in NRVMs, however, none of the genes tested 
showed a decrease in expression upon miR-223 overexpression, this includes previously 
validated targets NFIA and IGF1R. To further assess this unexpected finding in vivo, 
the levels of Nfia, Igf1r and Rab10 were analysed in the TG heart (Figure 6.10). 
Similar to in vitro observations, no detectable changes were found in the genes tested. 
These findings further confirm that NfIa and Igf1r are not regulated by miR-223 in the 
heart, and supports the hypothesis that miRNA mediated gene regulation could be 
tissue-specific.  
6.3.2.3 Effects of miR-223 overexpression on Glut expression and 
translocation 
Expression of Glut was analysed by immunoblotting in the TG heart. Total Glut4 
expression in the heart was not affected by miR-223 overexpression (Figure 6.11A). 
Although there is a trend of decreasing in Glut1 protein level in TG heart, this alteration 
was not statically significant (p=0.09, Student’s t-test). To assess the affect of miR-223 
overexpression in Glut4 sub-cellular localisation in vivo, LVs were collected from TG 
and WT littermates, membrane and protein fractions were extracted, and membrane 
Glut4 content was analysed by immunoblotting (Figure 6.11B). Compared to whole 
cell protein lysates (30µg), the amount of Glut4 protein was 3-fold higher in the 
membrane fractions. No difference in membrane or cytosolic Glut4 expression levels 
was observed between TG and WT mouse heart.   
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Figure 6.10 Immunoblotting analysis of predicted miR-223 targets. Left ventricles 
of eight-week-old TG and WT littermates were collected. Total protein extracts were 
purified and immunoblotting analysis was performed using specific antibodies. Gapdh 
is presented to show equal loading.   
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Figure 6.11 Immunoblots of Glut4 and Glut1 expression. A. Levels of total Glut4 
and Glut1 protein in the TG mouse heart compared to the WT. B. Levels of total and 
membrane Glut4 protein in the TG mouse heart compared to the WT. Upper panels, 
immunoblot of Glut1 and Glut4; lower panels, semi-quantitative densitometry on 
protein levels.  
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6.3.2.4 Effects of miR-223 overexpression on insulin signalling 
In chapter 4, overexpression of miR-223 in cultured cardiac myocytes was shown to 
decrease Akt and Gsk3β phosphorylation upon insulin stimulation. To test the effect of 
miR-223 overexpression in the transgenic model, levels of phospho-Akt and Gsk3β at 
the resting state were determined by immunoblotting. Twelve 8-months-old animals 
were examined in total; 6 TG mice were compared with and 6 WT littermates, no 
significant difference in Akt and Gsk3β phosphorylation (Ser473 and Ser9, respectively) 
was observed (Figure 6.12).   
6.3.2.5 Effects of cardiac-specific expression of miR-223 on heart 
physiology  
No apparent structural cardiac abnormality was observed in the TG mice and there was 
no significant difference in heart and LV weight between the TG and WT mice. To 
assess the effects of aging on cardiac function of the transgenic mice, 8 TG and 6 WT 
non-bred male mice were maintained separately for aging. Animals were sacrificed at 
10 months of age, tissues were collected, body, heart and LV weights were recorded and 
tibial lengths were measured. Indexed heart and LV weights were compared between 
TG and WT mice, and no difference was observed (Figure 6.13).    
 
Among the aged mice, the cardiac function of 3 TG and 3 WT mice were assessed by 
cardiac MRI at 10 months of age. Animals were scanned with a 9.4T MR Scanner in 
collaboration with the Biological Imaging Centre (CSC, MRC, Imperial College 
London). Transverse and cross-sectional images of the heart were obtained (Figure 
6.14). Compared to the WT controls, TG mice showed normal ventricular thickness and 
systolic function. No difference was observed in left ventricular stroke volume, ejection 
fraction, and percentage wall thickening between the TG and WT animals (Table 6.2). 
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Figure 6.12 Analysis of Akt and Gsk3β phosphorylation in the transgenic heart. 
Upper panel, immunoblot of phospho-Akt (Ser473) and phosphor-Gsk3β (Ser9); lower 
panel, semi-quantitative densitometry on protein levels.  
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Figure 6.13 Indexed heart and LV weight of 10-month-old TG mice. Non-bred male mice were sacrificed at 10-months of age. Body, heart, 
LV weights and tibial length were measured during tissue harvesting. No difference in heart and LV weights were observed between TG and WT 
mice. Data are presented as mean ±SEM, TG n=8; WT n=6.   
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Figure 6.14 Representative cardiac MR images of TG and WT transgenic mice. 
Ten months old non-bred male were scanned with 9.4T scanner. A, C, E and G shows 
images of TG mouse (animal 3), and B, D, G and H are images from the WT mouse 
(animal 5). A and B, transverse sectional view captured at diastole. C and D, transverse 
sectional view captured at systole. E and F, cross-sectional view at the papillary muscle 
level captured at diastole; G and H, cross-sectional view at papillary muscle level 
captured at systole. Images showed normal systolic function of the transgenic mouse 
heart. 
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Table 6.2. Cardiac function of miR-223 TG mice compared to WT as assessed by 
cardiac MRI. Cross sectional images of 1mm thickness were captured along the short-
axis to cover the entire ventricle. Stroke volume, ejection fraction and percentage wall 
thickening were calculated from images taken, as described in Section 6.2.3.3. Data are 
presented as mean ± SD. 
  
 WT (n=3) TG (n=3) 
LV stroke volume (mm3) 32.4 ± 2.94 34.02 ± 7.56 
Ejection fraction (%) 76.33 ± 2.05 73.9 ± 7.53 
% wall thickening 32.04 ± 17.71 39.55 ± 20.81 
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These results indicate miR-223 transgenic mice have normal cardiac function, and miR-
223 overexpression has no apparent effects on cardiac function in mouse in the absence 
of perturbation.   
6.4 Discussion 
In vivo functional studies are valuable tools for validation of in vitro observations. This 
chapter describes the application of both gain- and loss-of-function mouse models for 
miRNA studies. Anti-miR-223 ASOs were intravenously administered into wildtype 
C57/BL6 mice. Overall, significant reduction in miR-223 levels were observed in all 
tissues examined, with 48% knockdown observed in the heart, which was associated 
with a significant decrease in total Glut4 protein level in the heart (Figure 6.5A). This 
observation in the heart is in accordance with the findings described in vitro, where 
overexpression of miR-223 in cardiac myocytes induces total Glut4 protein levels. A 
significant reduction in blood glucose level was observed in mice treated with anti-
mmu-miR-223 (Figure 6.4). This could be caused by unexpected increase in Glut4 
protein level found in the SM (Figure 6.5B), although only 30% reduction of miR-223 
level was achieved.  
 
How can these apparently paradoxical observations be explained? Apart from 
conventional views that miRNA reduce the levels of its target protein, recent studies 
have shown miRNA can have different gene regulatory functions depending on the cell 
type (Vasudevan et al., 2008). Although similar in some ways, cardiac muscle is 
fundamentally different to skeletal muscle. The data presented in this chapter suggest, 
as a fine tuner of glucose metabolism, miR-223 could be controlling the same target in 
the heart and skeletal muscle, but regulating them in opposing ways. Alternatively, the 
in vivo observations could be caused by miRNA-silencing artefacts. Off-target effects in  
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siRNA studies have been noted to have observable phenotypic effects (Fedorov et al., 
2006; Xu et al., 2007), and the silencing efficiency could result in different phenotypic 
outcome. In this study, only 30% silencing of miR-223 was achieved in the skeletal 
muscle, whereas in the heart, the miRNA was knocked down by almost 50%. 
Nonetheless, further proteomics or gene expression analyses on these tissues or other 
animals subjected to prolonged miR-223 inhibition could give insights on miR-223 
targets in the heart and skeletal muscle, and possibly provide true explanation for these 
contradicting observations 
 
To study the effect of miR-223 overexpression in vivo, a heart specific gain-of-function 
model was generated. Although mature miR-223 level were increased in the heart 
(Figure 6.8), no detectable effects of miR-223 overexpression on cardiac function, 
metabolism or insulin signalling was observed. However, this does not imply miR-223 
expression has no effects in the heart in vivo. Studies of systemic deletion of miRNA in 
C. elegans revealed, individually, only a few miRNAs are essential for development and 
viability, and few miRNA-target relationships result in an overt phenotype (Miska et al., 
2007). This suggests, instead of gene switches that turn genes on or off completely, 
miRNA-mediated regulation acts as a buffering mechanism to increase the fidelity of 
processes (e.g. post-translational regulation). However, these subtle alterations can be 
challenging to detect using standard approaches. To detect the phenotypic effects in 
such cases, perhaps the best approach might be to subject miRNA loss- of gain-of-
function models to environmental stresses (Flynt and Lai, 2008). For this study, based 
on the role of miR-223 in glucose metabolism, gain- or loss-of-function mouse models 
could be achieved using insulin stimulation or by subjecting the heart to alterative 
stresses, such as myocardial infarction or ischemia.  
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CHAPTER SEVEN 
General discussion 
 
7.1 Summary of results 
1. miRNAs are differentially expressed in insulin resistant human heart as compared to 
control heart samples. Hsa-miR-223 is upregulated in hearts of type 2 diabetic 
patients and patients with LVD.   
 
2. In rodent heart, miR-223 is expressed at intermediate levels as compared to other 
organs and is expressed in both cardiac myocytes and fibroblasts with predominant 
peri-nuclear localisation. 
 
3. Adenoviral mediated overexpression of miR-223 in rat neonatal cardiac myocytes 
increases glucose uptake independent of PI3K/Akt activity and AMPK signalling. 
 
4. miR-223 overexpression inhibits insulin stimulated Akt/Gsk3β phosphorylation in 
neonatal cardiac myocytes.  
 
5. Glut4 protein levels are increased by miR-223 overexpression in both cardiac 
myocytes and COS7 cells 
 
6. A previously proven miR-223 target in immune cells, NfIa, is upregulated by miR-
223 in neonatal cardiac myocytes.  
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7. Systematic inhibition of miR-223 in vivo reduces blood glucose level, decreases 
Glut4 protein level in the heart and increases Glut4 protein levels in the skeletal 
muscle.    
 
8. Transgenic mice overexpressing miR-223 specifically in cardiac myocytes have 
normal cardiac physiology and function at baseline. 
7.2 General discussion and conclusion 
The studies presented in this dissertation were designed to assess whether miRNAs have 
a role in the insulin resistant heart. The initial study determined the overall expression 
patterns of miRNA in the human heart, which is followed by in vitro gain-of-function 
studies in rat neonatal cardiac myocytes, and then these findings were investigated 
further in vivo using loss- and gain-of-function studies. 
 
Chapter 3 presents the first quantitative miRNA expression analysis in the human heart 
using samples from patients with T2DM and LVD, diseases that are characterised by 
myocardial insulin resistance. Differences in miRNAs expression were observed in 
hearts from T2DM patients compared to previous end-stage LVD miRNA expression 
studies, suggesting a disease specific miRNA expression pattern in the heart. Among 
the dysregulated miRNAs identified, only one miRNA (miR-223) is co-ordinately 
upregulated in both T2DM and LVD patient hearts, suggesting a possible role for this 
miRNA in insulin resistance and glucose metabolism. 
 
Previous studies of miR-223 have focused predominantly on its role in the myeloid 
system. The first evidence of the involvement of miR-223 in insulin signalling and 
glucose uptake in the heart is presented in Chapter 4, where the function of miR-223 in 
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glucose metabolism and insulin signalling was analysed in vitro. It was found that, 
independent of AMPK activity, miR-223 increases cellular glucose uptake by 
upregulating Glut4 protein level. In parallel, miR-223 also inhibited insulin-stimulated 
Akt and GSK3β phosphorylation. Recent miRNA studies have shown miR-223 was 
increased post-MI in mouse (van Rooij et al., 2008b). It is known that MI and cardiac 
ischemia increases glucose uptake to the heart, and insulin-stimulated glucose uptake is 
beneficial during MI in humans (Bucciarelli-Ducci et al., 2006; Diaz et al., 1998; 
Krljanac et al., 2005). These findings indicate that glucose uptake induced by miR-223 
could provide protective mechanism for the heart in ischemic conditions, as the usual 
insulin induced glucose uptake could be impaired due to acidosis produced by the 
ischemia (Beauloye et al., 2001; Hue et al., 2002).  
 
In order to dissect the mechanism underlying miR-223 induced glucose uptake and 
Glut4 upregulation, predicted miR-223 mRNA targets were analysed in Chapter 5. 
Unexpectedly, none of the predicted targets tested showed direct interaction with miR-
223 in cardiac myocytes, including previously confirmed targets. There could be a 
number of explanations for this observation. 1) miRNA induced gene regulation could 
be highly tissue/cell type specific, and targets that have been identified in one tissue 
may not be regulated by the same miRNA in another. 2) Messenger RNA encoding the 
same gene may be alternatively sliced in different cell types, as a result, miRNA 
binding site could be abolished (Sandberg et al., 2008).  3) Current understanding of 
miRNA-target interactions have been previously deduced from miRNAs that are highly 
expressed (Bartel, 2009). For miR-223, all previous target validation studies were 
performed in cells of myeloid lineage, where the miRNA is most highly expressed. In 
the heart, miR-223 is only expressed at moderate level, and moderately expressed 
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miRNA could interact with its mRNA target in a different manner which still needs to 
be elucidated. 4) Target-site accessibility may also be affected by cell type. RNA-
binding cofactors that help miRNA binding to the target mRNA could be expressed 
only in certain tissue type, thus prevent miRNA-mRNA interaction when the cofactor’s 
expression is affected (Bhattacharyya et al., 2006). 5) miRNA may have opposite 
regulatory functions in dividing cells compared to cells at cell cycle arrest. Studies of 
the effect of cell cycle have revealed that miRNAs can actually activate translation in 
non-dividing cells (Vasudevan et al., 2007). This finding is particularly important for 
studying miRNA functions in the heart, as cardiac myocytes are terminally 
differentiated, thus miR-223 targets identified in other tissues (e.g. myeloid cells) may 
not be regulated in the same manner in cardiac myocytes.  
 
In addition to gene repression, miRNAs can also increase protein levels of target 
mRNAs (Vasudevan et al., 2007, 2008). This raises the question, is the increase in 
Glut4 protein level (Chapter 4) a direct effect of miR-223? This was investigated in 
Chapter 5. Although Glut4 does not have a miR-223 target sites in its 3’UTR, site 
prediction using the full length Glut4 cDNA, including the 5’UTR and ORF, suggested 
a number of sites that could potentially be interacting with the miRNA. This is 
supported by findings from the ENCODE project that identified multiple miRNA sites 
throughout the coding gene sequences (Birney et al., 2007). In situ hybridisation and 
immunofluorescence analyses demonstrated that both miR-223 and Glut4 protein are 
localised predominantly in the peri-nuclear regions in cardiac myocytes, and studies 
have confirmed that in both NRVM and COS7 cells Glut4 protein increases with miR-
223 overexpression, suggesting a direct interaction between the two. However, further 
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experimentations such as luciferase reporter analysis are required to confirm if miR-223 
directly upregulates Glut4.  
 
Two in vivo models were used to further investigate the biological function of miR-223. 
Chapter 6 presented physiological and molecular findings from both models. Both gain- 
and loss-of-function studies resulted in apparent healthy animals with normal cardiac 
physiology and function at baseline. Some differences were observed in the loss-of-
function study where blood glucose levels were decreased. Glut4 protein level was 
downregulated in the heart, which complements the in vitro findings described in 
Chapter 4. However, no change in basal insulin signalling was observed. Surprisingly, 
Glut4 protein levels were upregulated in skeletal muscle, this could explain the dramatic 
decrease in blood glucose concentration, although the mechanism behind these robust 
observations needs to be studied further in skeletal muscle cells. Overall, the in vivo 
studies were less informative than initially anticipated. Indeed, studies in other model 
systems have shown that disruption of a single miRNA may produce subtle phenotypes 
that are difficult to detect in vivo (Li, 2005; Miska et al., 2007; Xiao et al., 2007a). This 
could be explained by the fact that most conserved miRNA target genes also contain 
conserved binding sites of other miRNAs, thus disruption of the interaction with only 
one miRNA might not result in marked changes of mRNA or protein expression. 
Another explanation is that targets of miR-223 or miR-223 itself could be part of a 
regulatory buffering network, where the effect of disruption at one point of the network 
(i.e. miR-223) is counterbalanced by bifurcating pathways and feedback mechanisms 
(Hornstein and Shomron, 2006). In this case, such a network would have to be 
perturbed before the disrupted miRNA has an effect on the phenotype. Thus, cardiac 
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stress such as myocardial infarction in heart specific miR-223 transgenic mice could 
yield more phenotypic evidence on the function of miR-223.    
 
In conclusion, the work presented in this dissertation shows miR-223 is upregulated in 
the insulin resistant human heart and when overexpressed enhances PI3K/Akt-
independent glucose uptake to cardiac myocytes through increased Glut4 protein 
expression. In vivo systemic inhibition of miR-223 lowered blood glucose concentration 
and decreased Glut4 protein level in the heart. The findings presented here implicate the 
potential role for miRNAs in cardiac glucose metabolism through the non-canonical 
pathway, and provide insights for future investigations on diabetic cardiomyopathy and 
insulin resistant heart.  
References 
175 
REFERENCES 
 
Alvarez-Garcia, I., and Miska, E.A. (2005). MicroRNA functions in animal 
development and human disease. Development 132, 4653-4662. 
Ambros, V., Bartel, B., Bartel, D.P., Burge, C.B., Carrington, J.C., Chen, X., Dreyfuss, 
G., Eddy, S.R., Griffiths-Jones, S., Marshall, M., et al. (2003). A uniform system for 
microRNA annotation. Rna 9, 277-279. 
Anderson, R.D., Haskell, R.E., Xia, H., Roessler, B.J., and Davidson, B.L. (2000). A 
simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 7, 
1034-1038. 
Arad, M., Benson, D.W., Perez-Atayde, A.R., McKenna, W.J., Sparks, E.A., Kanter, 
R.J., McGarry, K., Seidman, J.G., and Seidman, C.E. (2002). Constitutively active AMP 
kinase mutations cause glycogen storage disease mimicking hypertrophic 
cardiomyopathy. J Clin Invest 109, 357-362. 
Auer, H., Lyianarachchi, S., Newsom, D., Klisovic, M.I., Marcucci, G., and Kornacker, 
K. (2003). Chipping away at the chip bias: RNA degradation in microarray analysis. 
Nat Genet 35, 292-293. 
Auerbach, A.B., Norinsky, R., Ho, W., Losos, K., Guo, Q., Chatterjee, S., and Joyner, 
A.L. (2003). Strain-dependent differences in the efficiency of transgenic mouse 
production. Transgenic Res 12, 59-69. 
Baehrecke, E.H. (2003). miRNAs: micro managers of programmed cell death. Curr Biol 
13, R473-475. 
Baek, D., Villen, J., Shin, C., Camargo, F.D., Gygi, S.P., and Bartel, D.P. (2008). The 
impact of microRNAs on protein output. Nature 455, 64-71. 
Bahi, N., Zhang, J., Llovera, M., Ballester, M., Comella, J.X., and Sanchis, D. (2006). 
Switch from caspase-dependent to caspase-independent death during heart development: 
essential role of endonuclease G in ischemia-induced DNA processing of differentiated 
cardiomyocytes. J Biol Chem 281, 22943-22952. 
References 
176 
Bak, M., Silahtaroglu, A., Moller, M., Christensen, M., Rath, M.F., Skryabin, B., 
Tommerup, N., and Kauppinen, S. (2008). MicroRNA expression in the adult mouse 
central nervous system. Rna 14, 432-444. 
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 
116, 281-297. 
Bartel, D.P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 
215-233. 
Beale, E.G., Harvey, B.J., and Forest, C. (2007). PCK1 and PCK2 as candidate diabetes 
and obesity genes. Cell Biochem Biophys 48, 89-95. 
Beauloye, C., Bertrand, L., Krause, U., Marsin, A.S., Dresselaers, T., Vanstapel, F., 
Vanoverschelde, J.L., and Hue, L. (2001). No-flow ischemia inhibits insulin signaling 
in heart by decreasing intracellular pH. Circ Res 88, 513-519. 
Bertrand, L., Horman, S., Beauloye, C., and Vanoverschelde, J.L. (2008). Insulin 
signalling in the heart. Cardiovasc Res 79, 238-248. 
Betel, D., Wilson, M., Gabow, A., Marks, D.S., and Sander, C. (2008). The 
microRNA.org resource: targets and expression. Nucleic Acids Res 36, D149-153. 
Bhattacharyya, S.N., Habermacher, R., Martine, U., Closs, E.I., and Filipowicz, W. 
(2006). Relief of microRNA-mediated translational repression in human cells subjected 
to stress. Cell 125, 1111-1124. 
Birney, E., Stamatoyannopoulos, J.A., Dutta, A., Guigo, R., Gingeras, T.R., Margulies, 
E.H., Weng, Z., Snyder, M., Dermitzakis, E.T., Thurman, R.E., et al. (2007). 
Identification and analysis of functional elements in 1% of the human genome by the 
ENCODE pilot project. Nature 447, 799-816. 
Boom, R., Sol, C.J., Salimans, M.M., Jansen, C.L., Wertheim-van Dillen, P.M., and van 
der Noordaa, J. (1990). Rapid and simple method for purification of nucleic acids. J 
Clin Microbiol 28, 495-503. 
Brennecke, J., Stark, A., Russell, R.B., and Cohen, S.M. (2005). Principles of 
microRNA-target recognition. PLoS Biol 3, e85. 
References 
177 
Bucciarelli-Ducci, C., Bianchi, M., De Luca, L., Battagliese, A., Di Russo, C., Proietti, 
P., Vizza, C.D., and Fedele, F. (2006). Effects of glucose-insulin-potassium infusion on 
myocardial perfusion and left ventricular remodeling in patients treated with primary 
angioplasty for ST-elevation acute myocardial infarction. Am J Cardiol 98, 1349-1353. 
Bustin, S.A. (2002). Quantification of mRNA using real-time reverse transcription PCR 
(RT-PCR): trends and problems. J Mol Endocrinol 29, 23-39. 
Cai, X., Hagedorn, C.H., and Cullen, B.R. (2004). Human microRNAs are processed 
from capped, polyadenylated transcripts that can also function as mRNAs. Rna 10, 
1957-1966. 
Camps, M., Castello, A., Munoz, P., Monfar, M., Testar, X., Palacin, M., and Zorzano, 
A. (1992). Effect of diabetes and fasting on GLUT-4 (muscle/fat) glucose-transporter 
expression in insulin-sensitive tissues. Heterogeneous response in heart, red and white 
muscle. Biochem J 282 ( Pt 3), 765-772. 
Card, D.A., Hebbar, P.B., Li, L., Trotter, K.W., Komatsu, Y., Mishina, Y., and Archer, 
T.K. (2008). Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem 
cells. Mol Cell Biol 28, 6426-6438. 
Care, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.L., 
Segnalini, P., Gu, Y., Dalton, N.D., et al. (2007). MicroRNA-133 controls cardiac 
hypertrophy. Nat Med 13, 613-618. 
Chakraborty, S., Khare, S., Dorairaj, S.K., Prabhakaran, V.C., Prakash, D.R., and 
Kumar, A. (2007). Identification of genes associated with tumorigenesis of 
retinoblastoma by microarray analysis. Genomics 90, 344-353. 
Chang, L., Chiang, S.H., and Saltiel, A.R. (2004). Insulin signaling and the regulation 
of glucose transport. Mol Med 10, 65-71. 
Chang, L., Chiang, S.H., and Saltiel, A.R. (2007). TC10alpha is required for insulin-
stimulated glucose uptake in adipocytes. Endocrinology 148, 27-33. 
References 
178 
Chen, C., Ridzon, D.A., Broomer, A.J., Zhou, Z., Lee, D.H., Nguyen, J.T., Barbisin, M., 
Xu, N.L., Mahuvakar, V.R., Andersen, M.R., et al. (2005). Real-time quantification of 
microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33, e179. 
Chen, C.Z., Li, L., Lodish, H.F., and Bartel, D.P. (2004). MicroRNAs modulate 
hematopoietic lineage differentiation. Science 303, 83-86. 
Chen, J.F., Mandel, E.M., Thomson, J.M., Wu, Q., Callis, T.E., Hammond, S.M., 
Conlon, F.L., and Wang, D.Z. (2006). The role of microRNA-1 and microRNA-133 in 
skeletal muscle proliferation and differentiation. Nat Genet 38, 228-233. 
Chen, J.F., Murchison, E.P., Tang, R., Callis, T.E., Tatsuguchi, M., Deng, Z., Rojas, M., 
Hammond, S.M., Schneider, M.D., Selzman, C.H., et al. (2008). Targeted deletion of 
Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci 
U S A 105, 2111-2116. 
Chendrimada, T.P., Finn, K.J., Ji, X., Baillat, D., Gregory, R.I., Liebhaber, S.A., 
Pasquinelli, A.E., and Shiekhattar, R. (2007). MicroRNA silencing through RISC 
recruitment of eIF6. Nature 447, 823-828. 
Cheung, P.C., Salt, I.P., Davies, S.P., Hardie, D.G., and Carling, D. (2000). 
Characterization of AMP-activated protein kinase gamma-subunit isoforms and their 
role in AMP binding. Biochem J 346 Pt 3, 659-669. 
Chomczynski, P., and Sacchi, N. (1987). Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162, 156-159. 
Cook, S.A., Aitman, T., and Naoumova, R.P. (2005). Therapy insight: heart disease and 
the insulin-resistant patient. Nat Clin Pract Cardiovasc Med 2, 252-260. 
Cook, S.A., Clerk, A., and Sugden, P.H. (2008). Are transgenic mice the 'alkahest' to 
understanding myocardial hypertrophy and failure? J Mol Cell Cardiol. 
Cook, S.A., Matsui, T., Li, L., and Rosenzweig, A. (2002). Transcriptional effects of 
chronic Akt activation in the heart. J Biol Chem 277, 22528-22533. 
Cooke, D.W., and Lane, M.D. (1999a). Transcription factor NF1 mediates repression of 
the GLUT4 promoter by cyclic-AMP. Biochem Biophys Res Commun 260, 600-604. 
References 
179 
Cooke, D.W., and Lane, M.D. (1999b). The transcription factor nuclear factor I 
mediates repression of the GLUT4 promoter by insulin. J Biol Chem 274, 12917-12924. 
Copland, J.A., Pardini, A.W., Wood, T.G., Yin, D., Green, A., Bodenburg, Y.H., Urban, 
R.J., and Stuart, C.A. (2007). IGF-1 controls GLUT3 expression in muscle via the 
transcriptional factor Sp1. Biochim Biophys Acta 1769, 631-640. 
Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M., and Hemmings, B.A. (1995). 
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. 
Nature 378, 785-789. 
da Costa Martins, P.A., Bourajjaj, M., Gladka, M., Kortland, M., van Oort, R.J., Pinto, 
Y.M., Molkentin, J.D., and De Windt, L.J. (2008). Conditional dicer gene deletion in 
the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 118, 
1567-1576. 
Davies, S.P., Carling, D., and Hardie, D.G. (1989). Tissue distribution of the AMP-
activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, 
studied using a specific and sensitive peptide assay. Eur J Biochem 186, 123-128. 
Diaz, R., Paolasso, E.A., Piegas, L.S., Tajer, C.D., Moreno, M.G., Corvalan, R., Isea, 
J.E., and Romero, G. (1998). Metabolic modulation of acute myocardial infarction. The 
ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 98, 
2227-2234. 
Dohm, G.L., Elton, C.W., Friedman, J.E., Pilch, P.F., Pories, W.J., Atkinson, S.M., Jr., 
and Caro, J.F. (1991). Decreased expression of glucose transporter in muscle from 
insulin-resistant patients. Am J Physiol 260, E459-463. 
Dutka, D.P., Pitt, M., Pagano, D., Mongillo, M., Gathercole, D., Bonser, R.S., and 
Camici, P.G. (2006). Myocardial glucose transport and utilization in patients with type 
2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll 
Cardiol 48, 2225-2231. 
Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. (1998). Cluster analysis and 
display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95, 14863-
14868. 
References 
180 
Elmen, J., Lindow, M., Schutz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., 
Hedtjarn, M., Hansen, H.F., Berger, U., et al. (2008). LNA-mediated microRNA 
silencing in non-human primates. Nature 452, 896-899. 
Engelhardt, S., Hein, L., Wiesmann, F., and Lohse, M.J. (1999). Progressive 
hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl 
Acad Sci U S A 96, 7059-7064. 
Esau, C., Davis, S., Murray, S.F., Yu, X.X., Pandey, S.K., Pear, M., Watts, L., Booten, 
S.L., Graham, M., McKay, R., et al. (2006). miR-122 regulation of lipid metabolism 
revealed by in vivo antisense targeting. Cell Metab 3, 87-98. 
Esquela-Kerscher, A., and Slack, F.J. (2006). Oncomirs - microRNAs with a role in 
cancer. Nat Rev Cancer 6, 259-269. 
Evans, R.K., Nawrocki, D.K., Isopi, L.A., Williams, D.M., Casimiro, D.R., Chin, S., 
Chen, M., Zhu, D.M., Shiver, J.W., and Volkin, D.B. (2004). Development of stable 
liquid formulations for adenovirus-based vaccines. J Pharm Sci 93, 2458-2475. 
Ewart, M.A., Clarke, M., Kane, S., Chamberlain, L.H., and Gould, G.W. (2005). 
Evidence for a role of the exocyst in insulin-stimulated Glut4 trafficking in 3T3-L1 
adipocytes. J Biol Chem 280, 3812-3816. 
Farese, R.V., Sajan, M.P., and Standaert, M.L. (2005). Atypical protein kinase C in 
insulin action and insulin resistance. Biochem Soc Trans 33, 350-353. 
Fazi, F., Rosa, A., Fatica, A., Gelmetti, V., De Marchis, M.L., Nervi, C., and Bozzoni, I. 
(2005). A minicircuitry comprised of microRNA-223 and transcription factors NFI-A 
and C/EBPalpha regulates human granulopoiesis. Cell 123, 819-831. 
Fedorov, Y., Anderson, E.M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, 
K., Leake, D., Marshall, W.S., and Khvorova, A. (2006). Off-target effects by siRNA 
can induce toxic phenotype. Rna 12, 1188-1196. 
Fischer, Y., Thomas, J., Sevilla, L., Munoz, P., Becker, C., Holman, G., Kozka, I.J., 
Palacin, M., Testar, X., Kammermeier, H., et al. (1997). Insulin-induced recruitment of 
glucose transporter 4 (GLUT4) and GLUT1 in isolated rat cardiac myocytes. Evidence 
References 
181 
of the existence of different intracellular GLUT4 vesicle populations. J Biol Chem 272, 
7085-7092. 
Flynt, A.S., and Lai, E.C. (2008). Biological principles of microRNA-mediated 
regulation: shared themes amid diversity. Nat Rev Genet 9, 831-842. 
Frey, N., and Olson, E.N. (2003). Cardiac hypertrophy: the good, the bad, and the ugly. 
Annu Rev Physiol 65, 45-79. 
Friedman, J.E., Dohm, G.L., Leggett-Frazier, N., Elton, C.W., Tapscott, E.B., Pories, 
W.P., and Caro, J.F. (1992). Restoration of insulin responsiveness in skeletal muscle of 
morbidly obese patients after weight loss. Effect on muscle glucose transport and 
glucose transporter GLUT4. J Clin Invest 89, 701-705. 
Gillingham, A.K., Koumanov, F., Pryor, P.R., Reaves, B.J., and Holman, G.D. (1999). 
Association of AP1 adaptor complexes with GLUT4 vesicles. J Cell Sci 112 ( Pt 24), 
4793-4800. 
Goff, L.A., Yang, M., Bowers, J., Getts, R.C., Padgett, R.W., and Hart, R.P. (2005). 
Rational probe optimization and enhanced detection strategy for microRNAs using 
microarrays. RNA Biol 2, 93-100. 
Gonzalez-Vilchez, F., Ayuela, J., Ares, M., Pi, J., Castillo, L., and Martin-Duran, R. 
(2005). Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 
diabetic patients. Int J Cardiol 101, 53-58. 
Gordon, J.W., and Ruddle, F.H. (1981). Integration and stable germ line transmission of 
genes injected into mouse pronuclei. Science 214, 1244-1246. 
Gordon, J.W., Scangos, G.A., Plotkin, D.J., Barbosa, J.A., and Ruddle, F.H. (1980). 
Genetic transformation of mouse embryos by microinjection of purified DNA. Proc 
Natl Acad Sci U S A 77, 7380-7384. 
Greco, S.J., and Rameshwar, P. (2007). MicroRNAs regulate synthesis of the 
neurotransmitter substance P in human mesenchymal stem cell-derived neuronal cells. 
Proc Natl Acad Sci U S A 104, 15484-15489. 
References 
182 
Gregory, R.I., and Shiekhattar, R. (2005). MicroRNA biogenesis and cancer. Cancer 
Res 65, 3509-3512. 
Griffiths-Jones, S., Grocock, R.J., van Dongen, S., Bateman, A., and Enright, A.J. 
(2006). miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids 
Res 34, D140-144. 
Griffiths-Jones, S., Saini, H.K., van Dongen, S., and Enright, A.J. (2008). miRBase: 
tools for microRNA genomics. Nucleic Acids Res 36, D154-158. 
Grimson, A., Farh, K.K., Johnston, W.K., Garrett-Engele, P., Lim, L.P., and Bartel, D.P. 
(2007). MicroRNA targeting specificity in mammals: determinants beyond seed pairing. 
Mol Cell 27, 91-105. 
Grun, D., Wang, Y.L., Langenberger, D., Gunsalus, K.C., and Rajewsky, N. (2005). 
microRNA target predictions across seven Drosophila species and comparison to 
mammalian targets. PLoS Comput Biol 1, e13. 
Grundy, S.M., Benjamin, I.J., Burke, G.L., Chait, A., Eckel, R.H., Howard, B.V., Mitch, 
W., Smith, S.C., Jr., and Sowers, J.R. (1999). Diabetes and cardiovascular disease: a 
statement for healthcare professionals from the American Heart Association. 
Circulation 100, 1134-1146. 
Gupta, S., Purcell, N.H., Lin, A., and Sen, S. (2002). Activation of nuclear factor-
kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 159, 
1019-1028. 
Hajduch, E., Turban, S., Le Liepvre, X., Le Lay, S., Lipina, C., Dimopoulos, N., Dugail, 
I., and Hundal, H.S. (2008). Targeting of PKCzeta and PKB to caveolin-enriched 
microdomains represents a crucial step underpinning the disruption in PKB-directed 
signalling by ceramide. Biochem J 410, 369-379. 
Hammar, E.B., Irminger, J.C., Rickenbach, K., Parnaud, G., Ribaux, P., Bosco, D., 
Rouiller, D.G., and Halban, P.A. (2005). Activation of NF-kappaB by extracellular 
matrix is involved in spreading and glucose-stimulated insulin secretion of pancreatic 
beta cells. J Biol Chem 280, 30630-30637. 
References 
183 
Handberg, A., Vaag, A., Damsbo, P., Beck-Nielsen, H., and Vinten, J. (1990). 
Expression of insulin regulatable glucose transporters in skeletal muscle from type 2 
(non-insulin-dependent) diabetic patients. Diabetologia 33, 625-627. 
Harary, I., and Farley, B. (1963a). In vitro studies on single beating rat heart cells. I. 
Growth and organization. Exp Cell Res 29, 451-465. 
Harary, I., and Farley, B. (1963b). In vitro studies on single beating rat heart cells. II. 
Intercellular communication. Exp Cell Res 29, 466-474. 
He, A., Zhu, L., Gupta, N., Chang, Y., and Fang, F. (2007). Overexpression of micro 
ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 
3T3-L1 adipocytes. Mol Endocrinol 21, 2785-2794. 
He, Z., Opland, D.M., Way, K.J., Ueki, K., Bodyak, N., Kang, P.M., Izumo, S., 
Kulkarni, R.N., Wang, B., Liao, R., et al. (2006). Regulation of vascular endothelial 
growth factor expression and vascularization in the myocardium by insulin receptor and 
PI3K/Akt pathways in insulin resistance and ischemia. Arterioscler Thromb Vasc Biol 
26, 787-793. 
Higuchi, M., Miyagi, K., Nakasone, J., and Sakanashi, M. (1995). Role of high 
glycogen in underperfused diabetic rat hearts with added norepinephrine. J Cardiovasc 
Pharmacol 26, 899-907. 
Hirsch, E., Costa, C., and Ciraolo, E. (2007). Phosphoinositide 3-kinases as a common 
platform for multi-hormone signaling. J Endocrinol 194, 243-256. 
Hogan, B. (1994). Manipulating the mouse embryo : a laboratory manual, 2nd ed. edn 
(Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press). 
Hoit, B.D. (2001). New approaches to phenotypic analysis in adult mice. J Mol Cell 
Cardiol 33, 27-35. 
Hong, W. (2005). SNAREs and traffic. Biochim Biophys Acta 1744, 493-517. 
Hornstein, E., and Shomron, N. (2006). Canalization of development by microRNAs. 
Nat Genet 38 Suppl, S20-24. 
References 
184 
Hou, J.C., Suzuki, N., Pessin, J.E., and Watson, R.T. (2006). A specific dileucine motif 
is required for the GGA-dependent entry of newly synthesized insulin-responsive 
aminopeptidase into the insulin-responsive compartment. J Biol Chem 281, 33457-
33466. 
Huang, W.Y., and Liew, C.C. (1997). A conserved GATA motif in a tissue-specific 
DNase I hypersensitive site of the cardiac alpha-myosin heavy chain gene. Biochem J 
325 ( Pt 1), 47-51. 
Hudson, E.R., Pan, D.A., James, J., Lucocq, J.M., Hawley, S.A., Green, K.A., Baba, O., 
Terashima, T., and Hardie, D.G. (2003). A novel domain in AMP-activated protein 
kinase causes glycogen storage bodies similar to those seen in hereditary cardiac 
arrhythmias. Curr Biol 13, 861-866. 
Hue, L., Beauloye, C., Marsin, A.S., Bertrand, L., Horman, S., and Rider, M.H. (2002). 
Insulin and ischemia stimulate glycolysis by acting on the same targets through 
different and opposing signaling pathways. J Mol Cell Cardiol 34, 1091-1097. 
Hwang, D.Y., and Ismail-Beigi, F. (2006). Control of Glut1 promoter activity under 
basal conditions and in response to hyperosmolarity: role of Sp1. Am J Physiol Cell 
Physiol 290, C337-344. 
Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K.L. (2002). TSC2 is phosphorylated and 
inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4, 648-657. 
Iwaki, K., Sukhatme, V.P., Shubeita, H.E., and Chien, K.R. (1990). Alpha- and beta-
adrenergic stimulation induces distinct patterns of immediate early gene expression in 
neonatal rat myocardial cells. fos/jun expression is associated with sarcomere assembly; 
Egr-1 induction is primarily an alpha 1-mediated response. J Biol Chem 265, 13809-
13817. 
Jacobus, W.E. (1985). Respiratory control and the integration of heart high-energy 
phosphate metabolism by mitochondrial creatine kinase. Annu Rev Physiol 47, 707-725. 
Jensen, J., Jebens, E., Brennesvik, E.O., Ruzzin, J., Soos, M.A., Engebretsen, E.M., 
O'Rahilly, S., and Whitehead, J.P. (2006). Muscle glycogen inharmoniously regulates 
References 
185 
glycogen synthase activity, glucose uptake, and proximal insulin signaling. Am J 
Physiol Endocrinol Metab 290, E154-E162. 
John, B., Enright, A.J., Aravin, A., Tuschl, T., Sander, C., and Marks, D.S. (2004). 
Human MicroRNA targets. PLoS Biol 2, e363. 
Johnnidis, J.B., Harris, M.H., Wheeler, R.T., Stehling-Sun, S., Lam, M.H., Kirak, O., 
Brummelkamp, T.R., Fleming, M.D., and Camargo, F.D. (2008). Regulation of 
progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451, 
1125-1129. 
Kawasaki, H., and Taira, K. (2006). Induction of DNA methylation and gene silencing 
by short interfering RNAs in human cells. Nature 441, 1176. 
Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role of site 
accessibility in microRNA target recognition. Nat Genet 39, 1278-1284. 
Khvorova, A., Reynolds, A., and Jayasena, S.D. (2003). Functional siRNAs and 
miRNAs exhibit strand bias. Cell 115, 209-216. 
Kim, V.N. (2005). MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev 
Mol Cell Biol 6, 376-385. 
Kloosterman, W.P., Wienholds, E., de Bruijn, E., Kauppinen, S., and Plasterk, R.H. 
(2006). In situ detection of miRNAs in animal embryos using LNA-modified 
oligonucleotide probes. Nat Methods 3, 27-29. 
Kramer, H.F., Witczak, C.A., Taylor, E.B., Fujii, N., Hirshman, M.F., and Goodyear, 
L.J. (2006). AS160 regulates insulin- and contraction-stimulated glucose uptake in 
mouse skeletal muscle. J Biol Chem 281, 31478-31485. 
Krek, A., Grun, D., Poy, M.N., Wolf, R., Rosenberg, L., Epstein, E.J., MacMenamin, P., 
da Piedade, I., Gunsalus, K.C., Stoffel, M., et al. (2005). Combinatorial microRNA 
target predictions. Nat Genet 37, 495-500. 
Krichevsky, A.M., King, K.S., Donahue, C.P., Khrapko, K., and Kosik, K.S. (2003). A 
microRNA array reveals extensive regulation of microRNAs during brain development. 
Rna 9, 1274-1281. 
References 
186 
Krljanac, G., Vasiljevic, Z., Radovanovic, M., Stankovic, G., Milic, N., Stefanovic, B., 
Kostic, J., Mitrovic, P., Radovanovic, N., Dragovic, M., et al. (2005). Effects of 
glucose-insulin-potassium infusion on ST-elevation myocardial infarction in patients 
treated with thrombolytic therapy. Am J Cardiol 96, 1053-1058. 
Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., and 
Stoffel, M. (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-
689. 
Latronico, M.V., Catalucci, D., and Condorelli, G. (2007). Emerging role of 
microRNAs in cardiovascular biology. Circ Res 101, 1225-1236. 
Laughlin, M.R., Petit, W.A., Jr., Shulman, R.G., and Barrett, E.J. (1990). Measurement 
of myocardial glycogen synthesis in diabetic and fasted rats. Am J Physiol 258, E184-
190. 
Laurie, S.M., Cain, C.C., Lienhard, G.E., and Castle, J.D. (1993). The glucose 
transporter GluT4 and secretory carrier membrane proteins (SCAMPs) colocalize in rat 
adipocytes and partially segregate during insulin stimulation. J Biol Chem 268, 19110-
19117. 
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Radmark, O., 
Kim, S., et al. (2003). The nuclear RNase III Drosha initiates microRNA processing. 
Nature 425, 415-419. 
Lee, Y., Kim, M., Han, J., Yeom, K.H., Lee, S., Baek, S.H., and Kim, V.N. (2004). 
MicroRNA genes are transcribed by RNA polymerase II. Embo J 23, 4051-4060. 
Lewis, B.P., Burge, C.B., and Bartel, D.P. (2005). Conserved seed pairing, often 
flanked by adenosines, indicates that thousands of human genes are microRNA targets. 
Cell 120, 15-20. 
Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P., and Burge, C.B. (2003). 
Prediction of mammalian microRNA targets. Cell 115, 787-798. 
Li, J., Hu, X., Selvakumar, P., Russell, R.R., 3rd, Cushman, S.W., Holman, G.D., and 
Young, L.H. (2004). Role of the nitric oxide pathway in AMPK-mediated glucose 
References 
187 
uptake and GLUT4 translocation in heart muscle. Am J Physiol Endocrinol Metab 287, 
E834-841. 
Li, L.V., and Kandror, K.V. (2005). Golgi-localized, gamma-ear-containing, Arf-
binding protein adaptors mediate insulin-responsive trafficking of glucose transporter 4 
in 3T3-L1 adipocytes. Mol Endocrinol 19, 2145-2153. 
Li, W.X. (2005). Functions and mechanisms of receptor tyrosine kinase Torso signaling: 
lessons from Drosophila embryonic terminal development. Dev Dyn 232, 656-672. 
Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., Bartel, 
D.P., Linsley, P.S., and Johnson, J.M. (2005). Microarray analysis shows that some 
microRNAs downregulate large numbers of target mRNAs. Nature 433, 769-773. 
Liu, C.G., Calin, G.A., Meloon, B., Gamliel, N., Sevignani, C., Ferracin, M., Dumitru, 
C.D., Shimizu, M., Zupo, S., Dono, M., et al. (2004). An oligonucleotide microchip for 
genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S 
A 101, 9740-9744. 
Liu, L.B., Omata, W., Kojima, I., and Shibata, H. (2007). The SUMO conjugating 
enzyme Ubc9 is a regulator of GLUT4 turnover and targeting to the insulin-responsive 
storage compartment in 3T3-L1 adipocytes. Diabetes 56, 1977-1985. 
Liu, Y.F., Paz, K., Herschkovitz, A., Alt, A., Tennenbaum, T., Sampson, S.R., Ohba, M., 
Kuroki, T., LeRoith, D., and Zick, Y. (2001). Insulin stimulates PKCzeta -mediated 
phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to 
negatively regulate the function of IRS proteins. J Biol Chem 276, 14459-14465. 
Lizunov, V.A., Matsumoto, H., Zimmerberg, J., Cushman, S.W., and Frolov, V.A. 
(2005). Insulin stimulates the halting, tethering, and fusion of mobile GLUT4 vesicles 
in rat adipose cells. J Cell Biol 169, 481-489. 
Lompre, A.M., Nadal-Ginard, B., and Mahdavi, V. (1984). Expression of the cardiac 
ventricular alpha- and beta-myosin heavy chain genes is developmentally and 
hormonally regulated. J Biol Chem 259, 6437-6446. 
References 
188 
Long, C.S., Kariya, K., Karns, L., and Simpson, P.C. (1992). Sympathetic modulation 
of the cardiac myocyte phenotype: studies with a cell-culture model of myocardial 
hypertrophy. Basic Res Cardiol 87 Suppl 2, 19-31. 
Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, 
A., Ebert, B.L., Mak, R.H., Ferrando, A.A., et al. (2005). MicroRNA expression 
profiles classify human cancers. Nature 435, 834-838. 
Luengo-Fernandez, R., Leal, J., Gray, A., Petersen, S., and Rayner, M. (2006). Cost of 
cardiovascular diseases in the United Kingdom. Heart 92, 1384-1389. 
Luiken, J.J., Coort, S.L., Koonen, D.P., Bonen, A., and Glatz, J.F. (2004a). Signalling 
components involved in contraction-inducible substrate uptake into cardiac myocytes. 
Proc Nutr Soc 63, 251-258. 
Luiken, J.J., Coort, S.L., Koonen, D.P., van der Horst, D.J., Bonen, A., Zorzano, A., and 
Glatz, J.F. (2004b). Regulation of cardiac long-chain fatty acid and glucose uptake by 
translocation of substrate transporters. Pflugers Arch 448, 1-15. 
Luo, X., Lin, H., Pan, Z., Xiao, J., Zhang, Y., Lu, Y., Yang, B., and Wang, Z. (2008). 
Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel 
genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem 283, 20045-20052. 
Mahdavi, V., Lompre, A.M., Chambers, A.P., and Nadal-Ginard, B. (1984). Cardiac 
myosin heavy chain isozymic transitions during development and under pathological 
conditions are regulated at the level of mRNA availability. Eur Heart J 5 Suppl F, 181-
191. 
Martin, S., Tellam, J., Livingstone, C., Slot, J.W., Gould, G.W., and James, D.E. (1996). 
The glucose transporter (GLUT-4) and vesicle-associated membrane protein-2 (VAMP-
2) are segregated from recycling endosomes in insulin-sensitive cells. J Cell Biol 134, 
625-635. 
Mathieu, O., and Bender, J. (2004). RNA-directed DNA methylation. J Cell Sci 117, 
4881-4888. 
References 
189 
Mathonnet, G., Fabian, M.R., Svitkin, Y.V., Parsyan, A., Huck, L., Murata, T., Biffo, S., 
Merrick, W.C., Darzynkiewicz, E., Pillai, R.S., et al. (2007). MicroRNA inhibition of 
translation initiation in vitro by targeting the cap-binding complex eIF4F. Science 317, 
1764-1767. 
Mendez, C.F., Leibiger, I.B., Leibiger, B., Hoy, M., Gromada, J., Berggren, P.O., and 
Bertorello, A.M. (2003). Rapid association of protein kinase C-epsilon with insulin 
granules is essential for insulin exocytosis. J Biol Chem 278, 44753-44757. 
Miinea, C.P., Sano, H., Kane, S., Sano, E., Fukuda, M., Peranen, J., Lane, W.S., and 
Lienhard, G.E. (2005). AS160, the Akt substrate regulating GLUT4 translocation, has a 
functional Rab GTPase-activating protein domain. Biochem J 391, 87-93. 
Misener, S., and Krawetz, S.A. (2000). Bioinformatics methods and protocols (Totowa, 
N.J., Humana). 
Miska, E.A., Alvarez-Saavedra, E., Abbott, A.L., Lau, N.C., Hellman, A.B., 
McGonagle, S.M., Bartel, D.P., Ambros, V.R., and Horvitz, H.R. (2007). Most 
Caenorhabditis elegans microRNAs are individually not essential for development or 
viability. PLoS Genet 3, e215. 
Molkentin, J.D., and Robbins, J. (2008). With great power comes great responsibility: 
Using mouse genetics to study cardiac hypertrophy and failure. J Mol Cell Cardiol. 
Moreno, H., Serrano, A.L., Santalucia, T., Guma, A., Canto, C., Brand, N.J., Palacin, 
M., Schiaffino, S., and Zorzano, A. (2003). Differential regulation of the muscle-
specific GLUT4 enhancer in regenerating and adult skeletal muscle. J Biol Chem 278, 
40557-40564. 
Morin, S., Charron, F., Robitaille, L., and Nemer, M. (2000). GATA-dependent 
recruitment of MEF2 proteins to target promoters. Embo J 19, 2046-2055. 
Moschos, S.A., Williams, A.E., Perry, M.M., Birrell, M.A., Belvisi, M.G., and Lindsay, 
M.A. (2007). Expression profiling in vivo demonstrates rapid changes in lung 
microRNA levels following lipopolysaccharide-induced inflammation but not in the 
anti-inflammatory action of glucocorticoids. BMC Genomics 8, 240. 
References 
190 
Moyers, J.S., Bilan, P.J., Reynet, C., and Kahn, C.R. (1996). Overexpression of Rad 
inhibits glucose uptake in cultured muscle and fat cells. J Biol Chem 271, 23111-23116. 
Nathan, D.M., Meigs, J., and Singer, D.E. (1997). The epidemiology of cardiovascular 
disease in type 2 diabetes mellitus: how sweet it is ... or is it? Lancet 350 Suppl 1, SI4-9. 
Neely, J.R., Rovetto, M.J., and Oram, J.F. (1972). Myocardial utilization of 
carbohydrate and lipids. Prog Cardiovasc Dis 15, 289-329. 
Nielsen, J.N., Wojtaszewski, J.F., Haller, R.G., Hardie, D.G., Kemp, B.E., Richter, E.A., 
and Vissing, J. (2002). Role of 5'AMP-activated protein kinase in glycogen synthase 
activity and glucose utilization: insights from patients with McArdle's disease. J Physiol 
541, 979-989. 
Nikiforova, M.N., Tseng, G.C., Steward, D., Diorio, D., and Nikiforov, Y.E. (2008). 
MicroRNA expression profiling of thyroid tumors: biological significance and 
diagnostic utility. J Clin Endocrinol Metab 93, 1600-1608. 
Niwa, K., Uchishiba, M., Aotsuka, H., Tobita, K., Matsuo, K., Fujiwara, T., Tateno, S., 
and Hamada, H. (1996). Measurement of ventricular volumes by cine magnetic 
resonance imaging in complex congenital heart disease with morphologically abnormal 
ventricles. Am Heart J 131, 567-575. 
Ogura, M., Agata, Y., Watanabe, K., McCormick, R.M., Hamaguchi, Y., Aso, Y., and 
Mitsuhashi, M. (1998). RNA chip: quality assessment of RNA by microchannel linear 
gel electrophoresis in injection-molded plastic chips. Clin Chem 44, 2249-2255. 
Olson, A.L., and Pessin, J.E. (1995). Transcriptional regulation of the human GLUT4 
gene promoter in diabetic transgenic mice. J Biol Chem 270, 23491-23495. 
Ottensmeyer, F.P., Beniac, D.R., Luo, R.Z., and Yip, C.C. (2000). Mechanism of 
transmembrane signaling: insulin binding and the insulin receptor. Biochemistry 39, 
12103-12112. 
Paternostro, G., Camici, P.G., Lammerstma, A.A., Marinho, N., Baliga, R.R., Kooner, 
J.S., Radda, G.K., and Ferrannini, E. (1996). Cardiac and skeletal muscle insulin 
References 
191 
resistance in patients with coronary heart disease. A study with positron emission 
tomography. J Clin Invest 98, 2094-2099. 
Pedersen, O., Bak, J.F., Andersen, P.H., Lund, S., Moller, D.E., Flier, J.S., and Kahn, 
B.B. (1990). Evidence against altered expression of GLUT1 or GLUT4 in skeletal 
muscle of patients with obesity or NIDDM. Diabetes 39, 865-870. 
Petersen, C.P., Bordeleau, M.E., Pelletier, J., and Sharp, P.A. (2006). Short RNAs 
repress translation after initiation in mammalian cells. Mol Cell 21, 533-542. 
Petersen, M., and Wengel, J. (2003). LNA: a versatile tool for therapeutics and 
genomics. Trends Biotechnol 21, 74-81. 
Petersen, S., Bahr, M., and Eckel, J. (1995). Insulin-dependent regulation of Glut4 gene 
expression in ventricular cardiomyocytes: evidence for a direct effect on Glut4 
transcription. Biochem Biophys Res Commun 213, 533-540. 
Pfaffl, M.W. (2001). A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acids Res 29, e45. 
Pham, F.H., Sugden, P.H., and Clerk, A. (2000). Regulation of protein kinase B and 4E-
BP1 by oxidative stress in cardiac myocytes. Circ Res 86, 1252-1258. 
Pineles, B.L., Romero, R., Montenegro, D., Tarca, A.L., Han, Y.M., Kim, Y.M., 
Draghici, S., Espinoza, J., Kusanovic, J.P., Mittal, P., et al. (2007). Distinct subsets of 
microRNAs are expressed differentially in the human placentas of patients with 
preeclampsia. Am J Obstet Gynecol 196, 261 e261-266. 
Poirier, P., Bogaty, P., Garneau, C., Marois, L., and Dumesnil, J.G. (2001). Diastolic 
dysfunction in normotensive men with well-controlled type 2 diabetes: importance of 
maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. 
Diabetes Care 24, 5-10. 
Potter, C.J., Pedraza, L.G., and Xu, T. (2002). Akt regulates growth by directly 
phosphorylating Tsc2. Nat Cell Biol 4, 658-665. 
References 
192 
Poy, M.N., Eliasson, L., Krutzfeldt, J., Kuwajima, S., Ma, X., Macdonald, P.E., Pfeffer, 
S., Tuschl, T., Rajewsky, N., Rorsman, P., et al. (2004). A pancreatic islet-specific 
microRNA regulates insulin secretion. Nature 432, 226-230. 
Proud, C.G., and Denton, R.M. (1997). Molecular mechanisms for the control of 
translation by insulin. Biochem J 328 ( Pt 2), 329-341. 
Randhawa, V.K., Bilan, P.J., Khayat, Z.A., Daneman, N., Liu, Z., Ramlal, T., Volchuk, 
A., Peng, X.R., Coppola, T., Regazzi, R., et al. (2000). VAMP2, but not 
VAMP3/cellubrevin, mediates insulin-dependent incorporation of GLUT4 into the 
plasma membrane of L6 myoblasts. Mol Biol Cell 11, 2403-2417. 
Rao, P.K., Kumar, R.M., Farkhondeh, M., Baskerville, S., and Lodish, H.F. (2006). 
Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl 
Acad Sci U S A 103, 8721-8726. 
Razeghi, P., Young, M.E., Cockrill, T.C., Frazier, O.H., and Taegtmeyer, H. (2002). 
Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer 
factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure. 
Circulation 106, 407-411. 
Rhoades, M.W., Reinhart, B.J., Lim, L.P., Burge, C.B., Bartel, B., and Bartel, D.P. 
(2002). Prediction of plant microRNA targets. Cell 110, 513-520. 
Rolfe, M., McLeod, L.E., Pratt, P.F., and Proud, C.G. (2005). Activation of protein 
synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the 
activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 
(TSC2). Biochem J 388, 973-984. 
Russell, R.R., 3rd, Li, J., Coven, D.L., Pypaert, M., Zechner, C., Palmeri, M., Giordano, 
F.J., Mu, J., Birnbaum, M.J., and Young, L.H. (2004). AMP-activated protein kinase 
mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, 
apoptosis, and injury. J Clin Invest 114, 495-503. 
Saddik, M., and Lopaschuk, G.D. (1991). Myocardial triglyceride turnover and 
contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 
266, 8162-8170. 
References 
193 
Sandberg, R., Neilson, J.R., Sarma, A., Sharp, P.A., and Burge, C.B. (2008). 
Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer 
microRNA target sites. Science 320, 1643-1647. 
Sano, H., Eguez, L., Teruel, M.N., Fukuda, M., Chuang, T.D., Chavez, J.A., Lienhard, 
G.E., and McGraw, T.E. (2007). Rab10, a target of the AS160 Rab GAP, is required for 
insulin-stimulated translocation of GLUT4 to the adipocyte plasma membrane. Cell 
Metab 5, 293-303. 
Santalucia, T., Moreno, H., Palacin, M., Yacoub, M.H., Brand, N.J., and Zorzano, A. 
(2001). A novel functional co-operation between MyoD, MEF2 and TRalpha1 is 
sufficient for the induction of GLUT4 gene transcription. J Mol Biol 314, 195-204. 
Savage, D.B., Petersen, K.F., and Shulman, G.I. (2005). Mechanisms of insulin 
resistance in humans and possible links with inflammation. Hypertension 45, 828-833. 
Sayed, D., Hong, C., Chen, I.Y., Lypowy, J., and Abdellatif, M. (2007). MicroRNAs 
play an essential role in the development of cardiac hypertrophy. Circ Res 100, 416-424. 
Schmittgen, T.D., Jiang, J., Liu, Q., and Yang, L. (2004). A high-throughput method to 
monitor the expression of microRNA precursors. Nucleic Acids Res 32, e43. 
Schratt, G.M., Tuebing, F., Nigh, E.A., Kane, C.G., Sabatini, M.E., Kiebler, M., and 
Greenberg, M.E. (2006). A brain-specific microRNA regulates dendritic spine 
development. Nature 439, 283-289. 
Scott, G.K., Goga, A., Bhaumik, D., Berger, C.E., Sullivan, C.S., and Benz, C.C. (2007). 
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA 
miR-125a or miR-125b. J Biol Chem 282, 1479-1486. 
Shishehbor, M.H., Hoogwerf, B.J., Schoenhagen, P., Marso, S.P., Sun, J.P., Li, J., Klein, 
A.L., Thomas, J.D., and Garcia, M.J. (2003). Relation of hemoglobin A1c to left 
ventricular relaxation in patients with type 1 diabetes mellitus and without overt heart 
disease. Am J Cardiol 91, 1514-1517, A1519. 
Shulman, G.I. (2000). Cellular mechanisms of insulin resistance. J Clin Invest 106, 171-
176. 
References 
194 
Sil, P., Misono, K., and Sen, S. (1993). Myotrophin in human cardiomyopathic heart. 
Circ Res 73, 98-108. 
Subramaniam, A., Jones, W.K., Gulick, J., Wert, S., Neumann, J., and Robbins, J. 
(1991). Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in 
transgenic mice. J Biol Chem 266, 24613-24620. 
Sykes, C.A., Wright, A.D., Malins, J.M., and Pentecost, B.L. (1977). Changes in 
systolic time intervals during treatment of diabetes mellitus. Br Heart J 39, 255-259. 
Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., 
Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., et al. (2004). Reduced expression of 
the let-7 microRNAs in human lung cancers in association with shortened postoperative 
survival. Cancer Res 64, 3753-3756. 
Thai, M.V., Guruswamy, S., Cao, K.T., Pessin, J.E., and Olson, A.L. (1998). Myocyte 
enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in 
transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient diabetes. 
J Biol Chem 273, 14285-14292. 
Thornton, C., Snowden, M.A., and Carling, D. (1998). Identification of a novel AMP-
activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. 
J Biol Chem 273, 12443-12450. 
Thum, T., Catalucci, D., and Bauersachs, J. (2008a). MicroRNAs: novel regulators in 
cardiac development and disease. Cardiovasc Res 79, 562-570. 
Thum, T., Galuppo, P., Wolf, C., Fiedler, J., Kneitz, S., van Laake, L.W., Doevendans, 
P.A., Mummery, C.L., Borlak, J., Haverich, A., et al. (2007). MicroRNAs in the human 
heart: a clue to fetal gene reprogramming in heart failure. Circulation 116, 258-267. 
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, 
S., Rottbauer, W., Frantz, S., et al. (2008b). MicroRNA-21 contributes to myocardial 
disease by stimulating MAP kinase signalling in fibroblasts. Nature. 
References 
195 
Truett, G.E., Heeger, P., Mynatt, R.L., Truett, A.A., Walker, J.A., and Warman, M.L. 
(2000). Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide 
and tris (HotSHOT). Biotechniques 29, 52, 54. 
Valadi, H., Ekstrom, K., Bossios, A., Sjostrand, M., Lee, J.J., and Lotvall, J.O. (2007). 
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of 
genetic exchange between cells. Nat Cell Biol 9, 654-659. 
Valoczi, A., Hornyik, C., Varga, N., Burgyan, J., Kauppinen, S., and Havelda, Z. (2004). 
Sensitive and specific detection of microRNAs by northern blot analysis using LNA-
modified oligonucleotide probes. Nucleic Acids Res 32, e175. 
van Rooij, E., Marshall, W.S., and Olson, E.N. (2008a). Toward microRNA-based 
therapeutics for heart disease: the sense in antisense. Circ Res 103, 919-928. 
van Rooij, E., Sutherland, L.B., Qi, X., Richardson, J.A., Hill, J., and Olson, E.N. 
(2007). Control of stress-dependent cardiac growth and gene expression by a 
microRNA. Science 316, 575-579. 
van Rooij, E., Sutherland, L.B., Thatcher, J.E., DiMaio, J.M., Naseem, R.H., Marshall, 
W.S., Hill, J.A., and Olson, E.N. (2008b). Dysregulation of microRNAs after 
myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U 
S A 105, 13027-13032. 
Vasudevan, S., Tong, Y., and Steitz, J.A. (2007). Switching from repression to 
activation: microRNAs can up-regulate translation. Science 318, 1931-1934. 
Vasudevan, S., Tong, Y., and Steitz, J.A. (2008). Cell-cycle control of microRNA-
mediated translation regulation. Cell Cycle 7, 1545-1549. 
Wakiyama, M., Takimoto, K., Ohara, O., and Yokoyama, S. (2007). Let-7 microRNA-
mediated mRNA deadenylation and translational repression in a mammalian cell-free 
system. Genes Dev 21, 1857-1862. 
Wang, X. (2006). Systematic identification of microRNA functions by combining target 
prediction and expression profiling. Nucleic Acids Res 34, 1646-1652. 
References 
196 
Watson, R.T., and Pessin, J.E. (2007). GLUT4 translocation: the last 200 nanometers. 
Cell Signal 19, 2209-2217. 
Welsh, G.I., Stokes, C.M., Wang, X., Sakaue, H., Ogawa, W., Kasuga, M., and Proud, 
C.G. (1997). Activation of translation initiation factor eIF2B by insulin requires 
phosphatidyl inositol 3-kinase. FEBS Lett 410, 418-422. 
Wienholds, E., Kloosterman, W.P., Miska, E., Alvarez-Saavedra, E., Berezikov, E., de 
Bruijn, E., Horvitz, H.R., Kauppinen, S., and Plasterk, R.H. (2005). MicroRNA 
expression in zebrafish embryonic development. Science 309, 310-311. 
Woods, A., Salt, I., Scott, J., Hardie, D.G., and Carling, D. (1996). The alpha1 and 
alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver 
but exhibit differences in substrate specificity in vitro. FEBS Lett 397, 347-351. 
Woolley, A.T., and Mathies, R.A. (1994). Ultra-high-speed DNA fragment separations 
using microfabricated capillary array electrophoresis chips. Proc Natl Acad Sci U S A 
91, 11348-11352. 
Xiao, C., Calado, D.P., Galler, G., Thai, T.H., Patterson, H.C., Wang, J., Rajewsky, N., 
Bender, T.P., and Rajewsky, K. (2007a). MiR-150 controls B cell differentiation by 
targeting the transcription factor c-Myb. Cell 131, 146-159. 
Xiao, J., Luo, X., Lin, H., Zhang, Y., Lu, Y., Wang, N., Yang, B., and Wang, Z. 
(2007b). MicroRNA miR-133 represses HERG K+ channel expression contributing to 
QT prolongation in diabetic hearts. J Biol Chem 282, 12363-12367. 
Xu, Y., Mirmalek-Sani, S.H., Lin, F., Zhang, J., and Oreffo, R.O. (2007). Adipocyte 
differentiation induced using nonspecific siRNA controls in cultured human 
mesenchymal stem cells. RNA 13, 1179-1183. 
Yamakuchi, M., Ferlito, M., and Lowenstein, C.J. (2008). miR-34a repression of SIRT1 
regulates apoptosis. Proc Natl Acad Sci U S A 105, 13421-13426. 
Yamashita, N., Nishida, M., Hoshida, S., Kuzuya, T., Hori, M., Taniguchi, N., Kamada, 
T., and Tada, M. (1994). Induction of manganese superoxide dismutase in rat cardiac 
References 
197 
myocytes increases tolerance to hypoxia 24 hours after preconditioning. J Clin Invest 94, 
2193-2199. 
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., 
et al. (2007). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic 
potential by targeting GJA1 and KCNJ2. Nat Med 13, 486-491. 
Yang, J., and Holman, G.D. (2005). Insulin and contraction stimulate exocytosis, but 
increased AMP-activated protein kinase activity resulting from oxidative metabolism 
stress slows endocytosis of GLUT4 in cardiomyocytes. J Biol Chem 280, 4070-4078. 
Yi, R., Qin, Y., Macara, I.G., and Cullen, B.R. (2003). Exportin-5 mediates the nuclear 
export of pre-microRNAs and short hairpin RNAs. Genes Dev 17, 3011-3016. 
Zang, M.X., Li, Y., Wang, H., Wang, J.B., and Jia, H.T. (2004). Cooperative interaction 
between the basic helix-loop-helix transcription factor dHAND and myocyte enhancer 
factor 2C regulates myocardial gene expression. J Biol Chem 279, 54258-54263. 
Zarich, S.W., Arbuckle, B.E., Cohen, L.R., Roberts, M., and Nesto, R.W. (1988). 
Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed 
Doppler echocardiography. J Am Coll Cardiol 12, 114-120. 
Zeigerer, A., Lampson, M.A., Karylowski, O., Sabatini, D.D., Adesnik, M., Ren, M., 
and McGraw, T.E. (2002). GLUT4 retention in adipocytes requires two intracellular 
insulin-regulated transport steps. Mol Biol Cell 13, 2421-2435. 
Zhao, Y., Ransom, J.F., Li, A., Vedantham, V., von Drehle, M., Muth, A.N., 
Tsuchihashi, T., McManus, M.T., Schwartz, R.J., and Srivastava, D. (2007). 
Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking 
miRNA-1-2. Cell 129, 303-317. 
Zhao, Y., Samal, E., and Srivastava, D. (2005). Serum response factor regulates a 
muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436, 214-
220. 
Zick, Y. (2005). Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin 
resistance. Sci STKE 2005, pe4. 
References 
198 
Zorzano, A., Sevilla, L., Camps, M., Becker, C., Meyer, J., Kammermeier, H., Munoz, 
P., Guma, A., Testar, X., Palacin, M., et al. (1997). Regulation of glucose transport, and 
glucose transporters expression and trafficking in the heart: studies in cardiac myocytes. 
Am J Cardiol 80, 65A-76A. 
 
 
Appendix A 
199 
APPENDIX A 
List of buffers and media 
All chemicals were purchased from Sigma-Aldrich, unless otherwise stated.  
All buffers and media were prepared with double distilled water (ddH2O). 
 
Buffers 
 
10× Orange G  40% (w/v) surcrose and 0.2% (w/v) Orange G, dissolve in 
ddH2O. 
 
10× TBE   1.1M Tris; 900mM Borate; 25mM EDTA; pH 8.3 
 
10× TBS   0.1M Tris-base, 1.5MNaCl, pH7.6 
 
ADS buffer 116mM NaCl, 20mM HEPES, 0.8mM NaH2PO4, 5.6mM 
Glucose, 5.4mM KCl, 0.8mM MgSO4, pH 7.35 
 
Alkaline lysis buffer  25mM NaOH, 0.2mM EDTA, pH 12 
 
DEPC treated water 1ml of diethyl pyrocarbonate (DEPC) per 500ml of 
ddH2O, shake and leave overnight at 37°C before 
autoclaving. 
 
Hybridisation buffer 1× TBS, 0.05% (v/v) Tween 20, 5% (w/v) non-fat milk 
(For immunoblotting) 
 
Neutralising buffer  40mM Tris-HCl, pH 5 
 
PBS 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 
mM NaCl, pH 7.4 
 
SDS-PAGE running buffer 25mM Tris-HCl, 192mM glycine, 2% (w/v) SDS, pH8.3 
 
TE (T10E0.1, pH 7.5)  10mM Tris-HCl, 0.1mM EDTA (pH 7.5) 
 
Transfer buffer 25mM Tris-HCl, 192mM glycine, 20% (v/v) methanol 
(Fisher Scientific) 
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Media 
 
For NRVM cultures 
 
Plating media 68% (v/v) DMEM (Invitrogen), 17% (v/v) M199 
(Invitrogen), 10% (v/v) horse serum (Autogen Bioclear); 
5% (v/v) FCS (Autogen Bioclear), 1 × Penicillin and 
streptomycin mix (Sigma; 100units/ml penicillin, 
100µg/ml streptomycin) 
 
Maintenance media  80% (v/v) DMEM (Invitrogen), 20% (v/v) M199 
(Invitrogen), 1 × Penicillin and streptomycin mix (Sigma; 
100units/ml penicillin, 100µg/ml streptomycin) 
 
Glucose free media 80% (v/v) glucose free DMEM (Invitrogen), 20% (v/v) 
M199 (Invitrogen) 
  
For COS7 cultures 
 
Maintenance media 90% (v/v) DMEM (Invitrogen), 10% (v/v) FCS (Autogen 
Bioclear), 1 × Penicillin and streptomycin mix (Sigma; 
100units/ml penicillin, 100µg/ml streptomycin) 
 
For bacteria cultures 
 
LB media 1.0% (w/v) Tryptone, 0.5% (w/v) Yeast Extract, 1.0% 
(w/v) NaCl, pH 7.0 Autoclave; cool to 55°C, add 50 
µg/ml of either ampicillin or kanamycin 
 
LB agar plate 1.0% (w/v) Tryptone, 0.5% (w/v) Yeast Extract, 1.0% 
(w/v) NaCl, pH 7.0, 1.5% (w/v) agar. Autoclave; cool to 
55°C, add 50 µg/ml of either ampicillin or kanamycin, 
pour into 10cm plates 
 
 
 
Appendix B 
201 
APPENDIX B 
Plasmid maps 
 
 
pBS2/αMHC  
 
Map is not drawn to scale. Sequence information of insert fragment, pri-rno-miR-223, is 
presented below the plasmid map. For details of the αMHC promoter region, refer to 
(Subramaniam, Jones et al. 1991) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
>pri-rno-miR-223 
GGTGTCTTAGCCAGTCATGTTAGTGTCTGCCATTTGTCTCACTCCCAGAGTAAGGTATAATCAGCCC
ATTTTTTTTCCTTTCAGGTGCATATCTTCCAGCATGTTCTTGCTGCTCATCCAAGGCTCCTGATCTG
GCCTTCTGCAGTGTTACGCTCCGTGTATTTGACAAGCTGAGTTGGACACTCTGTGTGGTAGAGTGTC
AGTTTGTCAAATACCCCAAGTGTGGCTCATGCTTATCAGCTCCAGGTCCAGGACTGAGCAGATAGCC
TGCTGTCTTCATATGAGTGCTTATGAAACATGAAGCTCTCTGGAGTTATTCTATGGCTTTTTGAGGG
AACTATAGCAATCCTTCAGAG 
 
Note: Pre-rno-miR-223 sequence is shown in bold. Mature rno-miR-223 is shown in 
bold and underlined.
BamHI 
Not I 
BamHI 
Not I 
EcoRI 
ccaaat 
~2.9kb Amp
R
 
T7 
T3 
SalI 
HindIII 
pBS2/αMHC 
pri-rno-miR-223  
tataaa Mouse α-MHC 5’UTR 
~6.1kb 
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pCR2.1-TOPO
®
 (Invitrogen, Paisley, UK)  
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psiCHECK-2 (Promega, Madison, WI, USA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
* 3’UTRs of NfIa, Rab10 and Mtpn were sub-cloned into the NotI/XhoI sites. 
 
> NfIa 3’UTR 
TTGGTTCAGCAGTCAGCAGTTACATACATAACACAACCCGCAAGGACAGTGAATCCGCTCCTGTTGCAGA
GCAATTTCCAAAAAGACGGCAAAGACTACTACTATCAGTTTGGTTGGGTTTTTGTTTTTTTGTTTTTT 
TTTTTTTTGTTTTTTTTTGTTTTTTTTGTTCTTAAGTTTTGAAATGCTGCACTTACATTTAAAAAAAAAC
ATTTTTCAACAATTTCAACAATGACACAAAAATTCACATGGAAATGGGGAAGATGGTCTGTTTTGACAGA
AACTGACAGGAATCAAAACAATCGAATTTTGAATTGAGTGAAGTGCAATTTCATTGGATAGCTAAGTATC
TTTGTAAGATAGAGATTGTTGAAAATTCTATTTTTGTTTTTCAAGTCCTCCCACC 
 
> Rab10 3’UTR 
TTAGGGTCCCCCTCACTTGACTCTATCATTGTTTACTAGTAAAAAGCAGCATTGCCAAATAATCCCTGAT
TTTCCACTATGAAAAATGCAATGTCTAAGCTTTTGAAGTTTGTAGGTTAAACCTACTGTTGTTAGTTAGA
TCTTTGCTGTTTGTGTTGCTTCCCTCTATCTGGATTGTGGCGGTCGCCTCTTTACTTTAAACTTTGTTTA
ACCCTTAATTCAGTGACTTAAGGTTTGGAGATACACACTGGGATTTTGGCTAACAGACTGACAGTTTTGT
TGTTTGCATAATTATAATCGGCACTGTACAGAGAAAAGATATGGCCTC 
 
> Mtpn 3’UTR 
GGATTTTCTCTCCCCTTTCACATCAATTTCATGTCTCTTTAGATAAAACTGACTAGTTTTATTTATAAAA
TGTTAAATTCTAGGAGCCTAAAGGAGGAATCATTCCAGTAGGCTTATTTCTTTTTTTCTCCTTTAGACTC
AGACATTTATATAACATTGAAACACTTTGAGACTCCTTCTGGTAGTAAAGGAGATTTAAAAATAAAATCA
TAGCCATAAGCGTGTTAGTATCTTATAAAGAGAGAACAGTTGTCTTAGTACCTATGGAGTTTCTTCATTT
GCTATTTGAGTGAGCCAGCCTTCGTTGTGTTTGGAGAATGAAGAATATTCTTTGGAATGCCTCTCAAAAA
CCCA 
 
Note: miR-223 recognition sites are shown in bold.  
3’UTR* 
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pTargeT™ (Promega, Madison, WI, USA). 
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pVQ Ad5CMV K-NpA (ViraQuest Inc, USA) 
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APPENDIX C 
List of primers 
 
 
 
Genotyping primers for miR-223 TG mouse 
Forward: 5’CCCACACCAGAAATGACAGACA3’  
Binds to αMHC (ENSMUST00000081857) intron 2, position 246-267 
Reverse: 5’cgtaaagcttCTCTGAAGGATTGCTATAGTT3’ 
Binds to Rat chromosome: RGSC3.4:X: 83869258 to 83869278 
Amplicon size: 419bp 
 
Glut4 ENSRNOT00000023256 (for SYBR qRT-PCR):  
Forward: 5’GATTCTGCTGCCCTTCTGTC3’ 
Binds to 792-811 of the transcript 
Reverse: 5’CAGCTCAGCTAGTGCGTCAG3’ 
Binds to 917-936 of the transcript 
Amplicon size: 145bp 
 
miR-223 ENSRNOT00000053628 (for generating adenovirus) 
Forward: 5’actggaattcGGTGTCTTAGCCAGTCATGT3’  
Binds to Rat chromosome:RGSC3.4:X: 83868923 to 83868942 
Reverse: 5’actggcggccgcCTCTGAAGGATTGCTATAGTT3’  
Binds to Rat chromosome:RGSC3.4:X: 83869258 to 83869278 
Amplicon size: 356bp 
 
miR-223 ENSRNOT00000053628 (for generating cardiac-specific transgenic mouse) 
Forward: 5’cgtagtcgacGGTGTCTTAGCCAGTCATGT3’  
Binds to Rat chromosome:RGSC3.4:X: 83868923 to 83868942 
Reverse: 5’cgtaaagcttCTCTGAAGGATTGCTATAGTT3’  
Binds to Rat chromosome:RGSC3.4:X: 83869258 to 83869278 
Amplicon size: 356bp 
 
miR-296 ENSRNOG00000035619 (for generating adenovirus) 
Forward: 5’actggaattcTTGTGTTGGGGAGACAGAGG3’ 
Binds to Rat chromosome:RGSC3.4:3: 165193701 to 165193720 
Reverse:  5’ actggcggccgcACCCCAAGAGCACTAACTGG3’  
Binds to Rat chromosome:RGSC3.4:3: 165193964 to 165193983 
Amplicon size: 283bp 
 
Mtpn ENSRNOT00000015808  3’UTR 
Forward: 5’GGATTTTCTCTCCCCTTTCAC3’ 
Binds to Rat chromosome:RGSC3.4:4:62896627 to 62896645 
Reverse: 5’TGGGTTTTTGAGAGGCATTC3’ 
Binds to Rat chromosome:RGSC3.4:4:62896961 to 62896980 
Amplicon size: 354bp 
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NfIa ENSRNOT00000004017 3’UTR 
Forward: 5’TTGGTTCAGCAGTCAGCAG3’ 
Binds to Rat chromosome:RGSC3.4: 5 118507126 to 118507144 
Reverse: 5’GGTGGGAGGACTTGAAAAAC3’ 
Binds to Rat chromosome:RGSC3.4: 5 118507491 to 118507510  
Amplicon size: 385bp 
 
Rab10 NM 017359.2 (RefSeq) 3’UTR 
Forward: 5’TTAGGGTCCCCCTCACTTG3’ 
Binds to Rat Chr6_random: 438050-438068 (UCSC) 
Reverse: 5’GAGGCCATATCTTTTCTCTG3’ 
Binds to Rat Chr6_random: 438358-438377 (UCSC) 
Amplicon size: 328 
 
T7 promoter 
5’TAATACGACTCACTATAGG3’ 
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APPENDIX D 
qRT-PCR data from individual patient samples (Table 3.3) 
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